
<html lang="en"     class="pb-page"  data-request-id="e3dc1eb7-2eb0-4292-bb2a-34572998ce8d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b02113;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders" /></meta><meta name="dc.Creator" content="Christa C.  Chrovian" /></meta><meta name="dc.Creator" content="Akinola  Soyode-Johnson" /></meta><meta name="dc.Creator" content="Brice  Stenne" /></meta><meta name="dc.Creator" content="Daniel J.  Pippel" /></meta><meta name="dc.Creator" content="Jeffrey  Schoellerman" /></meta><meta name="dc.Creator" content="Brian  Lord" /></meta><meta name="dc.Creator" content="Alexandra S.  Needham" /></meta><meta name="dc.Creator" content="Chungfang  Xia" /></meta><meta name="dc.Creator" content="Kevin J.  Coe" /></meta><meta name="dc.Creator" content="Kia  Sepassi" /></meta><meta name="dc.Creator" content="Freddy  Schoetens" /></meta><meta name="dc.Creator" content="Brian  Scott" /></meta><meta name="dc.Creator" content="Leslie  Nguyen" /></meta><meta name="dc.Creator" content="Xiaohui  Jiang" /></meta><meta name="dc.Creator" content="Tatiana  Koudriakova" /></meta><meta name="dc.Creator" content="Bartosz  Balana" /></meta><meta name="dc.Creator" content="Michael A.  Letavic" /></meta><meta name="dc.Description" content="Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to id..." /></meta><meta name="Description" content="Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to id..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 31, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02113" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02113" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02113" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02113" /></link>
        
    
    

<title>Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02113" /></meta><meta property="og:title" content="Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0017.jpeg" /></meta><meta property="og:description" content="Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to identify structurally novel, brain penetrant, GluN2B-selective inhibitors suitable for evaluation in a clinical setting in patients with major depressive disorder. We identified a new class of negative allosteric modulators of GluN2B that contain a 1,3-dihydro-imidazo[4,5-b]pyridin-2-one core. This series of compounds had poor solubility properties and poor permeability, which was addressed utilizing two approaches. First, a series of structural modifications was conducted which included replacing hydrogen bond donor groups. Second, enabling formulation development was undertaken in which a stable nanosuspension was identified for lead compound 12. Compound 12 was found to have robust target engagement in rat with an ED70 of 1.4 mg/kg. The nanosuspension enabled sufficient margins in preclinical toleration studies to nominate 12 for progression into advanced good laboratory practice studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02113"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02113">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02113&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02113&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02113&amp;href=/doi/10.1021/acs.jmedchem.9b02113" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 9181-9196</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00077" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00257" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Christa C. Chrovian</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christa C. Chrovian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#80e3e3e8f2eff6e9e1c0e9f4f3aeeaeeeaaee3efed"><span class="__cf_email__" data-cfemail="7a19191208150c131b3a130e095410141054191517">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christa+C.++Chrovian">Christa C. Chrovian</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4971-1538" title="Orcid link">http://orcid.org/0000-0002-4971-1538</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Akinola Soyode-Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akinola Soyode-Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akinola++Soyode-Johnson">Akinola Soyode-Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brice Stenne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brice Stenne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brice++Stenne">Brice Stenne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel J. Pippel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel J. Pippel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+J.++Pippel">Daniel J. Pippel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Schoellerman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Schoellerman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Schoellerman">Jeffrey Schoellerman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Lord</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Lord</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Lord">Brian Lord</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexandra S. Needham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexandra S. Needham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexandra+S.++Needham">Alexandra S. Needham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chungfang Xia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chungfang Xia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chungfang++Xia">Chungfang Xia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin J. Coe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin J. Coe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+J.++Coe">Kevin J. Coe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kia Sepassi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kia Sepassi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kia++Sepassi">Kia Sepassi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Freddy Schoetens</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Freddy Schoetens</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Freddy++Schoetens">Freddy Schoetens</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Scott</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Scott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Scott">Brian Scott</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leslie Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leslie Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leslie++Nguyen">Leslie Nguyen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaohui Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohui Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohui++Jiang">Xiaohui Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tatiana Koudriakova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatiana Koudriakova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana++Koudriakova">Tatiana Koudriakova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bartosz Balana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bartosz Balana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bartosz++Balana">Bartosz Balana</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael A. Letavic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael A. Letavic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Letavic">Michael A. Letavic</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7503-0189" title="Orcid link">http://orcid.org/0000-0002-7503-0189</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02113&amp;href=/doi/10.1021%2Facs.jmedchem.9b02113" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 9181–9196</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 February 2020</li><li><span class="item_label"><b>Published</b> online</span>31 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02113" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02113</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9181%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChrista%2BC.%2BChrovian%252C%2BAkinola%2BSoyode-Johnson%252C%2BBrice%2BStenne%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.9b02113%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2B3-Methyl-6-%25285-thiophenyl%2529-1%252C3-dihydro-imidazo%255B4%252C5-b%255Dpyridin-2-ones%2Bas%2BSelective%2BGluN2B%2BNegative%2BAllosteric%2BModulators%2Bfor%2Bthe%2BTreatment%2Bof%2BMood%2BDisorders%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9196%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02113"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1302</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02113" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Christa&quot;,&quot;last_name&quot;:&quot;C. Chrovian&quot;},{&quot;first_name&quot;:&quot;Akinola&quot;,&quot;last_name&quot;:&quot;Soyode-Johnson&quot;},{&quot;first_name&quot;:&quot;Brice&quot;,&quot;last_name&quot;:&quot;Stenne&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;J. Pippel&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Schoellerman&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Lord&quot;},{&quot;first_name&quot;:&quot;Alexandra&quot;,&quot;last_name&quot;:&quot;S. Needham&quot;},{&quot;first_name&quot;:&quot;Chungfang&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;J. Coe&quot;},{&quot;first_name&quot;:&quot;Kia&quot;,&quot;last_name&quot;:&quot;Sepassi&quot;},{&quot;first_name&quot;:&quot;Freddy&quot;,&quot;last_name&quot;:&quot;Schoetens&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Scott&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Xiaohui&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;Koudriakova&quot;},{&quot;first_name&quot;:&quot;Bartosz&quot;,&quot;last_name&quot;:&quot;Balana&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Letavic&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;9181-9196&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02113&quot;},&quot;abstract&quot;:&quot;Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to identify structurally novel, brain penetrant, GluN2B-selective inhibitors suitable for evaluation in a clinical setting in patients with major depressive disorder. We identified a new class of negative allosteric modulators of GluN2B that contain a 1,3-dihydro-imidazo[4,5-b]pyridin-2-one core. This series of compounds had poor solubility properties and poor permeability, which was addressed utilizing two approaches. First, a series of structural modifications was conducted which included replacing hydrogen bond donor groups. Second, enabling formulation development was undertaken in which a stable nanosuspension was identified for lead compound 12. Compound 12 was found to have robust target engagement in rat with an ED70 of 1.4 mg/kg. The nanosuspension enabled sufficient margins in preclinical toleration studies to &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02113&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02113" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02113&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02113" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02113&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02113" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02113&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02113&amp;href=/doi/10.1021/acs.jmedchem.9b02113" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02113" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02113" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02113%26sid%3Dliteratum%253Aachs%26pmid%3D32787105%26genre%3Darticle%26aulast%3DChrovian%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2B3-Methyl-6-%25285-thiophenyl%2529-1%252C3-dihydro-imidazo%255B4%252C5-b%255Dpyridin-2-ones%2Bas%2BSelective%2BGluN2B%2BNegative%2BAllosteric%2BModulators%2Bfor%2Bthe%2BTreatment%2Bof%2BMood%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D9181%26epage%3D9196%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292610" title="Antibiotic resistance">Antibiotic resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Selective inhibitors of the GluN2B subunit of <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to identify structurally novel, brain penetrant, GluN2B-selective inhibitors suitable for evaluation in a clinical setting in patients with major depressive disorder. We identified a new class of negative allosteric modulators of GluN2B that contain a 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core. This series of compounds had poor solubility properties and poor permeability, which was addressed utilizing two approaches. First, a series of structural modifications was conducted which included replacing hydrogen bond donor groups. Second, enabling formulation development was undertaken in which a stable nanosuspension was identified for lead compound <b>12</b>. Compound <b>12</b> was found to have robust target engagement in rat with an ED<sub>70</sub> of 1.4 mg/kg. The nanosuspension enabled sufficient margins in preclinical toleration studies to nominate <b>12</b> for progression into advanced good laboratory practice studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The neurotransmitter glutamate is prevalent to such an extent in the central nervous system (CNS) of complex organisms that it is involved in nearly all aspects of normal CNS functioning and it is used by most excitatory synaptic connections in the mammalian brain. Glutamate regulates the activity of two classes, or superfamilies, of receptors: metabotropic glutamate receptors that are G protein-coupled receptors (GPCRs) and ionotropic glutamate receptors (iGluRs) that are ion channels. iGluRs function as tetramers, and each contain two clamshell-shaped extracellular N-terminal domains, a ligand binding domain, a transmembrane domain, and an intracellular C-terminal domain.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The most well-studied iGluRs are α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptors (NMDARs). A key distinction between the two classes is that AMPA receptors are active during basal synaptic transmission, whereas NMDA receptors are activated only after a depolarization event of the surrounding neuronal membrane because Mg<sup>2+</sup> blocks the pore under basal conditions. When the Mg<sup>2+</sup> block is relieved after a depolarization event, the pore becomes permeable to Ca<sup>2+</sup>. The influx of Ca<sup>2+</sup> through NMDA receptors triggers signaling cascades and regulates gene expression that is critical for different forms of synaptic plasticity, including both long-term potentiation<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and long-term depression.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Growing evidence suggests that disturbances in brain and synaptic plasticity mediated by the glutamate system contribute to the pathophysiology of mood disorders.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a></div><div class="NLM_p">The NMDA receptor tetramers are comprised of two GluN1 and two GluN2 subunits. Four unique GluN2 subunits have been identified, and they have been assigned the nomenclature GluN2A–GluN2D. The receptors require coactivation by both glycine (<span class="smallcaps smallerCapital">d</span>-serine) and glutamate, which bind to GluN1 and GluN2, respectively.<a onclick="showRef(event, 'ref1 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref7">(1,7)</a></div><div class="NLM_p">The four GluN2 subunits of the NMDARs exhibit distinct distribution patterns across the mammalian brain, depending on the species and individual’s development age. For adult mammals, GluN2B subunits are expressed primarily in the cortex, striatum, and notably the hippocampus, a region consistently demonstrating the highest receptor density throughout the full life cycle.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a></div><div class="NLM_p">The NMDA receptor has been studied extensively since the early 1980s when it was determined that Mg<sup>2+</sup> confers a blockade of the ion channel under basal conditions, which is the salient feature conferring its voltage dependence.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Selectively blocking the function of GluN2B-containing receptors, on the other hand, was targeted later, when it was determined that ifenprodil (<b>1</b>) discriminates the subtypes of NMDAR.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>1</b> is an antihypertensive agent discovered in the 1960s that is a highly potent inhibitor of the GluN2B subunit, in addition to being a significant modulator of alpha adrenergic and sigma receptors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is a negative allosteric modulator (NAM) that was found to bind to the NMDAR complex at a site positioned between the GluN1 and GluN2B subunits.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The site is not present on the other three GluN2 subunits, and inhibitors binding at this interface have excellent selectivity for GluN2B over GluN2A, GluN2C, and GluN2D. This feature has enabled the scientific community the opportunity to evaluate the safety and pharmacology of several NMDAR small molecule modulators that are exquisitely selective for GluN2B versus the other three GluN2 subunits.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> Several NAMs have been evaluated in clinical settings, two of which were assessed in patients with depressive disorders.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GluN2B-selective NAMs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first reported GluN2B-selective NMDAR inhibitor assessed in patients diagnosed with major depressive disorder (MDD) was CP-101,606 (<b>2</b>, traxoprodil).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was originally discovered by Pfizer through a medicinal chemistry program based on <b>1</b>. It was identified as an inhibitor of NMDA receptor function and was shown to be neuroprotective <i>in vitro</i> against glutamate toxicity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> As the tetrameric structure of the NMDA receptor was unknown at the time, the selectivity of <b>2</b> for the GluN2B subunit was not revealed until later.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Compound <b>2</b> progressed into clinical trials and was assessed in subjects with traumatic brain injury.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Several years later, it was assessed in patients diagnosed with treatment resistant depression trials as an add-on therapy to paroxetine. It achieved a positive response in phase II clinical studies in 60% of subjects in a current depressive episode.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>2</b> has limited oral bioavailability, and its route of administration was intravenous (i.v.). The cardiovascular safety of <b>2</b> was also limited because of QT interval prolongation, and trials were ceased.</div><div class="NLM_p">CERC-301 (<b>3</b>, rislenemdaz, MK-0657) is an orally available GluN2B-selective NAM discovered by Merck and was originally intended for Parkinson’s disease or pain and related disorders.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21−22)</a> The results of a phase II study were reported in 2009 in which <b>3</b> did not result in motor function improvement in patients with Parkinson’s disease.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> It was later developed for the treatment of MDD and evaluated in two phase II trials in patients with MDD.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23−26)</a> The drug was generally well tolerated, and there were no discontinuations because of adverse events. Both trials failed to meet their primary endpoints, although in the second of the two phase II studies, a notable improvement in symptoms was measured on day 2 as determined by the secondary rating scale called the Hamilton depression rating scale (HDRS-17).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div><div class="NLM_p last">The goal of medicinal chemistry efforts in our drug discovery program was to identify novel GluN2B-selective NAMs that were well tolerated and suitable for once–a-day oral dosing in the clinic, in order to assess their performance in patients with psychiatric (mood) disorders.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A high-throughput screening (HTS) campaign identified compounds that inhibited functional activity of human GluN1a/GluN2B channels expressed in CHO cells as measured by Ca<sup>2+</sup> flux (FLIPR) elicited by addition of co-agonists glutamate and glycine. Confirmed hits were counter-screened in heterologous cells expressing human GluN1a/GluN2A. From this effort, a selective series of GluN2B inhibitors containing a 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core was identified. Compound <b>4</b> was potent in the FLIPR assay (hGluN2B IC<sub>50</sub> = 22 nM) and was selective over the GluN2A, GluN2C, and GluN2D subunits (IC<sub>50</sub>s all >10 μM). Two salient features of <b>4</b>, however, were its poor solubility (<4 μM at pHs 2 and 7) and high efflux ratio (B–A/A–B = 18). Compound <b>4</b> has two hydrogen bond donors and a characteristically insoluble urea moiety<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> imbedded in the core, likely contributing to its P-glycoprotein (Pgp) substrate potential, indicated by its high efflux ratio in the MDCK cell line transfected with MDR1. Compounds with efflux ratios >10 are expected substrates for Pgp and are less likely to cross the blood brain barrier (BBB). We were therefore encouraged to find that eliminating the H-bond donors by replacing the cyclopropyl of the secondary amide with azetidine to provide instead a tertiary amide, and adding <i>N</i>-methyl substitution at the urea N–H, resulted in compounds such as <b>5</b> that have comparable GluN2B potency to <b>4</b>. Compound <b>5</b> had a GluN2B IC<sub>50</sub> of 112 nM and measurable solubility (23 μM at pH 7). Compound <b>5</b> also had an improved efflux ratio (9.3) and a higher plasma free fraction (5.2%) than <b>4</b> (0.4%) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Neither <b>4</b> nor <b>5</b> displayed hERG channel inhibition. The majority of subsequent 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core compounds that were synthesized and assessed for hERG inhibition, including all of those described in this article, also had hERG IC<sub>50</sub> values >10 μM.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. GluN2B-selective NAMs. (A) Compound <b>4</b> was identified from a high throughput screen. (B) Compound <b>5</b> shows improved aqueous solubility, efflux ratio, and human plasma protein binding compared to HTS hit <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The early structure–activity relationship (SAR) of the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one series indicated that poor solubility was one of the prominent features of the core, which was predicted to be an obstacle. However, low metabolic turnover <i>in vitro</i> was also observed, a feature that was preferred. One trend that we focused on for optimization was the high efflux ratios that appeared to be the result of Pgp-mediated efflux. It was rationalized that if drug candidates could be identified that have both high intrinsic permeability and relatively low efflux liability, the need for high thermodynamic solubilities could be somewhat obviated.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Our strategy for 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones was to negotiate solubility properties in such a way that suitable absorption, distribution, metabolism, and excretion (ADME) in this series could be achieved, as well as good GluN2B potencies and brain uptake. Because much of the early SAR on the 1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridines has already been disclosed,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> a deeper focus of this disclosure will be late lead optimization SAR, <i>in vivo</i> data, and formulations that enabled clinical candidate selection.</div><div class="NLM_p">The first 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one compounds prepared had a <i>meta</i>-trifluoromethylphenyl group at the 6-position of the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core [referred to as left hand side (LHS) throughout this discussion, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>: <b>5–7</b>]. These analogues had moderate human GluN2B potencies (IC<sub>50</sub> values of 47–118 nM), and their efflux ratios were moderately high, ranging from 7 to 9 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In the presence of a Pgp inhibitor, their permeability was very good, ranging from <i>P</i><sub>app</sub> = 35 to 68 (×10<sup>–6</sup> cm/s), suggesting that the measured cellular efflux potential is Pgp-mediated. <i>N</i>-Azetidine-containing amides <b>5</b> and <b>7</b> had comparable solubilities in aqueous buffer, although <i>N</i>,<i>N</i>-dimethylamide <b>6</b> had measurably less (6 μM at pH 2 and 7).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. GluN2B Potency and Affinity and <i>In Vitro</i> ADME for 3-Methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0012.gif" alt="" id="GRAPHIC-d7e610-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0013.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined by a calcium mobilization assay in inducible CHO T-Rex cells heterologously expressing the hGluN1a/GluN2B receptor. Values reported are the mean ± SD of at least three experiments unless otherwise stated.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last"><i>K</i><sub><i>i</i></sub> values were determined using a radioligand competitive binding assay in rat cortex membranes using 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Values reported are the mean ± SD of at least three experiments unless otherwise stated.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Kinetic solubility in aqueous buffer.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Stability in human and rat liver microsomes. Data reported as microsomal ER.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Efflux ratio was measured using MDCK/MDR1 cells transfected with the Pgp (MDR-1). The efflux ratio is reported as the ratio of velocities (B–A/A–B).</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Papp is A to B permeability (10<sup>–6</sup> cm/s) measured in the presence of 2 μM of the Pgp inhibitor elacridar.</p></div></div><div></div></div><div class="NLM_p">A strategy to lower efflux ratios emerged at around this point in the SAR, when concurrent work on a second series of GluN2B NAMs containing a 1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridine core indicated that somewhat lower efflux ratios were measured for many of the examples had thiophenes on the LHS as phenyl bioisosteres.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> An example from that report in which 4-fluoro-3-methylphenyl was applied to the 1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridine core LHS (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) had an efflux ratio of 5.4 and a plasma <i>C</i><sub>max</sub> of 1380 ng/mL in rat, whereas the comparator molecule with a 5-(trifluoromethyl)thiophen-2-yl group in the place of 4-fluoro-3-methylphenyl (<b>9</b>) had an efflux ratio of 3.5 and a higher <i>C</i><sub>max</sub> of 2330 ng/mL in rat (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> We were thus prompted to apply these learnings and revisit thiophenes with the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-one core, hopeful that the combination of high plasma exposure and low efflux ratios in the pyrrolo[3,2-<i>b</i>]pyridine series would translate to the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-one core and also lead to pharmacologically relevant brain exposures.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of 1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridine series SAR.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The thiophene LHS SAR for the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core indicated that methyl- or fluoromethyl-groups incorporated at the 5-position (of thiophen-2-yl) were generally effective in both human GluN2B and rat GluN2B binding assays (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Analogues had poorer IC<sub>50</sub> and <i>K</i><sub><i>i</i></sub> values when the ring substitution was at the 4-position of the thiophene compared to the 5-position (<b>10</b><i>vs</i><b>11</b>). Trifluoromethyl thiophene analogues with <i>N</i>,<i>N</i>-dimethylacetamid- or 2-(azetidin-1-yl)-2-oxoethyl groups were potent NAMs (<b>12</b>: IC<sub>50</sub> = 31 nM, <b>13</b>: IC<sub>50</sub> = 29 nM) with robust rat GluN2B <i>K</i><sub><i>i</i></sub> values (<b>12</b>: <i>K</i><sub><i>i</i></sub> = 16 nM, <b>13</b>: <i>K</i><sub><i>i</i></sub> = 12 nM). 5-Cyclopropyl-substituted thiophenes were tolerated (<b>17</b>: IC<sub>50</sub> = 81 nM, <i>n</i> = 1) but were not as potent as the corresponding methyl (<b>11</b>: IC<sub>50</sub> = 25 nM) or fluoromethyl (<b>12</b>: IC<sub>50</sub> = 31 nM, <b>15</b>: IC<sub>50</sub> = 6 nM) analogues.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. GluN2B Potency and Affinity and <i>In Vitro</i> ADME for 3-Methyl-6-(thiophenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0014.gif" alt="" id="GRAPHIC-d7e841-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a–f</sup></sup><p class="last">Same as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">The efflux ratios for methyl- and trifluoromethyl-substituted thiophenes were in the desirable range of 1.4–3.7 (<b>10–14</b>) and lower than for compounds <b>5–7</b>, as we had hoped. Intrinsic permeability values (<i>P</i><sub>app</sub>) for <b>10–14</b> were excellent (37 to 68 × 10<sup>–6</sup> cm/s). Given their low efflux ratios (<4) and high <i>P</i><sub>app</sub>, compounds <b>10–14</b> were predicted to be BBB penetrant. Difluoromethyl thiophenes <b>15</b> and <b>16</b> had higher efflux ratios (5.8 and 9.1, respectively), and were also found to decompose in aqueous buffer after 24 h at pHs 2 and 7. Hence, despite its excellent potency, compound <b>15</b> (hGluN2B IC<sub>50</sub> = 6 nM) was deprioritized because of its chemical instability.</div><div class="NLM_p">The trifluoromethyl-substituted phenyl LHS (<b>5–7</b>) and thiophene LHS (<b>12–14</b>) showed excellent stability in human and rat liver microsomes. Extraction ratios (ER) were moderate for difluoromethyl-substituted thiophenes (<b>15–16</b>) and poor for 4- and 5-methyl-substituted thiophenes (<b>10–11</b>).</div><div class="NLM_p">The solubility of compounds <b>5–7</b> was moderately low at both pHs 2 and 7. Examples that contained trifluoromethylthiophene (<b>12–14</b>) displayed low solubility below the detection limit of the assay (<4 μM).</div><div class="NLM_p">Ultimately, compounds <b>12–14</b> were prioritized over the other examples because of their low microsomal turnover and GluN2B activity, both in the human recombinant cell line and in rat cortex binding assay. It is of note, however, that <b>12–14</b> were the least soluble of the series and possible challenges were anticipated because of their poor solubility properties. Compounds <b>15–16</b> looked promising but were not stable in aqueous buffer at pH 2 or 7 after 24 h. Compound <b>11</b> was soluble in buffer up to 39 and 48 μM at pHs 2 and 7, respectively, making it the most soluble of present examples. However, it had moderately high turnover in liver microsomes, with a human ER of 0.56. If <b>11</b> was to exhibit a good correlation between <i>in vitro</i> and <i>in vivo</i> PK (IVIVC) in rat, this predicted ER value would not preclude a therapeutically relevant <i>C</i><sub>max</sub> and oral bioavailability in human. Although it was foreseeable that intestinal dissolution may not be a limiting factor in absorption of <b>12–14</b>, in which case plasma drug concentrations could still reach levels well in the range of many drug substances that demonstrate robust bioavailabilities, because of the uncertainty surrounding proper absorption of <b>12–14</b> into systemic circulation, <b>11</b> was also selected for <i>in vivo</i> progression.</div><div class="NLM_p">The synthesis of <b>5–7</b> and <b>10–11</b> was conducted using a sequence beginning with 2-chloro-5-bromo-3-nitropyridine, which underwent an S<sub>N</sub>Ar reaction with aqueous methylamine at room temperature (rt) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The nitro group was reduced to the primary amine with zinc in the presence of ammonium chloride, and the 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-one core was formed in the next step using 1,1′-carbonyldiimidazole (CDI). Intermediate <b>18</b> was deprotonated with NaH and underwent S<sub>N</sub>2 addition to ethyl 2-bromoacetate to give <b>19</b> in 88% yield. Lithium hydroxide was used to saponify ester <b>19</b> to carboxylic acid <b>20</b>, which was subjected to amide forming conditions using propanephosphonic acid anhydride (T3P), followed by Suzuki coupling to provide final products <b>5–7</b> and <b>10–11</b>. For the formation of final products containing the 5-(trifluoromethyl)thiophen-2-yl moiety (<b>12–14</b>), ethyl ester <b>19</b> was subjected to Suzuki coupling conditions to first append the 5-(trifluoromethyl)thiophen-2-yl group to give <b>24</b>, and then, ester hydrolysis and amide formation gave final products <b>12–14</b>. The synthesis of final products <b>15–17</b> was conducted through Suzuki couplings of <b>22</b> and thiophene boronic esters.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Compounds <b>5–7</b> and <b>10–17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 40% NH<sub>2</sub>CH<sub>3</sub> in water, THF, 0 °C, then rt 16 h (99%); (b) zinc, ammonium chloride, acetone/water (10:1), rt, 72 h; (c) CDI, DMF, rt to 60 °C, 16 h (88% over 2 steps); (d) sodium hydride, DMF, rt, 30 min; then 2-bromoethylacetate, DMF, rt, 4 h, 88%; (e) lithium hydroxide, THF/water, rt, 16 h (83%); (f) secondary amine, <i>n</i>-propylphosphonic anhydride (T3P, 50% in ethyl acetate), Hunig’s base, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h (61–85%); (g) boronic Acid, cesium carbonate, PdCl<sub>2</sub>(dppf), dioxane, 100 °C, 16 h (9–46%); (h) bromothiophene, bis(pinacolato)diboron, potassium acetate, PdCl<sub>2</sub>(dppf), dioxane, 90 °C, 2 h; then add <b>22</b>, cesium carbonate, 90 °C, 3 h addnl. (10–48%); (i) 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane, potassium carbonate, PdCl<sub>2</sub>(dppf), toluene/water (10:1), 105 °C, 3 h (91%); (j) lithium hydroxide, THF/water, rt, 16 h (98%).</p></p></figure><div class="NLM_p">Compounds <b>12–14</b> were evaluated in PK experiments in rat followed by receptor occupancy studies in the rodent brain (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>11</b> was evaluated in rat PK experiments as well but showed very high i.v. CL, suggestive of extra-hepatic clearance mechanisms, as well as low bioavailability (1%). As such, it was not further assessed in receptor occupancy studies. Compounds <b>12</b>, <b>13,</b> and <b>14</b> all had low to moderate CL (14–30 mL/mg/kg) and moderate volumes of distribution (<i>V</i><sub>ss</sub>) (0.9–1.9 L/kg). All three compounds had excellent bioavailabilities, indicative of complete absorption. It is of note that <b>13</b> was found to be insoluble at 0.5 mg/mL in three standard excipients, 20% hydroxypropyl-β-cyclodextrin (HP-β-CD), 30% sulfobutylether-β-cyclodextrin (SBE-β-CD), and 100% polyethylene glycol 400 (PEG-400). The 20% HP-β-CD formulation did allow for a 0.1 mg/mL solution, which was enough to support a 0.5 mg/kg dose study.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Data (0.5 mg/kg i.v./2.5 mg/kg p.o., <i>n</i> = 3 ± SD, Vehicle: 20% HP-β-CD) and GluN2B Occupancy (3 mg/kg p.o., <i>n</i> = 2 ± SEM) Data for <b>11–14</b> in Rat</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="3" align="center">% occupancy timecourse (3 mg/kg p.o.)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (vehicle: 20% HP-β-CD)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">% <i>F</i></th><th class="colsep0 rowsep0" align="center">0.5 h</th><th class="colsep0 rowsep0" align="center">2.0 h</th><th class="colsep0 rowsep0" align="center">6.0 h</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max-brain</sub> (ng/g)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">114 ± 24</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">1 ± 1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">30 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">479 ± 172</td><td class="colsep0 rowsep0" align="left">1829 ± 535</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">132 ± 39</td><td class="colsep0 rowsep0" align="left">87 ± 2.3</td><td class="colsep0 rowsep0" align="left">76 ± 1.6</td><td class="colsep0 rowsep0" align="left">31, <i>n</i> = 1</td><td class="colsep0 rowsep0" align="left">765 ± 91</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">14 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">188 ± 68</td><td class="colsep0 rowsep0" align="left">912 ± 50</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">121 ± 38</td><td class="colsep0 rowsep0" align="left">79 ± 2.0</td><td class="colsep0 rowsep0" align="left">80 ± 0.9</td><td class="colsep0 rowsep0" align="left">77 ± 2.2</td><td class="colsep0 rowsep0" align="left">1257 ± 128</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">20 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1001 ± 235</td><td class="colsep0 rowsep0" align="left">3614 ± 240</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">109 ± 7</td><td class="colsep0 rowsep0" align="left">74 ± 3.9</td><td class="colsep0 rowsep0" align="left">71 ± 0.7</td><td class="colsep0 rowsep0" align="left">24 ± 1.0</td><td class="colsep0 rowsep0" align="left">728 ± 128</td><td class="colsep0 rowsep0" align="left">2.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>Ex vivo</i> GluN2B labelling was expressed as the percentage of GluN2B labelling in corresponding brain areas of vehicle-treated animals.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Vehicle is 1:1 PEG-400/water for PK study.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Doses were 0.1 mg/kg i.v. and 0.5 mg/kg p.o.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Vehicle is 30% SBE-β-CD for PK study.</p></div></div></div><div class="NLM_p">Next, GluN2B receptor occupancy and brain concentrations were measured for <b>12</b>, <b>13,</b> and <b>14</b> over a 6 h time course after oral administration in rat (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Receptor occupancy was assessed by autoradiography (ARG) by application of the GluN2B-selective <sup>3</sup>H radiotracer 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> to brain slices <i>ex vivo</i>. Thirty minutes after dosing at 3 mg/kg, all three compounds showed >70% occupancy as measured against background control. At 6 h, <b>13</b> had >70% GluN2B occupancy, although brain concentrations decreased from 1257 ng/mL at 2 h (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) to 598 ng/g at 6 h (full data shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf" class="ext-link">Supporting Information</a>). Because of the difficulty in formulating <b>13</b>, however, it was decided to deprioritize <b>13</b> and progress <b>12</b>.</div><div class="NLM_p">The brain biodistribution of <b>12</b> was evaluated in rodents in a microdosing experiment, in order to obtain a preliminary assessment of brain uptake of <b>12</b> in brain regions known to be enriched with the GluN2B subunit. Although NMDA-subunit expression has been shown to change in the mammalian brain from infancy to adulthood, the hippocampal region has the highest receptor density of GluN2B protein and mRNA throughout the lifetime. GluN2B is also highly expressed in the cortex and moderately in the striatum. GluN2B is not expressed in the cerebellum.</div><div class="NLM_p">Rats (<i>n</i> = 3 each group) were administered a single i.v. dose of 0.03 mg/kg of <b>12</b> formulated in 50% (w/v) PEG/water at pH 7.4. Animals were sacrificed at 5, 10, 30, 60, and 120 min following dosing. The cerebellum, cortex, striatum, and hippocampus were collected. The sample weight was measured and then homogenized to analyze levels of <b>12</b> by LC/MS/MS.</div><div class="NLM_p">Compound <b>12</b> was detected in all four brain regions at each timepoint (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In the cerebellum, concentrations were highest at the 5 min timepoint (19.3 ± 1.08 ng/mL) and decreased over time to 6.9 ± 0.65 ng/mL at 120 min, consistent with null expression of GluN2B in rat cerebellum. In the cortex, concentrations of <b>12</b> were higher at 10 min compared to 5 min and decreased at each of the subsequent timepoints. The highest levels of <b>12</b> were measured at 10, 30, and 60 min in the hippocampus, where GluN2B is highly enriched. Levels in the hippocampus reached a significance versus the cerebellum at 30 min (22.7 ± 2.49 <i>vs</i> 13.8 ± 1.62 ng/mL in cerebellum, <i>P</i> < 0.05) and 60 min (20.9 ± 3.47 <i>vs</i> 11.9 ± 1.27 ng/mL in cerebellum, <i>P</i> < 0.05) time points. At 120 min after dosing, both hippocampus and striatum showed higher levels of <b>12</b>, reaching significance (10.1 ± 0.13 and 9.8 ± 0.20 ng/mL, respectively) versus cerebellum (6.9 ± 0.65 ng/mL) <i>P</i> < 0.05.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Biodistribution of <b>12</b> in rat brain regions at different time points after a single i.v. injection of 30 μg/kg. Each animal group was sacrificed at different time points (5, 10, 30, 60 and 120 min after the injection). The result is normalized by tissue weight (g). <i>*P</i> < 0.05 significant increased <i>vs</i> cerebellum. <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of <b>12</b> on gram scale was conducted beginning from 6-bromo-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). It should be noted that this route was chosen in part because of the immediate availability of ethyl 6-bromo-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-1-carboxylate in house. In order to achieve the desired protecting group positioning on the core beginning with 6-bromo-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one, a carbamate-protecting group was selectively installed using ethyl pyridine-2-yl carbonate, which was followed by trityl protection of 3-position N–H. Ethyl carbamate was then deprotected with isopropylamine, and the resulting N–H was subjected to S<sub>N</sub>2 reaction conditions with 1-(azetidin-1-yl)-2-chloroethan-1-one. Finally, a Suzuki coupling followed by trityl deprotection and N-methylation provided <b>12</b>.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Multi-Gram Route for Compound <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl pyridin-2-yl carbonate, potassium carbonate, DMF, 75 °C (93%); (b) trityl chloride, triethylamine, rt (94%); (c) isopropylamine, THF, rt (100%); (d) sodium hydride, DMF, rt, 20 min; then 1-(azetidin-1-yl)-2-chloroethan-1-one, DMF, rt, 2 h (100%); (e) boronic Acid, cesium carbonate, PdCl<sub>2</sub>(dppf), dioxane, 100 °C, 16 h; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h (64% over 2 steps); (g) sodium hydride, DMF, rt, 30 min; then iodomethane, DMF, rt, 2 h (80%).</p></p></figure><div class="NLM_p">The dose dependency of <b>12</b> was obtained from GluN2B rat hippocampal occupancy measurements after oral administration at 8 different doses (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Receptor occupancy was determined at 60 min post dose (3 animals per group), by <i>ex vivo</i> ARG.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The calculations were made versus naïve control as described for the 6 h time course (<i>vide supra</i>). The 60 min time point measurement was chosen based on the <i>t</i><sub>max</sub> from the rat PK experiment. Compound <b>12</b> occupied the receptor in rat hippocampus with a plasma EC<sub>50</sub> of 407 ng/mL and a corresponding ED<sub>50</sub> of 0.86 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The receptor occupancy we targeted in order to both produce desired pharmacology and have the potential to minimize unwanted CNS effects<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> was 70% for 1–2 h. The total plasma concentration (bound + unbound) required to achieve 70% occupancy was 716 ng/mL (95% confidence interval 558–919 ng/mL).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>Ex vivo</i> GluN2B receptor occupancy with <b>12</b> in rat hippocampus: dose dependency after p.o. administration shown as (A) plasma concentration <i>vs</i> % GluN2B occupancy and (B) dose <i>vs</i> % GluN2B occupancy. Results are expressed as average percentage receptor occupancy <i>vs</i> naïve control rats ± SEM (<i>n</i> = 3) and vehicle is 20% HP-β-CD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>in vitro</i> profile of compound <b>12</b> is shown (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The unbound fractions in human and rat plasma were 4.6 and 5.3%, respectively, giving an unbound plasma EC<sub>70</sub> for <b>12</b> of 40 ng/mL in rat (based on total bound + unbound plasma EC<sub>70</sub> = 716 ng/mL). Compound <b>12</b> displayed no significant inhibition of cytochrome P450s (CYP) 3A4, 1A2, 2C19, 2C8, or 2C9 up to 50 μM and no time-dependent inhibition of CYP3A4. It was found to be a moderate inhibitor of CYP2D6 with an IC<sub>50</sub> of 15 μM. It showed no induction of CYP3A4 or CYP1A2. Compound <b>12</b> did not inhibit the hERG channel at any concentration assessed. It did not have any appreciable effect in a radioligand binding assay screen against a panel of 50 targets (GPCRs, ion channels, and transporters) at a concentration of 10 μM.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> ADME and Selectivity Data for Compound <b>12</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">GluN2B rat<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>/human <i>K</i><sub><i>i</i></sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (nM)</td><td class="colsep0 rowsep0" align="left">16 ± 7/15 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">GluN2- A/C/D IC<sub>50</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">h/rat/dog/mky CL<sub>int</sub> microsomes<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> μL/min/mg</td><td class="colsep0 rowsep0" align="left">5.4/26.3/14.7/16.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CYP isoform IC<sub>50</sub> (for IC<sub>50</sub> < 50 μM)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">2D6 (15 μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">3A4 time-dependent inhibition</td><td class="colsep0 rowsep0" align="left">no<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CYP induction</td><td class="colsep0 rowsep0" align="left">no<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Solubility (μM)</td><td class="colsep0 rowsep0" align="left">pH 4</td><td class="colsep0 rowsep0" align="left"><4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 7</td><td class="colsep0 rowsep0" align="left"><4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SGF</td><td class="colsep0 rowsep0" align="left">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SIF</td><td class="colsep0 rowsep0" align="left">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">hERG QPatch IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>30 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">h/r plasma protein (% free @ 0.5 μM)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">4.6/5.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub><i>i</i></sub> values were determined using a radioligand competitive binding assay in rat cortex membranes using ([<sup>3</sup>H]-1-(azetidin-1-yl)-2-(6-(4-fluoro-3-methylphenyl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)ethanone.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Values reported are the mean of three experiments ± SD, unless otherwise stated.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>K</i><sub><i>i</i></sub> measured in cortical neurons.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> values are reported in nM and were determined by a calcium mobilization assay in inducible CHO T-Rex cells heterologously expressing the hGluN1a/GluN2A, hGluN1a/GluN2C, or hGluN1a/GluN2D receptor.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Stability in human and rat liver microsomes. Data reported as microsomal ER.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">CYP IC<sub>50</sub> values were obtained from human liver microsomes for six isoforms: 1A2, 2C19, 2C8, 2C9, 2D6, and 3A4.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">No CYP3A4 inhibition was measured up to 10 μM of <b>12</b> either with or without 30 min pre-incubation.</p></div><div class="footnote" id="t4fn7"><sup><sup>g</sup></sup><p class="last">Showed <20% activation of human PXR (CYP3A) or AhR (CYP1A), compared to rifampicin and omeprazole, respectively.</p></div><div class="footnote" id="t4fn8"><sup><sup>h</sup></sup><p class="last">Equilibrium dialysis method.</p></div></div></div><div class="NLM_p">Preclinical PK data for <b>12</b> is shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The i.v. PK was characterized by low CL in monkey (9 mL/min/kg) and moderate CL in mouse, rat, and dog (54, 30 and 17 mL/min/kg, respectively). The CL values were reasonably well predicted <i>in vitro</i> from liver microsomes, except for monkey, which had lower <i>in vivo</i> CL than predicted (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>12</b> had moderate <i>V</i><sub>ss</sub> in preclinical species ranging from 0.8 to 3.2 L/kg. A short i.v. half-life was observed in all species (0.2 ≤ <i>t</i><sub>1/2</sub> ≥ 1.1 h). Oral bioavailability was moderate in dog (43%) and monkey (41%), moderately high in mouse (69%), and high in rat (132%) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vivo</i> PK Measurements of <b>12</b> in Dog, Monkey, Rat, and Mouse, <i>n</i> = 3 per Dose ± SD</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">dose</th><th class="rowsep1 colsep0" colspan="4" align="center">i.v.</th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">p.o.</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">i.v.</th><th class="colsep0 rowsep0" align="center" char=".">p.o.</th><th class="colsep0 rowsep0" align="center">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>inf</sub></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>max</sub></th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center" char="±">% <i>F</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="."><b>0.1</b></td><td class="colsep0 rowsep0" align="char" char="."><b>0.5</b></td><td class="colsep0 rowsep0" align="left">17 ± 9</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">126 ± 81</td><td class="colsep0 rowsep0" align="char" char="±">351 ± 28</td><td class="colsep0 rowsep0" align="char" char="±">268 ± 42</td><td class="colsep0 rowsep0" align="char" char="±">0.25 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">43 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char="."><b>0.1</b></td><td class="colsep0 rowsep0" align="char" char="."><b>0.5</b></td><td class="colsep0 rowsep0" align="left">9 ± 2</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.2</td><td class="colsep0 rowsep0" align="left">190 ± 46</td><td class="colsep0 rowsep0" align="char" char="±">167 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">385 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="."><b>0.5</b></td><td class="colsep0 rowsep0" align="char" char="."><b>2.5</b></td><td class="colsep0 rowsep0" align="left">30 ± 0.9</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.0</td><td class="colsep0 rowsep0" align="left">277 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">479 ± 172</td><td class="colsep0 rowsep0" align="char" char="±">1829 ± 535</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">132 ± 39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char="."><b>0.5</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="."><b>2.5</b></td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">156</td><td class="colsep0 rowsep0" align="char" char="±">413 ± 84</td><td class="colsep0 rowsep0" align="char" char="±">539 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">69 ± 0.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">For the i.v. arm, <i>n</i> = 2 animals.</p></div></div></div><div class="NLM_p">Next, <b>12</b> was evaluated in a single day dose ranging study in rats, in order to establish doses for an extended 14-day toleration study. The solubility of <b>12</b> was assessed and was found to be ≪10 mg/mL in 18 organic enabling excipients (and <1 mg/mL in 30% SBE-β-CD, 50% PEG-400, and 20% HP-β-CD). The poor solubility observed in the excipients assessed did not provide a path forward in supporting rat toleration studies. Given this limitation, high dose single day oral PK studies in rat were conducted using a suspension formulation [5% hydroxypropyl methylcellulose (HPMC)]. Compound <b>12</b> was administered by oral gavage formulated in HPMC to groups of 3 male Sprague Dawley rats at single dose levels of 125, 250, 500, and 1000 mg/kg in rat, and blood samples were collected at 6 time points ranging from 0.5 to 24 h. The resulting maximum plasma concentrations ranged from 4237 ± 585 ng/mL at 125 mg/kg to 7010 ± 1058 ng/mL at 1000 ng/mL (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat plasma concentrations of <b>12</b> over 24 h after four toleration doses administered as oral suspensions in 5% HPMC, <i>n</i> = 3. Error bars have been omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, maximum plasma levels in the single day dose ranging study in rat were less than 10-fold over the EC<sub>70</sub> for <b>12</b>, which would provide insufficient margins to properly assess its nonclinical safety and tolerability.</div><div class="NLM_p">In order to overcome the poor solubility and/or inadequate dissolution rate of <b>12</b><i>in vivo</i>, a nanosuspension formulation was next developed. Given its poor aqueous solubility, relatively high melting point (237 °C), and high crystallinity, we recognized that if a stable nanocrystal formulation could be accessed, plasma exposures could be improved with p.o. dosing of 12 if (1) low observed exposures were due to limited absorption of <b>12</b> and (2) poor absorption was due to insufficient dissolution rates of <b>12</b>. Because the rate of dissolution of a solid drug is directly proportional to particle size (available surface area), if points (1) and (2) are valid, and the intrinsic solubility of the API is at a critical minimum level, the dissolution rate in the gastrointestinal (GI) tract may be increased enough to translate into higher overall plasma exposures. Compound <b>12</b> was wet-milled with HPMC polymer (API/polymer = 4:1) to give a mean particle size of <i>d</i> = 0.10649 μm (<i>D</i>90 = 0.1195; <i>D</i>10 = 0.0827). The particle size data obtained on the stock solution after milling and again after storing the formulated product under refrigerated conditions for 5 days were stable; no agglomeration or particle growth was observed.</div><div class="NLM_p">The nanosuspension stock solution was then diluted with vehicle on the day of dosing to support rat studies at 100, 250, and 500 mg/kg. Compound <b>12</b> nanosuspension was administered by oral gavage to groups of 3 male Sprague Dawley rats at each dose level, and blood samples were collected at time points ranging from 0.5 to 24 h. In this case, the resulting maximum plasma exposures after nanosuspension p.o. delivery were dose-dependent, with maximum exposures at 500 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Compared to the standard suspension exposures, the <i>C</i><sub>max</sub> was three-fold higher using nanosuspension delivery, and AUC<sub>0–24h</sub> was >5-fold higher (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Rat plasma concentrations of <b>12</b> over 24 h after toleration doses administered as oral nanosuspensions (API/polymer = 4:1), <i>n</i> = 3 per dose ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparison of Rat Plasma <i>C</i><sub>max</sub>, <i>T</i><sub>max</sub> and AUC of <b>12</b> Administered as a Nanosuspension Orally at Toleration Doses vs Standard Suspension</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">suspension particle size</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–24h</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>/EC<sub>70</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Nano</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char="±">8996 ± 1539</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">51,858 ± 10,524</td><td class="colsep0 rowsep0" align="left">13×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="char" char="±">12,451 ± 2288</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">86,378 ± 5156</td><td class="colsep0 rowsep0" align="left">17×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="char" char="±">18,274 ± 1196</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">156,267 ± 40,536</td><td class="colsep0 rowsep0" align="left">26×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">standard</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char="±">4237 ± 685</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">22,777 ± 10,809</td><td class="colsep0 rowsep0" align="left">6×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="char" char="±">5477 ± 1157</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">19,729 ± 5370</td><td class="colsep0 rowsep0" align="left">8×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="char" char="±">6141 ± 271</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">22,537 ± 5277</td><td class="colsep0 rowsep0" align="left">9×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">1000</td><td class="colsep0 rowsep0" align="char" char="±">7010 ± 1058</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">22,276 ± 6154</td><td class="colsep0 rowsep0" align="left">10×</td></tr></tbody></table></div></div><div class="NLM_p">Compound <b>12</b> was next tested in rat repeated dose toleration studies using the nanosuspension formulation. In rats, the initial high dose toxicokinetic (TK) study of the nanosuspension described above was followed by a second single dose study that included a 1000 mg/kg group. Plasma drug exposures were similar among rats dosed 500 or 1000 mg/kg; therefore, 500 mg/kg/day was selected as the high dose in the 14-day repeated dose phase of the study.</div><div class="NLM_p">In the 14-day arm of the study, the most significant clinical observations in the high dose group were of aggressive behavior after 2 days. The animals were moved to individual caging on day 6, and no dose-limiting toxicity was identified up to 500 mg/kg/day for 14 days. At the end of the study, a dose of 500 mg/kg/day correlated with <i>C</i><sub>max</sub> and AUC<sub>0–24h</sub> values of 21,700 and 222,000 h·ng/mL, respectively; the <i>C</i><sub>max</sub> is 31-fold over the EC<sub>70</sub> for <b>12</b>.</div><div class="NLM_p">In order to estimate the human dose which would be predicted to provide 1–2 h coverage of <b>12</b> above its EC<sub>70</sub>, a systemic PK model for <b>12</b> was developed using a physiologically-based pharmacokinetic (PBPK) modeling and simulation software (GastroPlus 9.0, Simulations Plus, Lancaster, CA). This model predicted a human <i>V</i><sub>ss</sub> of 0.95 L/kg. For human, CL predictions were attempted by several mechanistic methods, and ultimately, the most consistent across species was a prediction from measured <i>in vitro</i> data in liver microsomes (intrinsic clearance [CL<sub>int</sub>]) without any binding corrections (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Human Clearance Prediction Summary for <b>12</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">predicted CL (mL/min/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><i>in vivo</i> plasma CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>in vivo</i> blood CL<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">method 1<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">method 2<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">method 3<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Blood CL calculated as plasma CL/blood to plasma ratio.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Well-stirred model using <i>in vitro</i> CL<sub>int</sub> with microsomal and plasma protein binding corrections (GastroPlus default scaling method).</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Well-stirred model with no binding corrections: CL = CL<sub>int</sub> × <i>Q</i>/(CL<sub>int</sub> + <i>Q</i>), where <i>Q</i>—species specific hepatic blood flow (21, 31, 44, 70 and 150 mL/min/kg in human, dog, monkey, rat, and mouse, respectively).</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">4-species allometry with maximum life span correction.</p></div></div></div><div class="NLM_p">This approach provided consistent CL predictions across species within a ∼2.2 fold range from the observed <i>in vivo</i> values. The predicted human CL from this method was 4.6 mL/min/kg. Using 4 species allometric scaling (dog, monkey, rat, and mouse) and unbound CL with the maximum lifespan potential correction, the estimated human CL value was 3.2 mL/min/kg. These two methods provided fairly similar predictions; however, the value of 4.6 (more conservative) was further used in human PK profile simulations.</div><div class="NLM_p">The plasma exposure over time profile in human was simulated by GastroPlus using a combination of the PBPK model and a GI absorption model (ACATTM) developed based on data from oral nanosuspension PK experiments in dog. Simulations were conducted in order to predict plasma levels above the calculated 70% effective concentration (EC<sub>70</sub>) of 716 ng/mL for approximately 1.5 h (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), which resulted in a predicted <i>C</i><sub>max</sub> of 904 ng/mL. The <i>C</i><sub>max</sub> on day 14 of the rat toleration study (21,700 ng/mL) versus the human-predicted <i>C</i><sub>max</sub> (904 ng/mL) represents a 24-fold margin. The human-predicted AUC<sub>inf</sub> was 4127 h·ng/mL which compared to the day 14 AUC<sub>0–24h</sub> of the maximum tolerated dose in rat (222,000 h·ng/mL) represents a 53-fold AUC margin.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Simulated human plasma concentration profile 120 mg of a single oral dose of <b>12</b> from a nanosuspension formulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Predicted Human PK Parameters for <b>12</b> Using PKPD Plus GI Absorption Models</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">oral dose (mg)</th><th class="colsep0 rowsep0" align="center">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>inf</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center">% <i>F</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">0.95</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">904</td><td class="colsep0 rowsep0" align="left">4127</td><td class="colsep0 rowsep0" align="left">67</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have identified a structurally novel class of GluN2B modulators containing a 1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one core system. These compounds in general had poor aqueous solubility but were prioritized because they demonstrated low turnover in liver microsomes. The poor solubility translated into slow dissolution rates and limited absorption in rats at high doses. As a result, lead compound <b>12</b> at high doses formulated in HPMC did not lead to high enough plasma concentrations in rat toleration studies to provide an acceptable margin above the plasma EC<sub>70</sub> value of 716 ng/mL needed to assess its safety. A stable nanosuspension formulation was subsequently developed in order to address this challenge. The nanosuspension enabled toleration studies with <b>12</b> which achieved a 24-fold <i>C</i><sub>max</sub> margin (highest plasma concentration of the maximum tolerated dose on day 14 in rat <i>vs</i> the highest human predicted plasma concentration) and a 53-fold AUC margin. Compound <b>12</b> was shown to have high receptor occupancy after oral administration with an ED<sub>70</sub> of 1.4 mg/kg in rat, as measured by ARG. Subsequent to this work, compound <b>12</b> was progressed into advanced good laboratory practice studies, the results of which shall be disclosed in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry General Methods</h3><div class="NLM_p">Solvents and reagents were used as supplied by the manufacturer. Concentrated refers to concentrated using a rotary evaporator under reduced pressure.</div><div class="NLM_p">Unless specified otherwise, normal-phase silica gel column chromatography (FCC) was performed on silica gel (SiO<sub>2</sub>) using prepackaged cartridges and the indicated solvents. Preparative reverse-phase high performance liquid chromatography (HPLC) was performed under one of three conditions<table class="listgroup" border="0" width="95%" id="list1" list-type="label"><tr class="li1"><td valign="top">1)</td><td colspan="5" valign="top" class="paragraph"><p class="last">An Agilent HPLC with a Waters XBridge C18 column or XTerra Prep RP<sub>18</sub> column (5 μm, 30 × 100 mm or 50 × 150 mm) and a gradient of 5–99% acetonitrile/water (20 mM NH<sub>4</sub>OH) over 12–18 min and a flow rate of 30 or 80 mL/min.</p></td></tr><tr class="li1"><td valign="top">2)</td><td colspan="5" valign="top" class="paragraph"><p class="last">A Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 μm, 50 × 100 mm); mobile phase of 5% ACN in H<sub>2</sub>O (both with 0.05% TFA) was held for 1 min, then a gradient of 5–99% ACN over 14 min, and then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.</p></td></tr><tr class="li1"><td valign="top">3)</td><td colspan="5" valign="top" class="paragraph"><p class="last">A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm, 30 × 100 mm, <i>T</i> = 45 °C); mobile phase of 5% ACN in H<sub>2</sub>O (both with 0.05% TFA) was held for 1 min, then a gradient of 5–99% ACN over 6 min, and then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.</p></td></tr></table></div><div class="NLM_p">High-resolution mass spectrometry (HRMS) was obtained on an Agilent G6230B time-of-flight (TOF) mass spectrometer, using a Dual AJS ESI in positive mode with a scan range of 100–1700 amu. The TOF was tuned using Agilent Technologies ESI-L low concentration tune mix (G1969-85000). This was diluted 10× with 90% acetonitrile in water, and to this mixture, 5 μL of 0.1 mM hexamethoxy-phosphazine (HP-0321) was added. The reference mass solution was made using the Agilent Technologies ES-TOF reference mass solution kit (G1969-85001), which contains 100 mM ammonium trifluoroacetate (TFANH<sub>4</sub>), 5 mM purine, and 2.5 mM hexakis (1<i>H</i>,1<i>H</i>,3<i>H</i>-tetrafluoropropoxy)phosphazine (HP-0921), all in 90:10 acetonitrile/water. The solution was made by adding 0.1 mL of TFANH<sub>4</sub>, 0.4 mL of purine, and 1.0 mL of HP-0921 to 1 L of 95:5 acetonitrile/water. This reference solution was continuously infused during the run. Samples were run through an ACE-3 C18 column (3 μm, 35 × 2.1 mm), with a mobile phase of 10–98% acetonitrile in 0.01% formic acid over 2 min and then held at 98% acetonitrile for 1 min, at a flow rate of 0.300 mL/min.</div><div class="NLM_p">Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Chemical shifts (δ) are expressed in parts per million, relative to internal tetramethylsilane; coupling constants (<i>J</i>) are in hertz (Hz). Measurements were made using 5 mm tubes.</div><div class="NLM_p last">All compounds tested were of a minimum of 95% purity as determined by HPLC. The HPLC method used for purity determinations is as follows: analytical LCMS was obtained on an Agilent 1100 Series using an ACE C18 column (3 μm, 3.0 × 50 mm, <i>T</i> = 50 °C) with a mobile phase of with a mobile phase of 5–99% ACN in 0.05% TFA over 1.5 min and then held at 99% ACN for 0.5 min, at a flow rate of 2.2 mL/min. The MS detector is an Agilent G1956B MSD set in positive mode. Alternatively, compound purity was assessed on a Waters Classic Acquity system using a Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm, <i>T</i> = 65 °C) with a mobile phase of 5–95% [(9:1 = water/10 mM NH<sub>4</sub>Ac)/ACN]/MeOH over 1.7 min and then hold at 95% MeOH for 0.3 min, at a flow rate of 0.7 mL/min. The MS detector is a Waters SQ detector (set in positive/negative mode).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Preparation of 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetic Acid (<b>20</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Step 1. 5-Bromo-<i>N</i>-methyl-3-nitropyridin-2-amine</h4><div class="NLM_p last">To a solution of 5-bromo-2-chloro-3-nitropyridine (15 g, 63 mmol) in tetrahydrofuran (THF) (570 mL) at 0 °C was added a solution of methylamine (40% in H<sub>2</sub>O, 10.9 mL, 126 mmol). The reaction mixture was stirred at rt for 16 h. Upon completion, the reaction mixture was extracted with EtOAc (3 × 500 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to yield the title compound as a yellow solid (14.6 g, 62.7 mmol, 99%), which was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.54 (d, <i>J</i> = 2.3 Hz, 1H), 8.46 (d, <i>J</i> = 2.3 Hz, 1H), 8.17 (br s, 1H), 3.16 (d, <i>J</i> = 4.9 Hz, 3H). MS (ESI): mass calcd for C<sub>6</sub>H<sub>6</sub>BrN<sub>3</sub>O<sub>2</sub>, 230.96; <i>m</i>/<i>z</i> found, 232 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Step 2. 5-Bromo-<i>N</i><sup>2</sup>-methylpyridine-2,3-diamine</h4><div class="NLM_p last">To a stirred suspension of 5-bromo-<i>N</i>-methyl-3-nitropyridin-2-amine (14.6 g, 62.7 mmol) and zinc (41 g, 627 mmol) in a mixture of water (29 mL) and acetone (291 mL) was added NH<sub>4</sub>Cl (33.6 g, 627 mmol). The reaction mixture was stirred at rt for 72 h. Upon completion, the mixture was filtered through Celite and rinsed with DCM. The filtrate was washed with water, and the aqueous layer was extracted with DCM (3×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to yield the title compound as an oil (12.7 g, 62.8 mmol, 100%), which was used in the next step without further purification. MS (ESI): mass calcd for CHBrN, 200.99; <i>m</i>/<i>z</i> found, 202 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Step 3. 6-Bromo-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>18</b>)</h4><div class="NLM_p last">To a solution of 5-bromo-<i>N</i><sup>2</sup>-methylpyridine-2,3-diamine (14 g, 69 mmol) in dimethylformamide (DMF) (702 mL) at rt was added CDI (29 g, 180 mmol). The reaction mixture was stirred for 16 h. LCMS analysis of the crude reaction mixture showed that the reaction was not complete, and the resulting residue was re-dissolved in THF, and CDI (11.2 g, 69 mmol) was added. The reaction mixture was stirred at 60 °C for 16 h. The reaction mixture was quenched with water and diluted with ether. The suspension was filtered, and the resulting solid was washed with ether then dried under vacuum to yield the title compound as a black solid (15.8 g, 35.7 mmol, 52%), which was used in the next step without further purification. MS (ESI): mass calcd for C<sub>7</sub>H<sub>6</sub>BrN<sub>3</sub>O, 226.97; <i>m</i>/<i>z</i> found, 227.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step 4. Ethyl 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate (<b>19</b>)</h4><div class="NLM_p last">Under a nitrogen atmosphere was added <b>18</b> (5 g, 21.9 mmol) to a suspension of sodium hydride (60% dispersion in mineral oil, 1.3 g, 32.9 mmol) in DMF (171 mL) at rt. After 10 min, ethyl bromoacetate (3.2 mL, 28.5 mmol) was added, and the reaction was stirred at rt. After 4 h, complete conversion was observed. The reaction was cooled to 0 °C, and water was added (200 mL). The precipitates were collected by filtration and washed with water to give the title compound (6.1 g, 19.2 mmol, 88%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.92 (d, <i>J</i> = 2.0 Hz, 1H), 4.76 (s, 2H), 4.16 (q, <i>J</i> = 7.1 Hz, 2H), 3.35 (s, 3H), 1.22 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI): mass calcd for C<sub>11</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>, 313.0; <i>m</i>/<i>z</i> found, 313.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step 5. 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetic Acid (<b>20</b>)</h4><div class="NLM_p last">Lithium hydroxide (2 M, 1.2 mL, 2.3 mmol) was added to a mixture of <b>19</b> (612 mg, 1.9 mmol) in THF (23 mL) at rt. The precipitates were collected by filtration and washed with THF to give the title compound (465 mg, 2.0 mmol, 83%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.02 (d, <i>J</i> = 2.0 Hz, 1H), 7.46 (d, <i>J</i> = 2.0 Hz, 1H), 4.03 (s, 2H), 3.31 (s, 3H). MS (ESI): mass calcd for C<sub>9</sub>H<sub>8</sub>BrN<sub>3</sub>O<sub>3</sub>, 285.0; <i>m</i>/<i>z</i> found, 286.0 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Amide Formation Procedure (<b>21–23</b>)</h3><div class="NLM_p">A mixture of <b>20</b> (1 equiv), amine (1.1 equiv), Hunig’s base (2 equiv), and T3P (50% solution in DMF, 3 equiv) in DMF or DCM (0.1 M) was stirred at rt or 50 °C. After reaction completion as indicated by consumption of starting material by LCMS, the reaction mixture was cooled to rt, and a saturated aqueous solution of NaHCO<sub>3</sub> (20 mL) was added. The mixture was extracted using DCM (3 × 30 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude product was purified by FCC (SiO<sub>2</sub>, 0–100% EtOAc in hexanes) or prep HPLC to give <b>21–23</b>.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-(6-Bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)-<i>N</i>,<i>N</i>-dimethylacetamide (<b>21</b>) (504 mg, 61%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.12–8.08 (d, <i>J</i> = 2.0 Hz, 1H), 7.81–7.77 (d, 2.0 Hz, 1H), 4.83–4.75 (s, 2H), 3.35–3.33 (s, 3H), 3.08–3.06 (s, 3H), 2.85–2.83 (s, 3H). MS (ESI): mass calcd for C<sub>11</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>2</sub>, 313.1; <i>m</i>/<i>z</i> found, 314.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>22</b>) (179 mg, 78%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.10 (d, <i>J</i> = 2.0 Hz, 1H), 7.78 (d, <i>J</i> = 2.0 Hz, 1H), 4.55 (s, 2H), 4.27 (t, <i>J</i> = 7.6 Hz, 2H), 3.91 (t, <i>J</i> = 7.7 Hz, 2H), 3.33 (s, 3H), 2.32–2.24 (m, 2H). MS (ESI): mass calcd for C<sub>11</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>2</sub>, 325.1; <i>m</i>/<i>z</i> found, 326.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 6-Bromo-1-(2-(3-fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>23</b>), (435 mg, 73%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.11 (d, <i>J</i> = 2.0 Hz, 1H), 7.79 (d, <i>J</i> = 2.0 Hz, 1H), 5.55–5.38 (m, 1H), 4.67–4.57 (m, 3H), 4.45–4.33 (m, 1H), 4.30–4.18 (m, 1H), 4.03–3.91 (m, 1H), 3.34 (s, 3H). MS (ESI): mass calcd for C<sub>12</sub>H<sub>12</sub>BrF<sub>4</sub>O<sub>2</sub>, 342.0 <i>m</i>/<i>z</i> found, 342.8 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure A for Suzuki Coupling (<b>5–7,10–11</b>)</h3><div class="NLM_p">A mixture of aryl bromide (<b>21–23</b>) (1 equiv), boronic acid (2 equiv), PdCl<sub>2</sub>(dppf)·DCM (0.07 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv) and dioxane (1.1 mL) sealed in a microwave vial under a nitrogen atmosphere was heated to 100 °C using an oil bath. After 16 h, the reaction mixture was cooled to rt to afford the crude compound. The crude product was dissolved in MeOH and purified by preparative HPLC to afford the desired compound.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>5</b>)</h4><div class="NLM_p last">General Suzuki coupling procedure A using <b>22</b> (6 mg, 10%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.04–7.97 (m, 2H), 7.90 (d, <i>J</i> = 2.0 Hz, 1H), 7.78–7.69 (m, 2H), 4.63 (s, 2H), 4.29 (t, <i>J</i> = 7.7 Hz, 2H), 3.91 (t, <i>J</i> = 7.7 Hz, 2H), 3.40 (s, 3H), 2.33–2.24 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 166.02, 159.45, 159.17, 158.90, 153.74, 143.05, 138.70, 138.60, 131.85, 131.64, 131.43, 131.21, 130.67, 130.47, 129.63, 124.90, 124.72, 124.60, 124.58, 124.55, 124.53, 124.00, 123.98, 123.95, 123.93, 123.09, 115.88, 114.50, 113.98, 77.23, 77.02, 76.81, 50.74, 48.98, 40.81, 26.73, 15.72. HRMS (ESI): calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 390.1320; found, 391.1390.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-methyl-2-oxo-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetamide (<b>6</b>)</h4><div class="NLM_p last">General Suzuki coupling procedure A using <b>21</b> (7 mg, 9%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.40 (d, <i>J</i> = 2.0 Hz, H), 8.03–7.96 (2H), 7.90 (d, <i>J</i> = 2.0 Hz, 1H), 7.77–7.69 (m, 2H), 4.87 (s, 2H), 3.40 (s, 3H), 3.11 (s, 3H), 2.85 (s, 3H). HRMS (ESI): calcd for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 384.3; found, 385.1.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(2-(3-Fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-6-(3-(trifluoromethyl)phenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>7</b>)</h4><div class="NLM_p last">General Suzuki coupling procedure A using <b>23</b> (19 mg, 31%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.40 (d, <i>J</i> = 1.9 Hz, 1H), 8.02–7.97 (m, 2H), 7.89 (d, <i>J</i> = 2.0 Hz, 1H), 7.78–7.70 (m, 2H), 5.58–5.37 (m, 1H), 4.76–4.57 (m, 3H), 4.47–4.34 (m, 1H), 4.31–4.18 (, 1H), 4.04–3.90 (m, 1H), 3.40 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 166.14, 153.78, 143.48, 139.57, 139.06, 131.62, 131.41, 130.80, 130.32, 129.63, 124.93, 123.13, 113.99, 82.41, 81.04, 77.23, 77.02, 76.80, 58.38, 58.20, 56.70, 56.53, 41.43, 26.45. HRMS (ESI): calcd for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 408.1222; found, 409.1296.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-methyl-6-(4-methylthiophen-2-yl)-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetamide (<b>10</b>)</h4><div class="NLM_p last">General Suzuki coupling procedure A using <b>21</b> (48 mg, 46%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30–8.27 (d, <i>J</i> = 1.9 Hz, H), 7.35–7.31 (d, <i>J</i> = 1.9 Hz, H), 7.08–7.04 (d, <i>J</i> = 1.4 Hz, 1H), 6.88–6.84 (m, 1H), 4.76–4.66 (s, 2H), 3.55–3.49 (s, 3H), 3.20–3.14 (s, 3H), 3.04–2.96 (s, 3H), 2.33–2.25 (d, <i>J</i> = 1.1 Hz, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.8, 154.1, 143.3, 140.9, 138.7, 125.9, 125.3, 124.4, 120.3, 112.3, 77.2, 77.1, 76.8, 42.4, 36.7, 35.9, 26.2, 15.8. HRMS (ESI): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 330.1160; found, 331.1233.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-methylthiophen-2-yl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>11</b>)</h4><div class="NLM_p">General Suzuki coupling procedure A using <b>22</b> (17 mg, 23%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.27–8.25 (d, <i>J</i> = 1.9 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 1.9 Hz, 1H), 7.06–7.04 (d, <i>J</i> = 3.5 Hz, 1H), 6.75–6.72 (m, 1H), 4.50–4.46 (s, 2H), 4.32–4.27 (m, 2H), 4.12–4.06 (m, 2H), 3.53–3.49 (s, 3H), 2.53–2.49 (d, <i>J</i> = 1.1 Hz, 3H), 2.39–2.31 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.81, 153.78, 142.78, 139.97, 138.49, 138.04, 126.26, 125.64, 124.25, 123.56, 112.37, 77.23, 77.02, 76.81, 50.51, 48.65, 40.92, 26.35, 15.76, 15.42. HRMS (ESI): calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 342.1169; found, 343.1243.</div><div class="NLM_p last">Compounds <b>12–14</b> were prepared from <b>19</b> using the general procedure A followed by ester hydrolysis as described for <b>19</b> → <b>20</b>. The last step can be conducted using general amide formation procedure.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Multi-gram synthesis of <b>12</b></h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-(2-Oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetic Acid</h4><div id="sec4_5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step 1. 6-Bromo-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one</h5><div class="NLM_p last">To a solution of 2,3-diamino-5-bromopyridine (5 g, 27 mmol) in THF (87 mL) was added CDI (3.02 g, 18.6 mmol), and the reaction mixture was stirred at 80 °C for 6 h. Then, water was added and the mixture was filtered. The solids were collected by filtration, washed with water and ether, and dried under vacuum to afford the title compound (5.3 g, 25 mmol, 93%), which was used in the next step without further purification. MS (ESI): mass calcd for C<sub>6</sub>H<sub>4</sub>BrN<sub>3</sub>O, 212.95; <i>m</i>/<i>z</i> found, 214 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 2. Ethyl 6-Bromo-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-1-carboxylate</h5><div class="NLM_p last">A mixture of 6-bromo-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (5.3 g, 25 mmol), ethyl pyridin-2-yl carbonate (5.36 g, 27.2 mmol) and K<sub>2</sub>CO<sub>3</sub> (3.77 g, 27.2 mmol) in DMF (245 mL) was heated to 75 °C for 3 h. The crude reaction mixture was concentrated <i>in vacuo</i> and diluted with water and 1 M HCl until the mixture reached pH 1. The solution was filtered and triturated with ether to afford the title compound (6.6 g, 23 mmol, 93%), which was used in the next step without further purification. MS (ESI): mass calcd for C<sub>9</sub>H<sub>8</sub>BrN<sub>3</sub>O<sub>3</sub>, 284.97; <i>m</i>/<i>z</i> found, 286 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 3. Ethyl 6-Bromo-2-oxo-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-1-carboxylate</h5><div class="NLM_p last">To a solution of ethyl 6-bromo-2-oxo-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-1-carboxylate (8.0 g, 11.8 mmol) in DCM (25 mL) at rt was added trityl chloride (5.36 g, 19.2 mmol) followed by Et<sub>3</sub>N (2.1 g, 21.0 mmol). The mixture was stirred at rt for 16 h and then concentrated. To the residue was added water (100 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to yield the title compound as an amorphous solid (8.0 g, 68%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.15 (d, <i>J</i> = 2.1 Hz, 1H), 7.90 (d, <i>J</i> = 2.2 Hz, 1H), 7.54–7.43 (m, 6H), 7.25–7.14 (m, 9H), 4.47 (q, <i>J</i> = 7. Hz, 2H), 1.42 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_5_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 4: 6-Bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one</h5><div class="NLM_p last">A mixture of ethyl 6-bromo-2-oxo-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridine-1-carboxylate (3.7 g, 7.0 mmol) and isopropylamine (0.72 mL, 8.4 mmol) in THF (35 mL) was stirred at rt for 2 h. Then, the reaction mixture was concentrated under vacuum to yield the title compound as yellow oil (3.2 g, 7.0 mmol, 100%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.87 (s, 1H), 7.80 (d, <i>J</i> = 2.1 Hz, 1H), 7.55–7.44 (m, 5H), 7.34–7.14 (m, 10H), 7.10 (d, <i>J</i> = 2.1 Hz, 1H).</div></div><div id="sec4_5_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Step 5. 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one</h5><div class="NLM_p last">Under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil, 1.03 g, 25.8 mmol) to a stirring solution of 6-bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (5.67 g, 12.3 mmol) in DMF (40 mL). After 20 min, 1-(azetidin-1-yl)-2-bromoethan-1-one (2.84 g, 15.9 mmol) in DMF (10 mL) was added to the reaction mixture. After 2 h, the reaction mixture was poured into ice water (500 mL). The precipitates were collected by suction filtration and isolated as a white solid (6.79 g, 12.3 mmol, 100%).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.82 (d, <i>J</i> = 2.0 Hz, 1H), 7.52–7.44 (m, 6H), 7.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.31–7.12 (m, 9H), 4.35 (s, 2H), 4.02 (t, <i>J</i> = 7.8 Hz, 2H), 3.82 (t, <i>J</i> = 7.7 Hz, 2H), 3.70 (s, 2H), 2.26–2.15 (m, 1H).</div></div><div id="sec4_5_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 6. 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>des-Methyl-12</b>)</h5><div class="NLM_p last">To a mixture of 1-(2-(azetidin-1-yl)-2-oxoethyl)-6-bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (6.79 g, 12.3 mmol), 5-(trifluoromethyl)thiophen-2-ylboronic acid (2.64 g, 13.5 mmol), Cs<sub>2</sub>CO<sub>3</sub> (7.99 g, 24.5 mmol) and PdCl<sub>2</sub>(dppf)·DCM (610 mg, 0.75 mmol) in a 500 mL rb flask under N<sub>2</sub> was added dioxane (100 mL). The reaction was stirred at 75 °C for 16 h under N<sub>2</sub>. The reaction was cooled to rt and diluted with EtOAc (100 mL) and water (200 mL). The layers were separated, and the water layer was extracted with DCM (2 × 100 mL). The combined organic layers were dried using MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0–100% EtOAc in hexanes) to afford 5.3 g of white solid (1-(2-(azetidin-1-yl)-2-oxoethyl)-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one.) The solid was diluted in DCM (100 mL), and TFA was added (50 mL). The mixture was stirred for 2 h at rt, and then, the solvents were removed <i>in vacuo</i>, following which DCM (200 mL) and sat NaHCO<sub>3</sub> (200 mL) were added. The resulting solids were collected by suction filtration. The mother liquor layers were separated, and the water layer was extracted with DCM (3 × 100 mL). The combined organic layers were dried using MgSO<sub>4</sub>, filtered, and concentrated under vacuum, and purified by FCC (0–10% {7 N NH<sub>3</sub> in MeOH}/DCM) to afford a white solid, which was combined with the first crop of solids to afford the title compound (3.01 g, 7.87 mmol, 64% over 2 steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85 (s, 1H), 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 7.79 (d, <i>J</i> = 2.0 Hz, 1H), 7.76 (dq, <i>J</i> = 3.9, 1.3 Hz, 1H), 7.58 (dt, <i>J</i> = 3.8, 1.3 Hz, 1H), 4.54 (s, 2H), 4.28 (t, <i>J</i> = 7.7 Hz, 2H), 3.91 (t, <i>J</i> = 7.7 Hz, 2H), 2.29 (p, <i>J</i> = 7.8 Hz, 2H). MS (ESI): mass calcd for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 382.3; <i>m</i>/<i>z</i> found, 383.0.</div></div><div id="sec4_5_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step 7. 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>12</b>)</h5><div class="NLM_p">To a solution of <b>des-methyl-12</b> (3.0 g, 7.8 mmol) in DMF (80 mL) was added NaH (60% dispersion in mineral oil, 377 mg, 9.42 mmol) in one portion at rt. Vigorous bubbling occurred, and the reaction was stirred until gas evolution had ceased (30 min), then iodomethane (0.73 mL, 11.8 mmol) was added and the reaction mixture was stirred at rt for an additional 2 h. The reaction was poured into ice water (400 mL). The resulting solids were collected by suction filtration and washed with water (200 mL). The mother liquor was extracted with EtOAc (8 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered. To this solution was added the filtered solids and 30 g of silica gel. The solvents were removed to dryness, and the residue was purified on 300 g of silica column (FCC, 0–10% {7 N NH<sub>3</sub> in MeOH}/DCM) to afford the title compound (2.5 g, 6.3 mmol, 80%). mp 237.40–237.87 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 1.9 Hz, 1H), 7.46 (d, <i>J</i> = 1.9 Hz, 1H), 7.43 (dq, <i>J</i> = 3.7, 1.1 Hz, 1H), 7.21 (dq, <i>J</i> = 3.7, 1.1 Hz, 1H), 4.51 (s, 2H), 4.36 (t, <i>J</i> = 7.8 Hz, 2H), 4.11 (t, <i>J</i> = 7.8 Hz, 2H), 3.55 (s, 3H), 2.43–2.35 (m, 2H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −55.34. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 165.56, 153.75, 145.16, 143.99, 138.72, 129.46, 129.42, 124.42, 123.64, 123.19, 112.78, 77.35, 77.23, 77.03, 76.71, 50.47, 48.62, 40.70, 26.39, 15.73. MS (ESI): calcd for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 396.1; found, 397.1.</div><div class="NLM_p last">For <i>in vivo</i> receptor occupancy and PK studies, compounds <b>12–14</b> were prepared using an alternative route.</div></div></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Synthetic Route for <i>In Vivo</i> Receptor Occupancy and PK Studies of <b>12–14</b></h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0016.gif" alt="" id="dgr1" /></img></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Synthesis of <b>13–14</b> from 6-Bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 1. Ethyl 2-(6-Bromo-2-oxo-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate</h4><div class="NLM_p last">Under a nitrogen atmosphere was added 6-bromo-3-trityl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (3.2 g, 7.0 mmol) to a suspension of NaH (60% dispersion in mineral oil, 393 mg, 9.8 mmol) in DMF (50 mL). After 20 min, ethyl bromoacetate (0.18 mL, 1.6 mmol) was added to the reaction mixture. After 2 h, the reaction mixture was quenched with water (200 mL). The precipitates were filtered off and isolated as a white solid.(3.8 g, 7.0 mmol, 99%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (d, <i>J</i> = 2.1 Hz, 1H), 7.43–7.39 (m, 6H), 7.25–7.20 (m, 6H), 7.19–7.13 (m, 3H), 4.68 (s, 2H), 4.08 (q, <i>J</i> = 7.1 Hz, 2H), 1.12 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 2. Ethyl 2-(2-Oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate</h4><div class="NLM_p last">A mixture of ethyl 2-(6-bromo-2-oxo-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate (230 mg, 0.4 mmol), 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane (153 mg, 0.6 mmol), Cs<sub>2</sub>CO<sub>3</sub> (240 mg, 0.7 mmol) and PdCl<sub>2</sub>(dppf)·DCM (21 mg, 0.06 mmol) in dioxane (3.5 mL) was combined in a microwave vial and stirred in a 75 °C oil bath. The reaction mixture was stirred at 75 °C for 16 h, then cooled down to rt, and quenched with a saturated aqueous solution of NaHCO<sub>3</sub>. The resulting reaction mixture was extracted with EtOAc (3 × 60 mL), and the combined organic layers were dried using MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The crude material was purified (FCC, SiO<sub>2</sub>, 0–40% EtOAc in hexanes) to afford the title compound. (215 mg, 0.4 mmol, 82%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.97–7.95 (d, <i>J</i> = 2.1 Hz, 1H), 7.45–7.40 (m, 6H), 7.30–7.27 (m, 1H), 7.19–7.14 (m, 6H), 7.14–7.09 (m, 3H), 7.04–7.03 (d, <i>J</i> = 2.0 Hz, 1H), 7.03–7.00 (m, 1H), 4.49–4.45 (s, 2H), 4.17–4.10 (m, 2H), 1.19–1.15 (m, 3H).</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step 3. 2-(2-Oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetic Acid</h4><div class="NLM_p last">To a solution of ethyl 2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate (1.0 g, 1.8 mmol) in THF (1 mL) and MeOH (1 mL) at rt was added LiOH (53 mg, 2.2 mmol) in water (0.033 mL, 1.8 mmol). The mixture was stirred for 5 h and then concentrated <i>in vacuo</i> to a white solid (1.03 g, 1.8 mmol, contains water). The solids were used in the next step without further characterization.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> General Amide Formation Procedure Followed by Trityl Deprotection (<b>des-Methyl 13–14</b>)</h3><div class="NLM_p">A mixture of 2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-3-trityl-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetic acid (1 equiv), amine (1.1 equiv), Hunig’s base (2 equiv), T3P (50% solution in DCM, 3 equiv) in DCM (0.1 M) was stirred at rt for 16 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified (FCC, SiO<sub>2</sub>, 0–100% EtOAc in hexanes). To the EA/hexanes solution containing the product was added 1 mL of TFA. The resulting reaction mixture stirred at rt for 16 h. The excess TFA was evaporated under reduced pressure, and the crude material was purified (FCC, SiO<sub>2</sub>, 0–15% 2 M NH<sub>3</sub>/MeOH in DCM) to afford the desired compound.</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>,<i>N</i>-Dimethyl-2-(2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetamide (<b>des-Methyl-13</b>), (25 mg, 33%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.8–11.7 (s, 1H), 8.34–8.32 (d, <i>J</i> = 2.0 Hz, 1H), 7.79–7.76 (s, 1H), 7.76–7.74 (d, <i>J</i> = 3.7 Hz, 1H), 7.57–7.55 (s, 1H), 4.80–4.75 (s, 2H), 3.10 (s, 3H), 2.85 (s, 3H). MS (ESI): mass calcd for C<sub>15</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 370.1; <i>m</i>/<i>z</i> found, 371.0.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-(2-(3-Fluoroazetidin-1-yl)-2-oxoethyl)-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>des-Methyl-14</b>), (108 mg, 70%)</h4><div class="NLM_p last">MS (ESI): mass calcd for C<sub>16</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S, 400.1; <i>m</i>/<i>z</i> found, 401.0.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> General Procedure for N-Methylation (<b>13–14</b>)</h3><div class="NLM_p">To a solution of <b>des-methyl-13</b> or <b>des-methyl-14</b> (1 equiv) in DMF (2 mL) was added NaH (60% dispersion in mineral oil, 1.2 equiv) in one portion at rt. The reaction was stirred until gas evolution had ceased, and then, iodomethane (1.5 equiv) was added. The mixture was stirred at rt overnight then diluted with water. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude solid was purified (FCC, SiO<sub>2</sub>, 0–50% IPA in EtOAc in DCM) to yield <b>13–14</b>.</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-methyl-2-oxo-6-(5-(trifluoromethyl)thiophen-2-yl)-2,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetamide (<b>13</b>), (37 mg, 82%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (d, <i>J</i> = 1.9 Hz, 1H), 7.43–7.38 (m, 1H), 7.34 (d, <i>J</i> = 2.0 Hz, 1H), 7.20–7.15 (m, 1H), 4.72 (s, 2H), 3.53 (s, 3H), 3.18 (s, 3H), 3.00 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.62, 154.04, 145.42, 144.27, 138.88, 129.44, 129.41, 124.64, 123.53, 123.12, 112.50, 77.24, 77.02, 76.81, 42.41, 36.67, 35.89, 26.32. HRMS (ESI): calcd for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 384.0883; found, 385.0953.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(2-(3-Fluoroazetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>14</b>), (279 mg, 32%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.33–8.30 (d, <i>J</i> = 1.9 Hz, 1H), 7.44–7.43 (d, <i>J</i> = 1.9 Hz, 1H), 7.43–7.40 (m, 1H), 7.21–7.18 (m, 1H), 5.45–5.28 (m, 1H), 4.68–4.12 (m, 7H), 3.55–3.50 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.98, 153.71, 145.06, 144.02, 138.97, 130.27, 129.49, 129.46, 124.26, 123.77, 123.29, 112.73, 82.35, 80.98, 77.23, 77.02, 76.81, 58.27, 58.09, 56.62, 56.44, 41.11, 26.45. HRMS (ESI): calcd for C<sub>17</sub>H<sub>14</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 414.0790; found, 415.0863.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> General Procedure B for Suzuki Coupling (<b>15–17</b>)</h3><div class="NLM_p">To a solution of the corresponding 2-bromo-5-substituted-thiophene (3 equiv) in dioxane (3 mL) was added bis(pinacolato)diboron (4 equiv), KOAc (12 equiv), and PdCl<sub>2</sub>(dppf)·DCM (0.5 equiv). The resulting reaction mixture was stirred at 90 °C for 2 h under a nitrogen atmosphere. The reaction mixture was then cooled to rt, and <b>22</b> (1 equiv) was added followed by Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), dioxane (2 mL) and again PdCl<sub>2</sub>(dppf)·DCM (0.5 equiv). The reaction mixture was stirred at 90 °C for an additional 2 h under a nitrogen atmosphere. The reaction was cooled to rt and washed with water. The organic layer was dried with MgSO<sub>4</sub>, concentrated, and the residue was purified by FCC (SiO<sub>2</sub>, 0–7% 2 M NH<sub>3</sub>/MeOH in DCM) followed by basic HPLC (Agilent) to provide the desired compound.</div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(5-(difluoromethyl)thiophen-2-yl)-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>15</b>), (56 mg, 48%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.33–8.27 (d, <i>J</i> = 2.0 Hz, 1 H), 7.47–7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.28–7.24 (m, 1H), 7.21–7.15 (m, 1H), 6.96–6.68 (t, <i>J</i> = 56.1 Hz, 1H), 4.53–4.43 (s, 2H), 4.38–4.25 (m, 2H), 4.12–4.05 (m, 2H), 3.55–3.50 (s, 3H), 2.43–2.26 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.65, 153.80, 144.26, 143.83, 138.77, 135.65, 135.48, 135.31, 128.58, 128.53, 128.49, 124.36, 124.20, 123.19, 113.05, 112.71, 111.48, 109.92, 77.23, 77.02, 76.81, 50.49, 48.64, 40.76, 26.34, 15.75. HRMS (ESI): calcd for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 378.0976; found, 379.1050.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(4-(difluoromethyl)thiophen-2-yl)-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>16</b>), (35.5 mg, 20%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.30–8.28 (d, <i>J</i> = 1.9 Hz, 1H), 7.51–7.47 (m, 1H), 7.45–7.41 (d, <i>J</i> = 1.9 Hz, 1H), 7.35–7.32 (d, <i>J</i> = 1.3 Hz, 1H), 6.81–6.54 (m, 1H), 4.51–4.45 (s, 2H), 4.37–4.29 (m, 2H), 4.13–4.06 (m, 2H), 3.55–3.48 (s, 3H), 2.41–2.30 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.72, 153.82, 143.71, 143.17, 138.72, 137.18, 137.02, 136.85, 124.57, 124.52, 124.47, 124.32, 124.29, 120.83, 120.80, 120.78, 113.15, 112.56, 111.58, 110.01, 77.24, 77.03, 76.82, 50.51, 48.66, 40.75, 26.30, 15.75. HRMS (ESI): calcd for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 378.0975; found, 379.1048.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(2-(Azetidin-1-yl)-2-oxoethyl)-6-(5-cyclopropylthiophen-2-yl)-3-methyl-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-one (<b>17</b>), (11 mg, 10%)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.26–8.23 (d, <i>J</i> = 1.8 Hz, 1H), 7.39–7.37 (d, <i>J</i> = 1.9 Hz, 1H), 7.05–7.01 (d, <i>J</i> = 3.6 Hz, 1H), 6.75–6.71 (m, 1H), 4.50–4.44 (s, 2H), 4.32–4.24 (m, 2H), 4.12–4.05 (m, 2H), 3.52–3.49 (s, 3H), 2.38–2.28 (m, 2H), 2.12–2.04 (m, 1H), 1.05–0.97 (m, 2H), 0.80–0.72 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 165.88, 153.87, 148.83, 142.91, 138.37, 137.38, 125.61, 124.13, 123.73, 123.28, 112.19, 77.23, 77.02, 76.81, 50.51, 48.65, 40.93, 26.22, 15.74, 11.28, 9.82. HRMS (ESI): calcd for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 368.1319; found, 369.1393.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Calcium Mobilization (FLIPR) Assay</h3><div class="NLM_p last">CHO-T-Rex cells expressing Biomyx hNR1a/NR2 clones (BIOMYX Inc., San Diego, CA): cells are grown to 75–90% confluence before passaging. Cells are lifted using 0.05% trypsin/EDTA solution. Each confluent T225 flask typically yields enough cells for 2 plates (384-well) at the plating density of 20,000 cells/50 μL/well. Twenty-four hours before measurements, the expression of the NMDA receptors in the stable cell line is induced with Tet-On inducible system in the presence of ketamine, a non-selective NMDA receptor blocker. On the day of the experiment, cell culture media is carefully washed and the cells are loaded with Calcium 5 dye kit (Molecular Devices) in dye loading buffer containing 137 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 10 mM HEPES, and 5 mM <span class="smallcaps smallerCapital">d</span>-glucose; pH 7.4. After 1 h incubation at the rt, the dye is washed away with the assay buffer (137 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 0.01 mM EDTA, 10 mM HEPES, and 5 mM <span class="smallcaps smallerCapital">d</span>-glucose; pH 7.4). In the FLIPR Tetra reader, various concentrations of the test compounds are added to the cells for 5 min, while fluorescence is monitored to detect potential agonist activity. Next, co-agonists, glutamate, and glycine are added for another 5 min. The concentration of glutamate corresponding to ∼EC<sub>80</sub> is used to maximize the assay’s signal window and ability to detect NMDA receptor antagonists and NAMs. A saturating concentration (10 μM) of glycine is also present in the assay. A non-selective NMDA receptor antagonist, (+)MK-801 is used as a positive control for antagonist activity. The fluorescent signal in the presence of test compounds is quantified and normalized to the signal defined by the appropriate control wells. Experiments were performed three independent times in duplicate except for compounds <b>5–7</b>, which were assayed in two independent experiments in duplicate.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Radioligand Binding Assay</h3><div class="NLM_p last">Rat adult cortex is homogenized in the assay buffer (50 mM Tris; pH 7.4). The resulting cortical membranes containing native NMDA receptors are purified by centrifugation and extensively washed and then resuspended in the assay buffer. The test compounds, 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and membranes are mixed together and incubated with shaking for 2 h at rt to reach binding equilibrium. Non-specific binding of 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone is determined by preincubation of brain membranes with 10 μM of <b>2</b> (CP-101,606). Following the incubation, the bound and unbound tracer is separated by filtration with cell harvester and GF/B filter plates (PerkinElmer) soaked with polyethylenimine. The extent of binding is measured by counting [<sup>3</sup>H] radioactivity retained on the filters plates with liquid scintillator counter. Binding affinity (equilibrium dissociation constant <i>K</i><sub><i>i</i></sub>) for the test compounds is determined by fitting experimental data with the following model log EC<sub>50</sub> = log(10<sup>log <i>K</i><sub><i>i</i></sub></sup> × (1 + [Radioligand]/HotKd)) and <i>Y</i> = Bottom + (Top – Bottom)/(1 + 10<sup>(<i>X</i> – log EC<sub>50</sub>)</sup>), where [Radioligand] is the concentration of 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone, HotKdNM is the equilibrium dissociation constant of 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone, and Top and Bottom are the curve plateaus in the units of <i>Y</i> axis. Experiments were performed three independent times in duplicate with the exception of compounds <b>6</b> and <b>16</b>, which were assayed in two independent experiments in duplicate.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35">(30−35)</a></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Solubility in Aqueous Systems</h3><div class="NLM_p last">The solubility of <b>12</b> in aq buffer (pH 2 and pH 7), simulated gastric and intestinal fluids, was conducted as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Liver Microsomal Stability</h3><div class="NLM_p last">Microsomal stability studies were conducted in duplicate as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> MDCK/MDR-1 Permeability</h3><div class="NLM_p last">Permeability assays were conducted at Cyprotex according to the company’s protocol using the MDCK/MDR1 cell line obtained from the NIH. In brief, cells between passage numbers 6–30 were seeded onto a MultiScreen plate (Millipore) at a cell density of 3.4 × 10<sup>5</sup> cells/cm<sup>2</sup> and cultured for three days before permeability studies were conducted. Test compounds were dissolved as 10 mM dimethyl sulfoxide (DMSO) solutions and added to Hanks balanced salt solution, pH 7.4 culture media at a final concentration of 5 μM (1% DMSO v/v). The working solution was applied to cells on the donor side and incubated at 37 °C for 60 min to determine the apical (A) to basolateral (B) and B to A permeability, respectively. In addition, A to B permeability was measured in the presence of the Pgp inhibitor elacridar (2 μM). All conditions for test compound were conducted in duplicate, and each assay includes the reference markers propranolol (high permeability) and prazosin (Pgp substrate). After incubation, samples were processed for LC/MS/MS analyses to determine the apparent permeability coefficient (<i>P</i><sub>app</sub>) of the test compound in the A to B direction in the presence and absence of the Pgp inhibitor and in the B to A direction. In addition, the percent recovery was measured for all incubation conditions. The integrity of each monolayer was monitored by examining the permeation of lucifer yellow by fluorimetric analysis.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Plasma Protein Binding</h3><div class="NLM_p last">Plasma protein binding for <b>12</b> was determined using the equilibrium dialysis method as previously described in triplicate.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The parent compound recovery at the end of the experiment was ≥100%.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Inhibition of CYP450s by <b>12</b> Using Probe Substrates</h3><div class="NLM_p last">The potential of compound <b>12</b> to inhibit human CYPs was investigated <i>via</i> incubating specific CYP probe substrates (Table S2 in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf" class="ext-link">Supporting Information</a>) with human liver microsomes in the presence of <b>12</b> as previously described<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> at various concentrations up to 20 μM (solubility limit). The IC<sub>50</sub> values for various CYPs were determined by measuring the effect of <b>12</b> on the metabolite formation by a probe substrate and are reported as the mean of two independent experiments. Known specific CYP inhibitors were used as positive controls to monitor the assay performance. Compound <b>12</b> at concentrations up to 20 μM did not show significant inhibition of CYPs, except CYP2D6 for which moderate inhibition with an IC<sub>50</sub> value of 15 μM was observed (Table S2 of <a href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf" class="ext-link">Supporting Information</a>). The possibility of clinically significant drug–drug interactions due to inhibition of other CYPs by <b>12</b> is considered low.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> CYP3A4 Time-Dependent Inhibition</h3><div class="NLM_p last">CYP3A4 inhibition was determined in human liver microsomes both with and without 30 min preincubation of various concentrations of <b>12</b> (0.4–10 μM) by the previously described method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The IC<sub>50</sub> values of CYP3A4 activity are calculated in this experiment as the average of two independent experiments from the percent CYP3A4 activity remaining after compound incubation at the various concentrations relative to vehicle. A greater than 2-fold shift in the IC<sub>50</sub> value as a result of preincubation versus no preincubation was considered a threshold for time-dependent inhibition. For compound <b>12</b>, no inhibition was seen either before or after preincubation through the highest concentration tested (10 μM).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> CYP450 Induction</h3><div class="NLM_p last">The potential of <b>12</b> to induce CYPs at the transcriptional level was assessed with the use of the Puracyp (Carlsbad, CA) DPX2 (CYP3A4, pregnane X receptor [PXR]) and dioxin response element (DRE, CYP1A, aryl hydrocarbon receptor [AhR]) luciferase-reporter cell line. Rifampicin and omeprazole served as positive controls for CYP3A and 1A induction, respectively. The DPX2 cell line is a derivative of HepG2 cells that is cotransfected with an expression vector containing human PXR and a modified luciferase vector harboring the CYP3A4 promoter. The distal and proximal enhancers are transfected to over-express the PXR. Analogously, the 1A2-DRE stably transfected cell line harbor the human AhR gene and a luciferase reporter gene linked to the human CYP1A2 promoter and 3 copies of the DRE enhancer. ONE-Glo assay kit from Promega is used to measure the increase in luminescence because of up-regulation of transfected cell lines, DPX2 or DRE, which are purchased and licensed from Puracyp, Inc.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> hERG QPatch</h3><div class="NLM_p last">Experiments were performed using CHO cells stably expressing the hERG potassium channel as previously described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> After establishing whole-cell configuration and a stability period, the vehicle was applied for 5 min followed by the test substance by increasing concentrations of 0.3, 3.0, 10, and 30 μM. Each concentration of the test substance was applied twice. The effect of each concentration was determined after 5 min as an average current of 3 sequential voltage pulses. To determine the extent of block, the residual current was compared with vehicle pretreatment. Data are presented as mean values ± standard error of the mean (SEM). Compound <b>12</b> did not notably affect the membrane potassium current <i>I</i><sub>Kr</sub> at 0.3, 3, and 10 μM (1.8, 1.0, and 4.2% decrease at 0.3, 3, and 10 μM, respectively, <i>vs</i> 0.2, 0.6, and 2.4% with vehicle) but mildly inhibited <i>I</i><sub>Kr</sub> at 30 μM (33.6% inhibition <i>vs</i> 6.4% with vehicle; IC<sub>50</sub> > 30 μM). No drug exposure analysis was conducted to confirm exposure in this high-throughput screen.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>In Vivo</i> Methods</h3><div class="NLM_p">Animal work was done in accordance with the Guide Care for and Use of Laboratory Animals adopted by the US National Institutes of Health. Animals were allowed to acclimate for 7 days after receipt. They were group-housed in accordance with institutional standards, received food and water <i>ad libitum</i>, and were maintained on a 12 h light/dark cycle. Male Sprague Daley rats were from Charles River Laboratories or Harlan (Envigo), aged between 8 and 12 weeks and approximately 300–400 g in body weight. The animals were euthanized using CO<sub>2</sub> and decapitated at the indicated timepoints after drug administration.</div><div id="sec4_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>Ex Vivo</i> Radioligand Binding ARG</h4><div class="NLM_p last">For time course studies, 2 animals per time point over 3 time points were used. For dose response studies, three animals per dose over 7–10 doses were tested. Brains were rapidly frozen, and 20 micron thick tissue sections were prepared for ARG (Letavic <i>et al. ACS Med. Chem. Lett.,</i><b>2013,</b><i>4,</i> 419–422). Sections were briefly incubated with the radiotracer 3-[<sup>3</sup>H] 1-(azetidin-1-yl)-2-[6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-<i>b</i>]pyridin-1-yl]ethanone.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><i>Ex vivo</i> GluN2B labelling was expressed as the percentage of GluN2B labelling in corresponding brain areas of vehicle-treated animals.</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Microdosing Experiment</h4><div class="NLM_p last">To evaluate the brain biodistribution of <b>12</b> in rodents at a microdose level, rats (<i>n</i> = 3 each group) were administered with a single i.v. dose of 0.03 mg/kg of compound formulated in 50% (w/v) PEG/water, pH 7.4. Animals were sacrificed at 5, 10, 30, 60, and 120 min following the dosing. The cerebellum, cortex, striatum, and hippocampus were collected. The sample weight was measured and then homogenized to analyze <b>17</b> levels by LC/MS/MS.</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> LC/MS/MS Analysis</h4><div class="NLM_p last">Compound <b>12</b> was extracted from brain homogenate samples were extracted using a protein precipitation method and analyzed on an API4000 Q-Trap MS/MS System (Applied Biosystems, Concord, Ontario, Canada) interfaced with a Shimadzu HPLC. Samples were loaded onto a 2.1 × 50 mm Gemini, NX-C18, 3 μm 110A column (Phenomenex, Torrance, CA, US) under a flow rate of 0.5 mL/min using water (0.1% formic acid) as mobile phase A and acetonitrile (0.1% formic acid) as mobile phase B. Starting with 85% mobile phase A for 0.5 min, mobile phase B was increased from 15% to 98% using a linear gradient for 1.1 min, held at 98% B for 0.6 min, and equilibrated at 15% B for 0.4 min for an overall run time of 2.5 min. Compound <b>12</b> was quantified by MS/MS in the positive ion mode by monitoring the transition of 397–312 <i>m</i>/<i>z</i>.</div></div><div id="sec4_20_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Pharmacokinetic Studies</h4><div class="NLM_p last">Single dose pharmacokinetic studies in males Sprague Dawley rats were conducted following i.v. (0.1 or 0.5 mg/kg) and p.o. (0.5 or 2.5 mg/kg) administration as a solution in either 20% HP-β-CD, 50% PEG-400, or 30% SBE-β-CD. Blood was sampled at predose and at 0.033 (i.v.), 0.083 (i.v.), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h postdose. Plasma concentrations were quantitated by LC/MS/MS. Pharmacokinetic parameters were derived from noncompartmental analysis of the plasma concentration versus time data using WinNonlin software (Pharsight, Palo Alto, CA).</div></div><div id="sec4_20_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Rat Toleration Studies</h4><div class="NLM_p last">For rat TK studies, animals (5 per dose group) were administered <b>12</b> as a suspension in 5% HPMC or as a stable nanosuspension at doses of 125, 250, 500, and 1000 mg/kg (single dose studies) or 125, 250, and 500 mg/kg (14 day repeat dose study). Blood samples for TKs were collected pre-dose and at 1, 2, 4, 7, 24, 48, and 55 h post-dose and again on day 13 at 0, 1, 2, 4, 7, and 24 h for the repeat dose study. Haematology and clinical chemistry were assessed. Animals were monitored for behavior (daily), body weight (daily), and food consumption (weekly). Gross pathology and organ weights were assessed on day 14 autopsy. A selection of harvested tissues were weighed and underwent microscopic examination. Drug plasma concentrations were quantitated by LC/MS/MS. TK parameters were derived from noncompartmental analysis of the plasma concentration versus time data using PKAW R1.0 software.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02113" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02113?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02113</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and IC<sub>50</sub> data of compounds <b>10–17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Plasma and brain levels for <b>12–14</b> from receptor occupancy time course studies, plasma and brain levels of <b>12</b> for dose response receptor occupancy studies, brain levels of <b>12</b> in rat from microdosing study, <i>in vitro</i> CL data for <b>12</b> in 5 species, CYP450 inhibition data for <b>12</b>, solubility results for <b>12</b> in enabling excipients, off target selectivity panel data for <b>12</b>, and RP-LCMS purity traces for key compounds <b>11–14</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_001.csv">jm9b02113_si_001.csv (0.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf">jm9b02113_si_002.pdf (950.94 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02113" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christa C. Chrovian</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4971-1538" title="Orcid link">http://orcid.org/0000-0002-4971-1538</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0c6f6f647e637a656d4c65787f22666266226f6361"><span class="__cf_email__" data-cfemail="f695959e8499809f97b69f8285d89c989cd895999b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akinola Soyode-Johnson</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brice Stenne</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel J. Pippel</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Schoellerman</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Lord</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandra S. Needham</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chungfang Xia</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin J. Coe</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kia Sepassi</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Freddy Schoetens</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Scott</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie Nguyen</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohui Jiang</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana Koudriakova</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bartosz Balana</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Letavic</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development,
LLC, 3210 Merryfield
Row, San Diego, California 92121-1126, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7503-0189" title="Orcid link">http://orcid.org/0000-0002-7503-0189</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Heather Mcallister for HRMS data, Khoa Tran, Compound Logistics LJ and Compound Logistic BE for analytical reports, Yafei Chen and Katie Turner for <i>in vivo</i> protocols, Minerva Batugo and Adam Beaupre for QC and bioanalytical methods, Sangho Yun for formulation studies, and Nick Carruthers and Pascal Bonaventure for helpful suggestions in the preparation of this manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">AE</td><td class="NLM_def"><p class="first last">adverse event</p></td></tr><tr><td class="NLM_term">AMPA</td><td class="NLM_def"><p class="first last">α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</p></td></tr><tr><td class="NLM_term">API</td><td class="NLM_def"><p class="first last">active pharmaceutical ingredient</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">clog <i>P</i></td><td class="NLM_def"><p class="first last">calculated partition co-efficient</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">EC</td><td class="NLM_def"><p class="first last">effective concentration</p></td></tr><tr><td class="NLM_term">ED</td><td class="NLM_def"><p class="first last">effective dose</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethyleneglycol-bis(2-aminoethylether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">extraction ratio</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FIH</td><td class="NLM_def"><p class="first last">first in human</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptors</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">[(dimethylamino)-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">HDRS</td><td class="NLM_def"><p class="first last">Hamilton depression rating scale</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid</p></td></tr><tr><td class="NLM_term">Het</td><td class="NLM_def"><p class="first last">heterocycle</p></td></tr><tr><td class="NLM_term">HP-β-CD</td><td class="NLM_def"><p class="first last">(2-hydroxypropyl)-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">HPMC</td><td class="NLM_def"><p class="first last">hydroxypropyl methylcellulose</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">inhibitory concentration</p></td></tr><tr><td class="NLM_term">iGluR</td><td class="NLM_def"><p class="first last">ionotropic glutamate receptors</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LiPE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">major depressive disorder</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulator</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NMDAR</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor</p></td></tr><tr><td class="NLM_term">NOAEL</td><td class="NLM_def"><p class="first last">no adverse event level</p></td></tr><tr><td class="NLM_term">PEG400</td><td class="NLM_def"><p class="first last">polyethylene glycol 400</p></td></tr><tr><td class="NLM_term">PFTBA</td><td class="NLM_def"><p class="first last">perfluorotributylamine</p></td></tr><tr><td class="NLM_term">PGP</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">p.o.</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">PoC</td><td class="NLM_def"><p class="first last">proof of concept</p></td></tr><tr><td class="NLM_term">q.d.</td><td class="NLM_def"><p class="first last">quaque die (once a day)</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TRD</td><td class="NLM_def"><p class="first last">treatment resistant depression</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynelis, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollmuth, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span> <span> </span><span class="NLM_article-title">Glutamate receptor ion channels: structure, regulation, and function</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1124/pr.109.002451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1124%2Fpr.109.002451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=20716669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=405-496&author=S.+F.+Traynelisauthor=L.+P.+Wollmuthauthor=C.+J.+McBainauthor=F.+S.+Mennitiauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=K.+B.+Hansenauthor=H.+Yuanauthor=S.+J.+Myersauthor=R.+Dingledine&title=Glutamate+receptor+ion+channels%3A+structure%2C+regulation%2C+and+function&doi=10.1124%2Fpr.109.002451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate receptor ion channels: structure, regulation, and function</span></div><div class="casAuthors">Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-496</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The mammalian ionotropic glutamate receptor family encodes 18 gene products that coassemble to form ligand-gated ion channels contg. an agonist recognition site, a transmembrane ion permeation pathway, and gating elements that couple agonist-induced conformational changes to the opening or closing of the permeation pore.  Glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system and are localized on neuronal and non-neuronal cells.  These receptors regulate a broad spectrum of processes in the brain, spinal cord, retina, and peripheral nervous system.  Glutamate receptors are postulated to play important roles in numerous neurol. diseases and have attracted intense scrutiny.  The description of glutamate receptor structure, including its transmembrane elements, reveals a complex assembly of multiple semiautonomous extracellular domains linked to a pore-forming element with striking resemblance to an inverted potassium channel.  In this review we discuss International Union of Basic and Clin. Pharmacol. glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacol., allosteric modulation, mechanisms of gating and permeation, roles in normal physiol. function, as well as the potential therapeutic use of pharmacol. agents acting at glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0rj4nMr5ObVg90H21EOLACvtfcHk0lgkCaHXmmrZpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ&md5=5d0a7945b5ad99113adf9f6312bafe13</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.109.002451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.109.002451%26sid%3Dliteratum%253Aachs%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26aulast%3DWollmuth%26aufirst%3DL.%2BP.%26aulast%3DMcBain%26aufirst%3DC.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMyers%26aufirst%3DS.%2BJ.%26aulast%3DDingledine%26aufirst%3DR.%26atitle%3DGlutamate%2520receptor%2520ion%2520channels%253A%2520structure%252C%2520regulation%252C%2520and%2520function%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D405%26epage%3D496%26doi%3D10.1124%2Fpr.109.002451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berberich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hvalby, Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhr, G.</span></span> <span> </span><span class="NLM_article-title">The role of NMDAR subtypes and charge transfer during hippocampal LTP induction</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2006.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuropharm.2006.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=16901514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhtFygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=77-86&author=S.+Berberichauthor=V.+Jensenauthor=%C3%98.+Hvalbyauthor=P.+H.+Seeburgauthor=G.+K%C3%B6hr&title=The+role+of+NMDAR+subtypes+and+charge+transfer+during+hippocampal+LTP+induction&doi=10.1016%2Fj.neuropharm.2006.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of NMDAR subtypes and charge transfer during hippocampal LTP induction</span></div><div class="casAuthors">Berberich Sven; Jensen Vidar; Hvalby Oivind; Seeburg Peter H; Kohr Georg</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">Activation of NMDA receptors (NMDARs) is a requirement for persistent synaptic alterations, such as long-term potentiation of synaptic transmission (LTP).  NMDARs are composed of NR1 and NR2 subunits, and NR2 subunit-dependent gating properties of NMDAR subtypes cause dramatic differences in the timing of charge transfer.  These postsynaptic temporal profiles are further influenced by the frequency of synaptic activation.  Here, we investigated in the CA1 region of hippocampal slices from P28 mice, whether particular NMDAR subtypes are recruited based on NR2 subunit-specific gating following different induction protocols.  For high frequency afferent stimulation (HFS), we found that genetic impairment of NR2A or pharmacological block of NR2A- or NR2B-type NMDARs can reduce field LTP.  In contrast, when pairing low frequency synaptic stimulation with postsynaptic depolarization (LFS pairing) in single CA1 neurons, pharmacological antagonism of either subtype modestly reduced the charge transfer during LFS pairing without reducing the LTP magnitude.  These results indicate that HFS-triggered LTP is induced by more than one NMDAR subtype, whereas a single subtype is sufficient during LFS pairing.  Analysis of charge transfer during LFS pairing in 13 different conditions revealed a threshold for LTP induction, which was independent of the NR2 antagonist tested.  Thus, at least for LFS pairing, the amount of charge transfer, and thus Ca2+ influx, during LTP induction is a factor more critical than the participation of a particular NMDAR subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbpgtPeBjOUSXXDYhVZBdlfW6udTcc2eZLNo36QHZsxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhtFygsQ%253D%253D&md5=16556c251d9b9221dc90d2c5ff483f88</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2006.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2006.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBerberich%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DV.%26aulast%3DHvalby%26aufirst%3D%25C3%2598.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26aulast%3DK%25C3%25B6hr%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520NMDAR%2520subtypes%2520and%2520charge%2520transfer%2520during%2520hippocampal%2520LTP%2520induction%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D52%26spage%3D77%26epage%3D86%26doi%3D10.1016%2Fj.neuropharm.2006.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massey, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moult, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collingridge, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, Z. I.</span></span> <span> </span><span class="NLM_article-title">Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7821</span>– <span class="NLM_lpage">7828</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.1697-04.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1523%2FJNEUROSCI.1697-04.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=15356193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVWntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=7821-7828&author=P.+V.+Masseyauthor=B.+E.+Johnsonauthor=P.+R.+Moultauthor=Y.+P.+Aubersonauthor=M.+W.+Brownauthor=E.+Molnarauthor=G.+L.+Collingridgeauthor=Z.+I.+Bashir&title=Differential+roles+of+NR2A+and+NR2B-containing+NMDA+receptors+in+cortical+long-term+potentiation+and+long-term+depression&doi=10.1523%2Fjneurosci.1697-04.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression</span></div><div class="casAuthors">Massey, Peter V.; Johnson, Benjamin E.; Moult, Peter R.; Auberson, Yves P.; Brown, Malcolm W.; Molnar, Elek; Collingridge, Graham L.; Bashir, Zafar I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">7821-7828</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">It is widely believed that long-term depression (LTD) and its counterpart, long-term potentiation (LTP), involve mechanisms that are crucial for learning and memory.  However, LTD is difficult to induce in adult cortex for reasons that are not known.  Here we show that LTD can be readily induced in adult cortex by the activation of NMDA receptors (NMDARs), after inhibition of glutamate uptake.  Interestingly there is no need to activate synaptic NMDARs to induce this LTD, suggesting that LTD is triggered primarily by extrasynaptic NMDA receptors.  We also find that de novo LTD requires the activation of NR2B-contg. NMDAR, whereas LTP requires activation of NR2A-contg. NMDARs.  Surprisingly another form of LTD, depotentiation, requires activation of NR2A-contg. NMDARs.  Therefore, NMDARs with different synaptic locations and subunit compns. are involved in various forms of synaptic plasticity in adult cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoM_I4GoJ6pbVg90H21EOLACvtfcHk0lgkCaHXmmrZpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVWntLc%253D&md5=397cbbd1e24743da5920b46ece2aad25</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1697-04.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1697-04.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DP.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMoult%26aufirst%3DP.%2BR.%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BW.%26aulast%3DMolnar%26aufirst%3DE.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26aulast%3DBashir%26aufirst%3DZ.%2BI.%26atitle%3DDifferential%2520roles%2520of%2520NR2A%2520and%2520NR2B-containing%2520NMDA%2520receptors%2520in%2520cortical%2520long-term%2520potentiation%2520and%2520long-term%2520depression%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D7821%26epage%3D7828%26doi%3D10.1523%2Fjneurosci.1697-04.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1038/nrd2462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnrd2462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=18425072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=426-437&author=G.+Sanacoraauthor=C.+A.+Zarateauthor=J.+H.+Krystalauthor=H.+K.+Manji&title=Targeting+the+glutamatergic+system+to+develop+novel%2C+improved+therapeutics+for+mood+disorders&doi=10.1038%2Fnrd2462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders</span></div><div class="casAuthors">Sanacora, Gerard; Zarate, Carlos A.; Krystal, John H.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-437</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is mounting evidence of the involvement of the glutamatergic system in mood-disorder pathophysiol. as well as of the efficacy of glutamatergic agents in mood disorders.  In this review, the authors examine the contribution of abnormalities in the glutamatergic system to the impairments in neural plasticity that are obsd. in patients with mood disorders, and how this knowledge can be applied to the development of antidepressants with more rapid and sustained effects.  Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide.  To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiol. studies of mood disorders, and most therapeutics target these systems.  However, there is growing evidence that the glutamatergic system is central to the neurobiol. and treatment of these disorders.  Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiol. as well as the efficacy of glutamatergic agents in mood disorders.  We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBmJwxpcwdt7Vg90H21EOLACvtfcHk0ljKmUQ0LzE5hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbw%253D&md5=93fb1fc22d329aa9337ba38f5efe4677</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2462%26sid%3Dliteratum%253Aachs%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DTargeting%2520the%2520glutamatergic%2520system%2520to%2520develop%2520novel%252C%2520improved%2520therapeutics%2520for%2520mood%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D426%26epage%3D437%26doi%3D10.1038%2Fnrd2462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuron.2019.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=30946828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Olt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2019&pages=75-90&author=R.+S.+Dumanauthor=G.+Sanacoraauthor=J.+H.+Krystal&title=Altered+connectivity+in+depression%3A+GABA+and+glutamate+neurotransmitter+deficits+and+reversal+by+novel+treatments&doi=10.1016%2Fj.neuron.2019.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments</span></div><div class="casAuthors">Duman, Ronald S.; Sanacora, Gerard; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-90</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanisms underlying the pathophysiol. and treatment of depression and stress-related disorders remain unclear, but studies in depressed patients and rodent models are beginning to yield promising insights.  These studies demonstrate that depression and chronic stress exposure cause atrophy of neurons in cortical and limbic brain regions implicated in depression, and brain imaging studies demonstrate altered connectivity and network function in the brains of depressed patients.  Studies of the neurobiol. basis of the these alterations have focused on both the principle, excitatory glutamate neurons, as well as inhibitory GABA interneurons.  They demonstrate structural, functional, and neurochem. deficits in both major neuronal types that could lead to degrdn. of signal integrity in cortical and hippocampal regions.  The mol. mechanisms underlying these changes have not been identified but are thought to be related to stress induced excitotoxic effects in combination with elevated adrenal glucocorticoids and inflammatory cytokines as well as other environmental factors.  Transcriptomic studies are beginning to demonstrate important sex differences and, together with genomic studies, are starting to reveal mechanistic domains of overlap and uniqueness with regards to risk and pathophysiol. mechanisms with schizophrenia and bipolar disorder.  These studies also implicate GABA and glutamate dysfunction as well as immunol. mechanisms.  While current antidepressants have significant time lag and efficacy limitations, new rapid-acting agents that target the glutamate and GABA systems address these issues and offer superior therapeutic interventions for this widespread and debilitating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM2GZdT3C2qLVg90H21EOLACvtfcHk0ljKmUQ0LzE5hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Olt74%253D&md5=433761ac0a26ddbff59aedbfb20bd141</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DAltered%2520connectivity%2520in%2520depression%253A%2520GABA%2520and%2520glutamate%2520neurotransmitter%2520deficits%2520and%2520reversal%2520by%2520novel%2520treatments%26jtitle%3DNeuron%26date%3D2019%26volume%3D102%26spage%3D75%26epage%3D90%26doi%3D10.1016%2Fj.neuron.2019.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treccani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, M.</span></span> <span> </span><span class="NLM_article-title">Towards a glutamate hypothesis of depression</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuropharm.2011.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=21827775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaktbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=63-77&author=G.+Sanacoraauthor=G.+Treccaniauthor=M.+Popoli&title=Towards+a+glutamate+hypothesis+of+depression&doi=10.1016%2Fj.neuropharm.2011.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a glutamate hypothesis of depression</span></div><div class="casAuthors">Sanacora, Gerard; Treccani, Giulia; Popoli, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-77</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Half a century after the first formulation of the monoamine hypothesis, compelling evidence implies that long-term changes in an array of brain areas and circuits mediating complex cognitive-emotional behaviors represent the biol. underpinnings of mood/anxiety disorders.  A large no. of clin. studies suggest that pathophysiol. is assocd. with dysfunction of the predominant glutamatergic system, malfunction in the mechanisms regulating clearance and metab. of glutamate, and cytoarchitectural/morphol. maladaptive changes in a no. of brain areas mediating cognitive-emotional behaviors.  Concurrently, a wealth of data from animal models have shown that different types of environmental stress enhance glutamate release/transmission in limbic/cortical areas and exert powerful structural effects, inducing dendritic remodeling, redn. of synapses and possibly volumetric redns. resembling those obsd. in depressed patients.  Because a vast majority of neurons and synapses in these areas and circuits use glutamate as neurotransmitter, it would be limiting to maintain that glutamate is in some way involved' in mood/anxiety disorders; rather it should be recognized that the glutamatergic system is a primary mediator of psychiatric pathol. and, potentially, also a final common pathway for the therapeutic action of antidepressant agents.  A paradigm shift from a monoamine hypothesis of depression to a neuroplasticity hypothesis focused on glutamate may represent a substantial advancement in the working hypothesis that drives research for new drugs and therapies.  Importantly, despite the availability of multiple classes of drugs with monoamine-based mechanisms of action, there remains a large percentage of patients who fail to achieve a sustained remission of depressive symptoms.  The unmet need for improved pharmacotherapies for treatment-resistant depression means there is a large space for the development of new compds. with novel mechanisms of action such as glutamate transmission and related pathways.  This article is part of a Special Issue entitled Anxiety and Depression'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQIbSu99Fht7Vg90H21EOLACvtfcHk0ljKmUQ0LzE5hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaktbnI&md5=3f98d26ae55b973366de4f7f1c4902c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DTreccani%26aufirst%3DG.%26aulast%3DPopoli%26aufirst%3DM.%26atitle%3DTowards%2520a%2520glutamate%2520hypothesis%2520of%2520depression%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D63%26epage%3D77%26doi%3D10.1016%2Fj.neuropharm.2011.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomeli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span> <span> </span><span class="NLM_article-title">Heteromeric NMDA receptors: molecular and functional distinction of subtypes</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1126/science.256.5060.1217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1126%2Fscience.256.5060.1217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1350383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1217-1221&author=H.+Monyerauthor=R.+Sprengelauthor=R.+Schoepferauthor=A.+Herbauthor=M.+Higuchiauthor=H.+Lomeliauthor=N.+Burnashevauthor=B.+Sakmannauthor=P.+H.+Seeburg&title=Heteromeric+NMDA+receptors%3A+molecular+and+functional+distinction+of+subtypes&doi=10.1126%2Fscience.256.5060.1217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Heteromeric NMDA receptors:  molecular and functional distinction of subtypes</span></div><div class="casAuthors">Monyer, Hannah; Sprengel, Rolf; Schoepfer, Ralf; Herb, Anne; Higuchi, Miyoko; Lomeli, Hilda; Burnashev, Nail; Sakmann, Bert; Seeburg, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5060</span>),
    <span class="NLM_cas:pages">1217-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The N-methyl-D-aspartate (NMDA) receptor subtype of glutamate-gated ion channels possesses high calcium permeability and unique voltage-dependent sensitivity to magnesium and is modulated by glycine.  Mol. cloning identified three cDNA species of rat brain, encoding NMDA receptor subunits NMDAR2A (NR2A), NR2B, and NR2C, which are 55 to 70% identical in sequence.  These are structurally related, with less than 20% sequence identity, to other excitatory amino acid receptor subunits, including the NMDA receptor subunit NMDAR1 (NR1).  Upon expression in cultured cells, the new subunits yielded prominent, typical glutamate- and NMDA-activated currents only when they were in heteromeric configurations with NR1.  NR1-NR2A and NR1-NR2C channels differed in gating behavior and magnesium sensitivity.  Such heteromeric NMDA receptor subtypes may exist in neurons, since NR1 mRNA is synthesized throughout the mature rat brain, while NR2 mRNA show a different distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4zIpgEOOwfbVg90H21EOLACvtfcHk0liri7R_qCqIIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOrs7o%253D&md5=5f8027d13a038707c014b2654db628b7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.256.5060.1217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.256.5060.1217%26sid%3Dliteratum%253Aachs%26aulast%3DMonyer%26aufirst%3DH.%26aulast%3DSprengel%26aufirst%3DR.%26aulast%3DSchoepfer%26aufirst%3DR.%26aulast%3DHerb%26aufirst%3DA.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DLomeli%26aufirst%3DH.%26aulast%3DBurnashev%26aufirst%3DN.%26aulast%3DSakmann%26aufirst%3DB.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26atitle%3DHeteromeric%2520NMDA%2520receptors%253A%2520molecular%2520and%2520functional%2520distinction%2520of%2520subtypes%26jtitle%3DScience%26date%3D1992%26volume%3D256%26spage%3D1217%26epage%3D1221%26doi%3D10.1126%2Fscience.256.5060.1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrn3504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnrn3504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=23686171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=383-400&author=P.+Paolettiauthor=C.+Belloneauthor=Q.+Zhou&title=NMDA+receptor+subunit+diversity%3A+impact+on+receptor+properties%2C+synaptic+plasticity+and+disease&doi=10.1038%2Fnrn3504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</span></div><div class="casAuthors">Paoletti, Pierre; Bellone, Camilla; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">383-400</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  NMDA receptors (NMDARs) are glutamate-gated ion channels and are crucial for neuronal communication.  NMDARs form tetrameric complexes that consist of several homologous subunits.  The subunit compn. of NMDARs is plastic, resulting in a large no. of receptor subtypes.  As each receptor subtype has distinct biophys., pharmacol. and signaling properties, there is great interest in detg. whether individual subtypes carry out specific functions in the CNS in both normal and pathol. conditions.  Here, we review the effects of subunit compn. on NMDAR properties, synaptic plasticity and cellular mechanisms implicated in neuropsychiatric disorders.  Understanding the rules and roles of NMDAR diversity could provide new therapeutic strategies against dysfunctions of glutamatergic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqubMsb4ZP2U7Vg90H21EOLACvtfcHk0liri7R_qCqIIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSit7Y%253D&md5=f69790da360242d491bf1a5eb146613d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrn3504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn3504%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DBellone%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DNMDA%2520receptor%2520subunit%2520diversity%253A%2520impact%2520on%2520receptor%2520properties%252C%2520synaptic%2520plasticity%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2013%26volume%3D14%26spage%3D383%26epage%3D400%26doi%3D10.1038%2Fnrn3504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyton, J.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor subunits: function and pharmacology</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2006.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.coph.2006.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=17088105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=39-47&author=P.+Paolettiauthor=J.+Neyton&title=NMDA+receptor+subunits%3A+function+and+pharmacology&doi=10.1016%2Fj.coph.2006.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor subunits: function and pharmacology</span></div><div class="casAuthors">Paoletti, Pierre; Neyton, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels widely expressed in the central nervous system that play key roles in excitatory synaptic transmission.  Because of their involvement in numerous neurol. disorders, NMDARs are also targets of therapeutic interest.  NMDARs occur as multiple subtypes which differ in their subunit compn. and in their biophys. and pharmacol. properties.  In particular, NMDARs contain a diversity of sites at which endogenous ligands or pharmacol. agents can act to modulate receptor activity in a subunit-selective manner, and recent structural and functional data have started to reveal the mol. determinants for this subunit selectivity.  These include the binding sites for glutamate, the ion-channel pore and the recently identified allosteric sites on the N-terminal domain.  Other potential sites yet unexplored by medicinal chem. programs are also considered, in particular at the interface between subunits.  Given the growing body of evidence that diverse brain disorders implicate different NMDAR subtypes, such as NR2B in pain or NR3A in white matter injury, there is a growing interest in exploiting the pharmacol. heterogeneity of NMDARs for the development of novel NMDAR subtype-selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5E8KNWeeb7Vg90H21EOLACvtfcHk0liri7R_qCqIIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlGitQ%253D%253D&md5=18296410fb9b50af0b2a7ceae124faf4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DNeyton%26aufirst%3DJ.%26atitle%3DNMDA%2520receptor%2520subunits%253A%2520function%2520and%2520pharmacology%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D39%26epage%3D47%26doi%3D10.1016%2Fj.coph.2006.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregestovski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochiantz, A.</span></span> <span> </span><span class="NLM_article-title">Magnesium gates glutamate-activated channels in mouse central neurones</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1038/307462a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2F307462a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=6320006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaL2cXhtVSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=1984&pages=462-465&author=L.+Nowakauthor=P.+Bregestovskiauthor=P.+Ascherauthor=A.+Herbetauthor=A.+Prochiantz&title=Magnesium+gates+glutamate-activated+channels+in+mouse+central+neurones&doi=10.1038%2F307462a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Magnesium gates glutamate-activated channels in mouse central neurons</span></div><div class="casAuthors">Nowak, L.; Bregestovski, P.; Ascher, P.; Herbet, A.; Prochiantz, A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5950</span>),
    <span class="NLM_cas:pages">462-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Studies on mouse embryo mesencephalic or striatal neurons using the patch-clamp technique indicated a link between voltage sensitivity and Mg2+ sensitivity.  In Mg2+-free solns., L-glutamate, L-aspartate, and N-methyl-D-aspartate (NMDA) opened cation channels, the properties of which were voltage independent.  In the presence of Mg2+, the single-channel currents measured at resting potential were chopped in bursts and the probability of opening the channels was reduced.  Both effects increased with hyperpolarization, thereby accounting for the neg. slope of the I-V relation of the glutamate response.  Thus, the voltage dependence of the NMDA receptor-linked conductance appears to be a consequence of the voltage dependence of the Mg2+ block, and its interpretation does not require the implication of an intramembrane voltage-dependent gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNI5KPbMeMT7Vg90H21EOLACvtfcHk0liri7R_qCqIIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhtVSktrg%253D&md5=cc393236b9af6184c9b936bf2b61c83b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F307462a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F307462a0%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DL.%26aulast%3DBregestovski%26aufirst%3DP.%26aulast%3DAscher%26aufirst%3DP.%26aulast%3DHerbet%26aufirst%3DA.%26aulast%3DProchiantz%26aufirst%3DA.%26atitle%3DMagnesium%2520gates%2520glutamate-activated%2520channels%2520in%2520mouse%2520central%2520neurones%26jtitle%3DNature%26date%3D1984%26volume%3D307%26spage%3D462%26epage%3D465%26doi%3D10.1038%2F307462a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, P. B.</span></span> <span> </span><span class="NLM_article-title">Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1038/309261a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2F309261a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=6325946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaL2cXktFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=1984&pages=261-263&author=M.+L.+Mayerauthor=G.+L.+Westbrookauthor=P.+B.+Guthrie&title=Voltage-dependent+block+by+Mg2%2B+of+NMDA+responses+in+spinal+cord+neurones&doi=10.1038%2F309261a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Voltage-dependent block by magnesium(2+) of NMDA responses in spinal cord neurons</span></div><div class="casAuthors">Mayer, Mark L.; Westbrook, Gary L.; Guthrie, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5965</span>),
    <span class="NLM_cas:pages">261-3</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Voltage-clamp expts. on mouse spinal cord neurons showed that the voltage-sensitivity of N-methyl-D-aspartic acid (NMDA)  [6384-92-5] action is greatly reduced on the withdrawal of physiol. concns. (∼1 mM) of Mg2+ from the extracellular fluid.  Thus, Mg2+ blocks inward current flow through ion channels linked to NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLE_6GreNx3rVg90H21EOLACvtfcHk0lj_70mnVtE3Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktFyjtrk%253D&md5=5f44b8f339efde1dc09259c308373c8d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F309261a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F309261a0%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DM.%2BL.%26aulast%3DWestbrook%26aufirst%3DG.%2BL.%26aulast%3DGuthrie%26aufirst%3DP.%2BB.%26atitle%3DVoltage-dependent%2520block%2520by%2520Mg2%252B%2520of%2520NMDA%2520responses%2520in%2520spinal%2520cord%2520neurones%26jtitle%3DNature%26date%3D1984%26volume%3D309%26spage%3D261%26epage%3D263%26doi%3D10.1038%2F309261a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span> <span> </span><span class="NLM_article-title">Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">859</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=7901753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2cXitlCnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1993&pages=851-859&author=K.+Williams&title=Ifenprodil+discriminates+subtypes+of+the+N-methyl-D-aspartate+receptor%3A+selectivity+and+mechanisms+at+recombinant+heteromeric+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors</span></div><div class="casAuthors">Williams, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">851-9</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The effects of the atypical N-methyl-D-aspartate (NMDA) receptor antagonist ifenprodil were studied by voltage-clamp recording of Xenopus oocytes expressing heteromeric NMDA receptors from cloned NR1 and NR2 subunit RNAs.  In oocytes voltage-clamped at -70 mV, ifenprodil inhibited NMDA-induced currents at NR1A/NR2B receptors with high affinity (IC50 = 0.34 μM).  The affinity of NR1A/NR2A receptors for ifenprodil (IC50 = 146 μM) was 400-fold lower than that of NR1A/NR2B receptors.  The rate of onset of inhibition by low concns. of ifenprodil acting at NR1A/NR2B receptors was considerably slower than the onset of inhibition seen with high concns. of ifenprodil acting at NR1A/NR2A receptors.  The onset and recovery of blockade by ifenprodil at NR1A/NR2B receptors were not activity dependent.  The inhibitory effects of low concns. of ifenprodil at NR1A/NR2B receptors were not voltage dependent.  In contrast, the inhibitory effects of high concns. of ifenprodil at NR1A/NR2A receptors were partially voltage dependent, and a greater inhibition of NMDA-induced currents was seen at hyperpolarized membrane potentials than at depolarized membrane potentials.  The reversal potential of NMDA currents was not altered in the presence of ifenprodil.  Ifenprodil may act as a weak open-channel blocker of NR1A/NR2A receptors.  The degree of inhibition seen with 100 μM ifenprodil at NR1A/NR2A receptors was not altered by changes in the concn. of extracellular glycine.  However, the inhibitory effect of 1 μM ifenprodil at NR1A/NR2B receptors was reduced by increasing the concn. of glycine.  Thus, part of the mechanism of action of ifenprodil at NR1A/NR2B receptors may involve noncompetitive antagonism of the effects of glycine.  Apparently, the mechanism of action of ifenprodil, as well as the potency of this antagonist, is different at NR1A/NR2B and NR1A/NR2A receptors expressed in Xenopus oocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffD1y7apqXrVg90H21EOLACvtfcHk0lj_70mnVtE3Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlCnsw%253D%253D&md5=27f84915114a10b17c5f5c02740d84f8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%26atitle%3DIfenprodil%2520discriminates%2520subtypes%2520of%2520the%2520N-methyl-D-aspartate%2520receptor%253A%2520selectivity%2520and%2520mechanisms%2520at%2520recombinant%2520heteromeric%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D1993%26volume%3D44%26spage%3D851%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carron, M. C. E.</span>; <span class="NLM_string-name">Carron, C. L. C.</span>; <span class="NLM_string-name">Bucher, B. P.</span></span> <i>1-(p-Hydroxyphenyl)-2-(4-alkyl- or -aralkyl-1-piperidino)-1-propanols Vasodilators</i>, FR 1966-77770, <span class="NLM_year">1966</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&author=M.+C.+E.+Carron&author=C.+L.+C.+Carron&author=B.+P.+Bucher&title=1-%28p-Hydroxyphenyl%29-2-%284-alkyl-+or+-aralkyl-1-piperidino%29-1-propanols+Vasodilators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DCarron%26aufirst%3DM.%2BC.%2BE.%26jtitle%3D1-%2528p-Hydroxyphenyl%2529-2-%25284-alkyl-%2520or%2520-aralkyl-1-piperidino%2529-1-propanols%2520Vasodilators%26date%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perin-Dureau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5955</span>– <span class="NLM_lpage">5965</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.22-14-05955.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1523%2FJNEUROSCI.22-14-05955.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=12122058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFOjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=5955-5965&author=F.+Perin-Dureauauthor=J.+Rachlineauthor=J.+Neytonauthor=P.+Paoletti&title=Mapping+the+binding+site+of+the+neuroprotectant+ifenprodil+on+NMDA+receptors&doi=10.1523%2Fjneurosci.22-14-05955.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors</span></div><div class="casAuthors">Perin-Dureau, Florent; Rachline, Julie; Neyton, Jacques; Paoletti, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5955-5965</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ifenprodil is a noncompetitive antagonist of NMDA receptors highly selective for the NMDA receptor 2B (NR2B) subunit.  It is widely used as a pharmacol. tool to discriminate subpopulations of NMDA receptors, and derivs. are currently being developed as candidate neuroprotectants.  Despite numerous studies on the mechanism of action of ifenprodil on NMDA receptors, the structural determinants responsible for the subunit selectivity have not been identified.  By combining functional studies on recombinant NMDA receptors and biochem. studies on isolated domains, we now show that ifenprodil binds to the N-terminal leucine/isoleucine/valine-binding protein (LIVBP)-like domain of NR2B.  In this domain, several residues, both hydrophilic and hydrophobic, were found to control ifenprodil inhibition.  Their location in a modeled three-dimensional structure suggests that ifenprodil binds in the cleft of the LIVBP-like domain of NR2B by a mechanism (Venus-flytrap) resembling that of the binding of Zn on the LIVBP-like domain of NR2A.  These results reinforce the proposal that the LIVBP-like domains of NMDA receptors, and possibly of other ionotropic glutamate receptors, bind modulatory ligands.  Moreover, they identify the LIVBP-like domain of the NR2B subunit as a promising therapeutic target and provide a framework for designing structurally novel NR2B-selective antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8blkWf0Z1c7Vg90H21EOLACvtfcHk0lj_70mnVtE3Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFOjsb4%253D&md5=996a97d37425b46d1bf74e26139c7339</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.22-14-05955.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.22-14-05955.2002%26sid%3Dliteratum%253Aachs%26aulast%3DPerin-Dureau%26aufirst%3DF.%26aulast%3DRachline%26aufirst%3DJ.%26aulast%3DNeyton%26aufirst%3DJ.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DMapping%2520the%2520binding%2520site%2520of%2520the%2520neuroprotectant%2520ifenprodil%2520on%2520NMDA%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2002%26volume%3D22%26spage%3D5955%26epage%3D5965%26doi%3D10.1523%2Fjneurosci.22-14-05955.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mony, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kew, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthorpe, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00304.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1111%2Fj.1476-5381.2009.00304.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19594762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=1301-1317&author=L.+Monyauthor=J.+N.+Kewauthor=M.+J.+Gunthorpeauthor=P.+Paoletti&title=Allosteric+modulators+of+NR2B-containing+NMDA+receptors%3A+molecular+mechanisms+and+therapeutic+potential&doi=10.1111%2Fj.1476-5381.2009.00304.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of NR2B-Containing NMDA receptors: Molecular mechanisms and therapeutic potential</span></div><div class="casAuthors">Mony, Laetitia; Kew, James N. C.; Gunthorpe, Martin J.; Paoletti, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1301-1317</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate receptors (NMDARs) are ion channels gated by glutamate, the major excitatory neurotransmitter in the mammalian central nervous system (CNS).  They are widespread in the CNS and are involved in numerous physiol. and pathol. processes including synaptic plasticity, chronic pain and psychosis.  Aberrant NMDAR activity also plays an important role in the neuronal loss assocd. with ischemic insults and major degenerative disorders including Parkinson's and Alzheimer's disease.  Agents that target and alter NMDAR function may, thus, have therapeutic benefit.  Interestingly, NMDARs are endowed with multiple extracellular regulatory sites that recognize ions or small mol. ligands, some of which are likely to regulate receptor function in vivo.  These allosteric sites, which differ from agonist-binding and channel-permeation sites, provide means to modulate, either pos. or neg., NMDAR activity.  The present review focuses on allosteric modulation of NMDARs contg. the NR2B subunit.  Indeed, the NR2B subunit confers a particularly rich pharmacol. with distinct recognition sites for exogenous and endogenous allosteric ligands.  Moreover, NR2B-contg. receptors, compared with other NMDAR subtypes, appear to contribute preferentially to pathol. processes linked to overexcitation of glutamatergic pathways.  The actions of extracellular H+, Mg2+, Zn2+, of polyamines and neurosteroids, and of the synthetic compds. ifenprodil and derivs. ('prodils') are presented.  Particular emphasis is put upon the structural determinants and mol. mechanisms that underlie the effects exerted by these agents.  A better understanding of how NR2B-contg. NMDARs (and NMDARs in general) operate and how they can be modulated should help define new strategies to counteract the deleterious effects of dysregulated NMDAR activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyWhJvTXZ9FLVg90H21EOLACvtfcHk0ljtRxQUVfJpMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu77M&md5=9ca937f24cea113866e9467f298c95ed</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00304.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00304.x%26sid%3Dliteratum%253Aachs%26aulast%3DMony%26aufirst%3DL.%26aulast%3DKew%26aufirst%3DJ.%2BN.%26aulast%3DGunthorpe%26aufirst%3DM.%2BJ.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DAllosteric%2520modulators%2520of%2520NR2B-containing%2520NMDA%2520receptors%253A%2520molecular%2520mechanisms%2520and%2520therapeutic%2520potential%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D1301%26epage%3D1317%26doi%3D10.1111%2Fj.1476-5381.2009.00304.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malchow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falkai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span> <span> </span><span class="NLM_article-title">Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders</span>. <i>Eur. Arch. Psychiatr. Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1007/s00406-013-0399-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1007%2Fs00406-013-0399-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=23455590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BC3svis12lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2013&pages=367-377&author=K.+Hashimotoauthor=B.+Malchowauthor=P.+Falkaiauthor=A.+Schmitt&title=Glutamate+modulators+as+potential+therapeutic+drugs+in+schizophrenia+and+affective+disorders&doi=10.1007%2Fs00406-013-0399-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders</span></div><div class="casAuthors">Hashimoto Kenji; Malchow Berend; Falkai Peter; Schmitt Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe psychiatric disorders such as schizophrenia are related to cognitive and negative symptoms, which often are resistant to current treatment approaches.  The glutamatergic system has been implicated in the pathophysiology of schizophrenia and affective disorders.  A key component is the dysfunction of the glutamatergic N-methyl-D-aspartate (NMDA) receptor.  Substances regulating activation/inhibition of the NMDA receptor have been investigated in schizophrenia and major depression and are promising in therapeutic approaches of negative symptoms, cognition, and mood.  In schizophrenia, add-on treatments with glycine, D-serine, D-alanine, D-cycloserine, D-amino acid oxidase inhibitors, glycine transporter-1 (GlyT-1) inhibitors (e.g., sarcosine, bitopertin) and agonists (e.g., LY2140023) or positive allosteric modulator (e.g., ADX71149) of group II metabotropic glutamate receptors (mGluRs) have been studied.  In major depression, the NMDA receptor antagonists (e.g., ketamine, AZD6765), GluN2B subtype antagonists (e.g., traxoprodil, MK-0657), and partial agonists (e.g., D-cycloserine, GLYX-13) at the glycine site of the NMDA receptor have been proven to be effective in animal studies and first clinical trials.  In addition, clinical studies of mGluR2/3 antagonist BCI-838 (a prodrug of BCI-632 (MGS0039)), mGluR2/3-negative allosteric modulators (NMAs) (e.g., RO499819, RO4432717), and mGluR5 NAMs (e.g., AZD2066, RO4917523) are in progress.  Future investigations should include effects on brain structure and activation to elucidate neural mechanisms underlying efficacy of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7MlQKb0V41QHqQV89nF-2fW6udTcc2eakpPx-WA2LM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svis12lsg%253D%253D&md5=7048ce47b308c5f34a71fb3f6f0f2277</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00406-013-0399-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-013-0399-y%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DMalchow%26aufirst%3DB.%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DSchmitt%26aufirst%3DA.%26atitle%3DGlutamate%2520modulators%2520as%2520potential%2520therapeutic%2520drugs%2520in%2520schizophrenia%2520and%2520affective%2520disorders%26jtitle%3DEur.%2520Arch.%2520Psychiatr.%2520Clin.%2520Neurosci.%26date%3D2013%26volume%3D263%26spage%3D367%26epage%3D377%26doi%3D10.1007%2Fs00406-013-0399-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preskorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolluri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, J. W.</span></span> <span> </span><span class="NLM_article-title">An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1097/jcp.0b013e31818a6cea</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1097%2FJCP.0b013e31818a6cea" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19011431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=631-637&author=S.+H.+Preskornauthor=B.+Bakerauthor=S.+Kolluriauthor=F.+S.+Mennitiauthor=M.+Kramsauthor=J.+W.+Landen&title=An+innovative+design+to+establish+proof+of+concept+of+the+antidepressant+effects+of+the+NR2B+subunit+selective+N-methyl-D-aspartate+antagonist%2C+CP-101%2C606%2C+in+patients+with+treatment-refractory+major+depressive+disorder&doi=10.1097%2Fjcp.0b013e31818a6cea"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder</span></div><div class="casAuthors">Preskorn, Sheldon H.; Baker, Bryan; Kolluri, Sheela; Menniti, Frank S.; Krams, Michael; Landen, Jaren W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This randomized, placebo-controlled, double-blind study was the first to evaluate the antidepressant efficacy, safety, and tolerability of an NR2B subunit-selective N-methyl-D-aspartate receptor antagonist, CP-101,606.  Subjects had major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and a history of treatment refractoriness to least 1 adequate trial of a selective serotonin reuptake inhibitor.  The study had 2 treatment periods.  In period 1, subjects first received a 6-wk open-label trial of paroxetine and a single-blind, i.v. placebo infusion.  Period 1 nonresponders (n = 30) then received a randomized double-blind single infusion of CP-101,606 or placebo plus continued treatment with paroxetine for up to an addnl. 4 wk (period 2).  Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale.  On the prespecified main outcome measure (change from baseline in the Montgomery-Åsberg Depression Rating Scale total score at day 5 of period 2), CP-101,606 produced a greater decrease than did placebo (mean difference, 8.6; 80% confidence interval, -12.3 to -4.5) (P < 0.10).  Hamilton Depression Rating Scale response rate was 60% for CP-101,606 vs. 20% for placebo.  Seventy-eight percent of CP-101,606-treated responders maintained response status for at least 1 wk after the infusion.  CP-101,606 was safe, generally well tolerated, and capable of producing an antidepressant response without also producing a dissociative reaction.  Antagonism of the NR2B subtype of the N-methyl-D-aspartate receptor may be a fruitful target for the development of a new antidepressant with more robust effects and a faster onset compared with those currently available and capable of working when existing antidepressants do not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZntM4kxsekrVg90H21EOLACvtfcHk0ljtRxQUVfJpMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqu7zE&md5=78d4ce7302daed034db7cb802a36a673</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e31818a6cea&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e31818a6cea%26sid%3Dliteratum%253Aachs%26aulast%3DPreskorn%26aufirst%3DS.%2BH.%26aulast%3DBaker%26aufirst%3DB.%26aulast%3DKolluri%26aufirst%3DS.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DKrams%26aufirst%3DM.%26aulast%3DLanden%26aufirst%3DJ.%2BW.%26atitle%3DAn%2520innovative%2520design%2520to%2520establish%2520proof%2520of%2520concept%2520of%2520the%2520antidepressant%2520effects%2520of%2520the%2520NR2B%2520subunit%2520selective%2520N-methyl-D-aspartate%2520antagonist%252C%2520CP-101%252C606%252C%2520in%2520patients%2520with%2520treatment-refractory%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2008%26volume%3D28%26spage%3D631%26epage%3D637%26doi%3D10.1097%2Fjcp.0b013e31818a6cea" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C. B.</span></span> <span> </span><span class="NLM_article-title">(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3138</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1021/jm00016a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00016a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2MXmvF2htLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3138-3145&author=B.+L.+Chenardauthor=J.+Bordnerauthor=T.+W.+Butlerauthor=L.+K.+Chambersauthor=M.+A.+Collinsauthor=D.+L.+De+Costaauthor=M.+F.+Ducatauthor=M.+L.+Dumontauthor=C.+B.+Fox&title=%281S%2C2S%29-1-%284-Hydroxyphenyl%29-2-%284-hydroxy-4-phenylpiperidino%29-1-propanol%3A+a+potent+new+neuroprotectant+which+blocks+N-methyl-D-aspartate+responses&doi=10.1021%2Fjm00016a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses</span></div><div class="casAuthors">Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins, M. A.; De Costa, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3138-45</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(+)-4-Hydroxy-α-(4-hydroxyphenyl)-β-methyl-4-phenyl-1-piperidinethanol (CP-101,606) was identified as a potent and selective N-methyl-D-aspartate (NMDA) antagonist through a structure activity relation (SAR) program based on ifenprodil, a known antihypertensive agent with NMDA antagonist activity.  Sites on the threo-ifenprodil skeleton explored in this report include the pendent Me group (H, Me, and Et nearly equipotent; Pr much weaker), the spacer group connecting the C-4 Ph group to the piperidine ring (an alternating potency pattern with 0 and 2 carbon atoms yielding the greatest potency), and simple Ph substitution (little effect).  While potent NMDA antagonists were obtained with a two atom spacer, this arrangement also increased α1 adrenergic affinity.  Introduction of a hydroxyl group into the C-4 position on the piperidine ring resulted in substantial redn. in α1 adrenergic affinity.  The combination of these observations was instrumental in the discovery of CP-101,606 .  This compd. potently protects cultured hippocampal neurons from glutamate toxicity (IC50 = 10 nM) while possessing little of the undesired α1 adrenergic affinity (IC50 ∼ 20 μM) of ifenprodil.  Furthermore, CP-101,606 appears to lack the psychomotor stimulant effects of nonselective competitive and channel-blocking NMDA antagonists.  Thus, CP-101,606 shows great promise as a neuroprotective agent and may lack the side effects of compds. currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHHnh0i9mUbVg90H21EOLACvtfcHk0lhBCOf_ah5dUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvF2htLs%253D&md5=a926516f42014a514e771e7a4f78501a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm00016a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00016a017%26sid%3Dliteratum%253Aachs%26aulast%3DChenard%26aufirst%3DB.%2BL.%26aulast%3DBordner%26aufirst%3DJ.%26aulast%3DButler%26aufirst%3DT.%2BW.%26aulast%3DChambers%26aufirst%3DL.%2BK.%26aulast%3DCollins%26aufirst%3DM.%2BA.%26aulast%3DDe%2BCosta%26aufirst%3DD.%2BL.%26aulast%3DDucat%26aufirst%3DM.%2BF.%26aulast%3DDumont%26aufirst%3DM.%2BL.%26aulast%3DFox%26aufirst%3DC.%2BB.%26atitle%3D%25281S%252C2S%2529-1-%25284-Hydroxyphenyl%2529-2-%25284-hydroxy-4-phenylpiperidino%2529-1-propanol%253A%2520a%2520potent%2520new%2520neuroprotectant%2520which%2520blocks%2520N-methyl-D-aspartate%2520responses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3138%26epage%3D3145%26doi%3D10.1021%2Fjm00016a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F.</span></span> <span> </span><span class="NLM_article-title">CP-101,606, a potent neuroprotectant selective for forebrain neurons</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(97)10092-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS0014-2999%2897%2910092-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=9274969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2sXksFeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=1997&pages=117-126&author=F.+Mennitiauthor=B.+Chenardauthor=M.+Collinsauthor=M.+Ducatauthor=I.+Shalabyauthor=F.+White&title=CP-101%2C606%2C+a+potent+neuroprotectant+selective+for+forebrain+neurons&doi=10.1016%2Fs0014-2999%2897%2910092-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CP-101,606, a potent neuroprotectant selective for forebrain neurons</span></div><div class="casAuthors">Menniti, Frank; Chenard, Bertrand; Collins, Mary; Ducat, Mary; Shalaby, Ismail; White, Frost</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">117-126</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The neuroprotective activity of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606), an N-methyl-D-aspartate (NMDA) receptor antagonist structurally similar to ((±)-(R*,S*)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidineethanol) (ifenprodil), was investigated in neurons in primary culture.  CP-101,606 potently and efficaciously protected hippocampal neurons from glutamate toxicity but was >900-fold less effective for cerebellar granule neurons.  The neuroprotective activity in the hippocampal neurons is mediated through a high affinity binding site distinct from the agonist and thienylcyclohexylpiperidine (TCP) binding sites of the NMDA receptor.  Autoradiog. indicates the CP-101,606 binding site is localized in forebrain, most notably in hippocampus and the outer layers of cortex.  The functional selectivity for hippocampal neurons, forebrain localization of binding sites, and structural relation to ifenprodil suggest that CP-101,606 is an NMDA antagonist highly selective for NR2B subunit contg. receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8dsxm9cYtFLVg90H21EOLACvtfcHk0lhBCOf_ah5dUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFeitLs%253D&md5=b982493b88c4f85b88d86242706452e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2910092-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252910092-9%26sid%3Dliteratum%253Aachs%26aulast%3DMenniti%26aufirst%3DF.%26aulast%3DChenard%26aufirst%3DB.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDucat%26aufirst%3DM.%26aulast%3DShalaby%26aufirst%3DI.%26aulast%3DWhite%26aufirst%3DF.%26atitle%3DCP-101%252C606%252C%2520a%2520potent%2520neuroprotectant%2520selective%2520for%2520forebrain%2520neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D331%26spage%3D117%26epage%3D126%26doi%3D10.1016%2Fs0014-2999%2897%2910092-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmack, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span> <span> </span><span class="NLM_article-title">A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>890</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07979.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1111%2Fj.1749-6632.1999.tb07979.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10668412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=890&publication_year=1999&pages=42-50&author=R.+E.+Merchantauthor=M.+R.+Bullockauthor=C.+A.+Carmackauthor=A.+K.+Shahauthor=K.+D.+Wilnerauthor=G.+Koauthor=S.+A.+Williams&title=A+double-blind%2C+placebo-controlled+study+of+the+safety%2C+tolerability+and+pharmacokinetics+of+CP-101%2C606+in+patients+with+a+mild+or+moderate+traumatic+brain+injury&doi=10.1111%2Fj.1749-6632.1999.tb07979.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury</span></div><div class="casAuthors">Merchant, Randall E.; Bullock, M. Ross; Carmack, Cynthia A.; Shah, Ajit K.; Wilner, Keith D.; Ko, Grant; Williams, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">890</span>
        (<span class="NLM_cas:issue">Neuroprotective Agents</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">CP-101,606 is a postsynaptic antagonist of the glutamate-mediated NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor.  When administered i.v. (i.v.) at the time of injury, CP-101,606 is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia.  Minimal adverse effects have been obsd. in normal human volunteers given i.v. doses of up to 3 mg/kg/h for 72 h.  The objective of the present clin. trial was to assess the safety, pharmacokinetics, and tolerability of CP-101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9-14) or hemorrhagic stroke.  Patients began receiving treatment within 12 h of brain injury.  A total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double-blind fashion to receive CP-101,606 or placebo (4 drug:1 placebo).  Drug/placebo was administered by i.v. infusion (0.75 mg/kg/h) for 2 h and then stopped (n = 25) or continued for 22 h (n = 4) or 70 h (n = 24) at a rate of 0.37 mg/kg/h.  Mean plasma drug concns. were well above the predicted therapeutic concn. of 200 ng/mL within two hours of initiating treatment and were sustained as long as drug was infused.  All the patients tolerated their drug/placebo treatment, and there were no clin. significant cardiovascular or hematol. abnormalities in either group.  A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo.  Modified Kurtzke Scoring also showed a similar pattern of improvement irresp. of type of head injury or drug/placebo treatment.  This study suggests that CP-101,606, infused for up to 72 h has no psychotropic effects and is well-tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwfoQV3IRudbVg90H21EOLACvtfcHk0lh35ORa5Hlu6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVGjsg%253D%253D&md5=a09833feed7a3bc99964a39b725025ca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07979.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07979.x%26sid%3Dliteratum%253Aachs%26aulast%3DMerchant%26aufirst%3DR.%2BE.%26aulast%3DBullock%26aufirst%3DM.%2BR.%26aulast%3DCarmack%26aufirst%3DC.%2BA.%26aulast%3DShah%26aufirst%3DA.%2BK.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKo%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520the%2520safety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520CP-101%252C606%2520in%2520patients%2520with%2520a%2520mild%2520or%2520moderate%2520traumatic%2520brain%2520injury%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D890%26spage%3D42%26epage%3D50%26doi%3D10.1111%2Fj.1749-6632.1999.tb07979.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span>; <span class="NLM_string-name">Claiborne, C. F.</span>; <span class="NLM_string-name">Claremon, D. A.</span>; <span class="NLM_string-name">McCauley, J. A.</span></span> <span> </span><span class="NLM_article-title">Heteroarylamino-Substituted 3-Fluoro-piperidines as NMDA/NR2B Antagonists, and their Preparation, Pharmaceutical Compositions, and Methods of Use</span>. <span class="NLM_patent">WO 2004108705 A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+J.+Liverton&author=C.+F.+Claiborne&author=D.+A.+Claremon&author=J.+A.+McCauley&title=Heteroarylamino-Substituted+3-Fluoro-piperidines+as+NMDA%2FNR2B+Antagonists%2C+and+their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DHeteroarylamino-Substituted%25203-Fluoro-piperidines%2520as%2520NMDA%252FNR2B%2520Antagonists%252C%2520and%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Methods%2520of%2520Use%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Addy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hreniuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinnah, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitz, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetrud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoch, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesdiener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span> <span> </span><span class="NLM_article-title">Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1177/0091270009336735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1177%2F0091270009336735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19491335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Smsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=856-864&author=C.+Addyauthor=C.+Assaidauthor=D.+Hreniukauthor=M.+Strohauthor=Y.+Xuauthor=W.+J.+Herringauthor=A.+Ellenbogenauthor=H.+A.+Jinnahauthor=L.+Kirbyauthor=M.+T.+Leibowitzauthor=R.+M.+Stewartauthor=D.+Tarsyauthor=J.+Tetrudauthor=S.+A.+Stochauthor=K.+Gottesdienerauthor=J.+Wagner&title=Single-dose+administration+of+MK-0657%2C+an+NR2B-selective+NMDA+antagonist%2C+does+not+result+in+clinically+meaningful+improvement+in+motor+function+in+patients+with+moderate+Parkinson%E2%80%99s+disease&doi=10.1177%2F0091270009336735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease</span></div><div class="casAuthors">Addy, Carol; Assaid, Chris; Hreniuk, David; Stroh, Mark; Xu, Yang; Herring, W. Joseph; Ellenbogen, Aaron; Jinnah, H. A.; Kirby, Louis; Leibowitz, Mark T.; Stewart, R. Malcolm; Tarsy, Daniel; Tetrud, James; Stoch, S. Aubrey; Gottesdiener, Keith; Wagner, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The glutamatergic system is thought to contribute to the motor disturbances obsd. in Parkinson's disease.  Blockade of glutamatergic activity by a selective antagonist of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor is assocd. with improvement in motor symptoms in a preclin. model of Parkinson's disease.  A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study was conducted in patients with moderate Parkinson's disease to evaluate the pharmacol. activity of MK-0657, an NR2B-selective NMDA receptor antagonist.  Patients (n = 16) received single oral doses of MK-0657 7 mg, carbidopa/levodopa 25/250 mg (LD) as a pos. control, and placebo, after which motor function was serially evaluated by means of the Unified Parkinson's Disease Rating Scale-Motor Examn. (UPDRS-ME).  LD administration resulted in significant improvement in the UPDRS-ME relative to placebo (P = .025), confirming the sensitivity of the test paradigm; however, the UPDRS-ME change following MK-0657 administration showed no improvement compared with placebo (P = .110) despite exceeding the target MK-0657 plasma concn. of 400 nM.  Although the administration of MK-0657 was generally well tolerated, it was assocd. with increases in systolic and diastolic blood pressure relative to placebo.  The results of this study do not support ongoing clin. development of MK-0657 as a novel monotherapy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8Pl1Bga_47Vg90H21EOLACvtfcHk0lh35ORa5Hlu6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Smsbc%253D&md5=809bbc2c5023b6771592313a407008c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270009336735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009336735%26sid%3Dliteratum%253Aachs%26aulast%3DAddy%26aufirst%3DC.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DHreniuk%26aufirst%3DD.%26aulast%3DStroh%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHerring%26aufirst%3DW.%2BJ.%26aulast%3DEllenbogen%26aufirst%3DA.%26aulast%3DJinnah%26aufirst%3DH.%2BA.%26aulast%3DKirby%26aufirst%3DL.%26aulast%3DLeibowitz%26aufirst%3DM.%2BT.%26aulast%3DStewart%26aufirst%3DR.%2BM.%26aulast%3DTarsy%26aufirst%3DD.%26aulast%3DTetrud%26aufirst%3DJ.%26aulast%3DStoch%26aufirst%3DS.%2BA.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%26atitle%3DSingle-dose%2520administration%2520of%2520MK-0657%252C%2520an%2520NR2B-selective%2520NMDA%2520antagonist%252C%2520does%2520not%2520result%2520in%2520clinically%2520meaningful%2520improvement%2520in%2520motor%2520function%2520in%2520patients%2520with%2520moderate%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D856%26epage%3D864%26doi%3D10.1177%2F0091270009336735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGranados, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1097/jcp.0b013e31825d70d6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1097%2FJCP.0b013e31825d70d6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=22722512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=551-557&author=L.+Ibrahimauthor=N.+DiazGranadosauthor=L.+Jolkovskyauthor=N.+Brutscheauthor=D.+A.+Luckenbaughauthor=W.+J.+Herringauthor=W.+Z.+Potterauthor=C.+A.+Zarate&title=A+randomized%2C+placebo-controlled%2C+crossover+pilot+trial+of+the+oral+selective+NR2B+antagonist+MK-0657+in+patients+with+treatment-resistant+major+depressive+disorder&doi=10.1097%2Fjcp.0b013e31825d70d6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder</span></div><div class="casAuthors">Ibrahim, Lobna; Diaz Granados, Nancy; Jolkovsky, Libby; Brutsche, Nancy; Luckenbaugh, David A.; Herring, W. Joseph; Potter, William Z.; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-557</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of novel therapeutics for major depressive disorder (MDD), particularly agents assocd. with rapid antidepressant effects.  Diverse glutamatergic modulators targeting N-methyl-D-aspartate receptors have shown efficacy in MDD, but their assocd. psychotomimetic effects presently preclude their use in larger samples.  This small, randomized, double-blind, placebo-controlled, crossover pilot study evaluated the potential antidepressant efficacy and tolerability of an oral formulation of the selective N-methyl-D-aspartate NR2B antagonist MK-0657 in patients with treatment-resistant MDD (TRD).  The TRD subjects underwent a 1-wk drug-free period and were subsequently randomized to receive either MK-0657 monotherapy (4-8 mg/d) or placebo for 12 days.  Because of recruitment challenges and the discontinuation of the compd.'s development by the manufacturer, only 5 of the planned 21 patients completed both periods of the crossover administration of MK-0657 and placebo.  Significant antidepressant effects were obsd. as early as day 5 in patients receiving MK-0657 compared with those receiving placebo, as assessed by the Hamilton Depression Rating Scale and Beck Depression Inventory; however, no improvement was noted when symptoms were assessed with the Montgomery-Asberg Depression Rating Scale, the primary efficacy measure.  No serious or dissociative adverse effects were obsd. in patients receiving this oral formulation of MK-0657.  Despite the small sample size, this pilot study suggests that an oral formulation of the NR2B antagonist MK-0657 may have antidepressant properties in TRD patients.  Further studies with larger sample sizes are necessary to confirm these preliminary findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorGhDGnv54AbVg90H21EOLACvtfcHk0lhJl-DjEGCzow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjtrjO&md5=23417cfe7941393c1792fd61df8f373f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e31825d70d6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e31825d70d6%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DL.%26aulast%3DDiazGranados%26aufirst%3DN.%26aulast%3DJolkovsky%26aufirst%3DL.%26aulast%3DBrutsche%26aufirst%3DN.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DHerring%26aufirst%3DW.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520crossover%2520pilot%2520trial%2520of%2520the%2520oral%2520selective%2520NR2B%2520antagonist%2520MK-0657%2520in%2520patients%2520with%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2012%26volume%3D32%26spage%3D551%26epage%3D557%26doi%3D10.1097%2Fjcp.0b013e31825d70d6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, B.</span>; <span class="NLM_string-name">Fraser, H.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Marcus, R.</span></span> <span> </span><span class="NLM_article-title">A Randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment</span>.  <i>2015 National Network of Depression Centers Annual Conference, November 15, Ann Arbor, MI, USA</i>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+Paterson&author=H.+Fraser&author=C.+Wang&author=R.+Marcus&title=A+Randomized%2C+double-blind%2C+placebo-controlled%2C+sequential+parallel+study+of+CERC-301+in+the+adjunctive+treatment+of+subjects+with+severe+depression+and+recent+active+suicidal+ideation+despite+antidepressant+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DB.%26atitle%3DA%2520Randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520sequential%2520parallel%2520study%2520of%2520CERC-301%2520in%2520the%2520adjunctive%2520treatment%2520of%2520subjects%2520with%2520severe%2520depression%2520and%2520recent%2520active%2520suicidal%2520ideation%2520despite%2520antidepressant%2520treatment%26jtitle%3D2015%2520National%2520Network%2520of%2520Depression%2520Centers%2520Annual%2520Conference%252C%2520November%252015%252C%2520Ann%2520Arbor%252C%2520MI%252C%2520USA%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Cerecor</span>. <a href="https://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" class="extLink">https://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study</a> (accessed June 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cerecor.+https%3A%2F%2Fir.cerecor.com%2Fpress-releases%2Fdetail%2F30%2Fcerecor-reports-top-line-data-from-cerc-301-phase-2-study+%28accessed+June+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span> <span> </span><span class="NLM_article-title">A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.drudis.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=30447328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=606-615&author=S.+T.+Wilkinsonauthor=G.+Sanacora&title=A+new+generation+of+antidepressants%3A+an+update+on+the+pharmaceutical+pipeline+for+novel+and+rapid-acting+therapeutics+in+mood+disorders+based+on+glutamate%2FGABA+neurotransmitter+systems&doi=10.1016%2Fj.drudis.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems</span></div><div class="casAuthors">Wilkinson, Samuel T.; Sanacora, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">606-615</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mood disorders represent the largest cause of disability worldwide.  The monoaminergic deficiency hypothesis, which has dominated the conceptual framework for researching the pathophysiol. of mood disorders and the development of novel treatment strategies, cannot fully explain the underlying neurobiol. of mood disorders.  Mounting evidence collected over the past two decades suggests the amino acid neurotransmitter systems (glutamate and GABA) serve central roles in the pathophysiol. of mood disorders.  Here, we review progress in the development of compds. that act on these systems as well as their purported mechanisms of action.  We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_UMrNA-mQYrVg90H21EOLACvtfcHk0lhJl-DjEGCzow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymsrfE&md5=46fd4d154103a9e1a6ab408a17f16b02</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DS.%2BT.%26aulast%3DSanacora%26aufirst%3DG.%26atitle%3DA%2520new%2520generation%2520of%2520antidepressants%253A%2520an%2520update%2520on%2520the%2520pharmaceutical%2520pipeline%2520for%2520novel%2520and%2520rapid-acting%2520therapeutics%2520in%2520mood%2520disorders%2520based%2520on%2520glutamate%252FGABA%2520neurotransmitter%2520systems%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D606%26epage%3D615%26doi%3D10.1016%2Fj.drudis.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohar, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushelle, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batley, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahring, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span> <span> </span><span class="NLM_article-title">Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure–Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1915</span>– <span class="NLM_lpage">1926</span>, <span class="refDoi"> DOI: 10.1021/jm0004291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0004291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Sgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1915-1926&author=M.+C.+Schroederauthor=J.+M.+Hambyauthor=C.+J.+C.+Connollyauthor=P.+J.+Groharauthor=R.+T.+Wintersauthor=M.+R.+Barvianauthor=C.+W.+Mooreauthor=S.+L.+Boushelleauthor=S.+M.+Creanauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=G.+H.+Luauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=T.+C.+Majorauthor=R.+L.+Panekauthor=A.+M.+Dohertyauthor=H.+D.+H.+Showalter&title=Soluble+2-Substituted+Aminopyrido%5B2%2C3-d%5Dpyrimidin-7-yl+Ureas.+Structure%E2%80%93Activity+Relationships+against+Selected+Tyrosine+Kinases+and+Exploration+of+in+Vitro+and+in+Vivo+Anticancer+Activity&doi=10.1021%2Fjm0004291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure-Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity</span></div><div class="casAuthors">Schroeder, Mel C.; Hamby, James M.; Connolly, Cleo J. C.; Grohar, Patrick J.; Winters, R. Thomas; Barvian, Mark R.; Moore, Charles W.; Boushelle, Stacey L.; Crean, Sheila M.; Kraker, Alan J.; Driscoll, Denise L.; Vincent, Patrick W.; Elliott, William L.; Lu, Gina H.; Batley, Brian L.; Dahring, Tawny K.; Major, Terry C.; Panek, Robert L.; Doherty, Annette M.; Showalter, H. D. Hollis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1915-1926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a search for medicinal agents to treat proliferative diseases, 2-substituted aminopyrido[2,3-d]pyrimidin-7-ylureas were discovered as a novel class of sol., potent, broadly active tyrosine kinase (TK) inhibitors.  An efficient route was developed that enabled the synthesis of a wide variety of analogs with substitution on several positions of the template.  From the lead structure, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-2-yl]-3-tert.-butylurea , several series of analogs were made that examd. the C-6 aryl substituent, a variety of water solubilizing substituents at the C-2 position, and urea or other acyl functionality at the N-7 position.  Compds. of this series were competitive with ATP and displayed submicromolar to low nanomolar potency against a panel of TKs, including receptor (platelet-derived growth factor, PDGFr; fibroblast growth factor, FGFr;) and non-receptor (c-Src) classes.  Several of the most potent compds. displayed submicromolar inhibition of PDGF-mediated receptor autophosphorylation in rat aortic vascular smooth muscle cells and low micromolar inhibition of cellular growth in five human tumor cell lines.  One of the more thoroughly evaluated members, I, with IC50 values of 0.21 μM (PDGFr), 0.049 μM (bFGFr), and 0.018 μM (c-Src), was evaluated in in vivo studies against a panel of five human tumor xenografts, with known and/or inferred dependence on the EGFr, PDGFr, and c-Src TKs.  I produced a tumor growth delay of 14 days against the Colo-205 colon xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcRg2byGKHbVg90H21EOLACvtfcHk0lhJl-DjEGCzow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Sgtbg%253D&md5=c9ba4118c6610b92bbab7603b9f79067</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0004291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0004291%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DGrohar%26aufirst%3DP.%2BJ.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26aulast%3DBoushelle%26aufirst%3DS.%2BL.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3DSoluble%25202-Substituted%2520Aminopyrido%255B2%252C3-d%255Dpyrimidin-7-yl%2520Ureas.%2520Structure%25E2%2580%2593Activity%2520Relationships%2520against%2520Selected%2520Tyrosine%2520Kinases%2520and%2520Exploration%2520of%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Anticancer%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1915%26epage%3D1926%26doi%3D10.1021%2Fjm0004291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/s1056-8719(00)00107-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=11274893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability&doi=10.1016%2Fs1056-8719%2800%2900107-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski C A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-49</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">There are currently about 10000 drug-like compounds.  These are sparsely, rather than uniformly, distributed through chemistry space.  True diversity does not exist in experimental combinatorial chemistry screening libraries.  Absorption, distribution, metabolism, and excretion (ADME) and chemical reactivity-related toxicity is low, while biological receptor activity is higher dimensional in chemistry space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME experimental screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biological receptor activity precedes or is concurrent with screening for properties related to "drugability." In the future, "drugability" screening may precede biological receptor activity screening.  The level of permeability or solubility needed for oral absorption is related to potency.  The relative importance of poor solubility and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clinical candidates leads to time-dependent higher molecular weight, higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher molecular weight, unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aqueous solubility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTa_EeosoOnpOLfW6udTcc2eamTOJIQxGw_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D&md5=aeb705afe1eccaceaf441c7a19f13ecc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2000%26volume%3D44%26spage%3D235%26epage%3D249%26doi%3D10.1016%2Fs1056-8719%2800%2900107-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoellerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">1<i>H</i>-Pyrrolo[3,2-<i>b</i>]pyridine GluN2B-selective negative allosteric modulators</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=261-266&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=J.+L.+Wallauthor=J.+C.+Rechauthor=J.+Schoellermanauthor=B.+Lordauthor=K.+J.+Coeauthor=N.+I.+Carruthersauthor=L.+Nguyenauthor=X.+Jiangauthor=T.+Koudriakovaauthor=B.+Balanaauthor=M.+A.+Letavic&title=1H-Pyrrolo%5B3%2C2-b%5Dpyridine+GluN2B-selective+negative+allosteric+modulators&doi=10.1021%2Facsmedchemlett.8b00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Wall, Jessica L.; Rech, Jason C.; Schoellerman, Jeff; Lord, Brian; Coe, Kevin J.; Carruthers, Nicholas I.; Nguyen, Leslie; Jiang, Xiaohui; Koudriakova, Tatiana; Balana, Bartosz; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-266</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we disclose a series of selective GluN2B neg. allosteric modulators contg. a 1H-pyrrolo[3,2-b]pyridine core.  Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P 450 inhibition and hERG channel binding.  The series was also optimized to reduce metabolic turnover in human and rat.  Compds. 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance.  They were assessed in vivo to det. their target engagement.  All four compds. achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat.  Compd. 9 receptor occupancy was measured in a dose-response expt., and its ED50 was found to be 2.0 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7WstLp_w3rVg90H21EOLACvtfcHk0lhXZlcP1Kv3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCnsA%253D%253D&md5=6f0d5a3297578f89d3101fea650174c8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00542%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DWall%26aufirst%3DJ.%2BL.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSchoellerman%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DBalana%26aufirst%3DB.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3D1H-Pyrrolo%255B3%252C2-b%255Dpyridine%2520GluN2B-selective%2520negative%2520allosteric%2520modulators%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D261%26epage%3D266%26doi%3D10.1021%2Facsmedchemlett.8b00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleichman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessain, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balice-Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. R.</span></span> <span> </span><span class="NLM_article-title">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/s1474-4422(08)70224-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS1474-4422%2808%2970224-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=18851928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCrsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1091-1098&author=J.+Dalmauauthor=A.+J.+Gleichmanauthor=E.+G.+Hughesauthor=J.+E.+Rossiauthor=X.+Pengauthor=M.+Laiauthor=S.+K.+Dessainauthor=M.+R.+Rosenfeldauthor=R.+Balice-Gordonauthor=D.+R.+Lynch&title=Anti-NMDA-receptor+encephalitis%3A+case+series+and+analysis+of+the+effects+of+antibodies&doi=10.1016%2Fs1474-4422%2808%2970224-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</span></div><div class="casAuthors">Dalmau, Josep; Gleichman, Amy J.; Hughes, Ethan G.; Rossi, Jeffrey E.; Peng, Xiaoyu; Lai, Meizan; Dessain, Scott K.; Rosenfeld, Myrna R.; Balice-Gordon, Rita; Lynch, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1098</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A severe form of encephalitis assocd. with antibodies against NR1-NR2 heteromers of the NMDA receptor was recently identified.  We aimed to analyze the clin. and immunol. features of patients with the disorder and examine the effects of antibodies against NMDA receptors in neuronal cultures.  We describe the clin. characteristics of 100 patients with encephalitis and NR1-NR2 antibodies.  HEK293 cells ectopically expressing single or assembled NR1-NR2 subunits were used to det. the epitope targeted by the antibodies.  Antibody titers were measured with ELISA.  The effect of antibodies on neuronal cultures was detd. by quant. anal. of NMDA-receptor clusters.  Median age of patients was 23 years (range 5-76 years); 91 were women.  All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased consciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.  58 (59%) Of 98 patients for whom results of oncol. assessments were available had tumors, most commonly ovarian teratoma.  Patients who received early tumor treatment (usually with immunotherapy) had better outcome (p=0.004) and fewer neurol. relapses (p=0.009) than the rest of the patients.  Seventy-five patients recovered or had mild deficits and 25 had severe deficits or died.  Improvement was assocd. with a decrease of serum antibody titers.  The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit.  Patients' antibodies decreased the nos. of cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect that could be reversed by antibody removal.  A well-defined set of clin. characteristics are assocd. with anti-NMDA-receptor encephalitis.  The pathogenesis of the disorder seems to be mediated by antibodies.  Funding National Institutes for Health, University of Pennsylvania Institute for Translational Medicine, Lankenau Institute for Medical Research, Foederer Foundation of the Children's Hospital of Philadelphia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvbKVlmZeRbVg90H21EOLACvtfcHk0lhXZlcP1Kv3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCrsLrF&md5=cfa7bfdcd2c41b075c7f473ea559d10b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2808%2970224-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252808%252970224-2%26sid%3Dliteratum%253Aachs%26aulast%3DDalmau%26aufirst%3DJ.%26aulast%3DGleichman%26aufirst%3DA.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BG.%26aulast%3DRossi%26aufirst%3DJ.%2BE.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DDessain%26aufirst%3DS.%2BK.%26aulast%3DRosenfeld%26aufirst%3DM.%2BR.%26aulast%3DBalice-Gordon%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DD.%2BR.%26atitle%3DAnti-NMDA-receptor%2520encephalitis%253A%2520case%2520series%2520and%2520analysis%2520of%2520the%2520effects%2520of%2520antibodies%26jtitle%3DLancet%2520Neurol.%26date%3D2008%26volume%3D7%26spage%3D1091%26epage%3D1098%26doi%3D10.1016%2Fs1474-4422%2808%2970224-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGiorgio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinov, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpe, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, B.</span></span> <span> </span><span class="NLM_article-title">A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.1038/nm1101-1189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnm1101-1189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=11689882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlKltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1189-1193&author=L.+A.+DeGiorgioauthor=K.+N.+Konstantinovauthor=S.+C.+Leeauthor=J.+A.+Hardinauthor=B.+T.+Volpeauthor=B.+Diamond&title=A+subset+of+lupus+anti-DNA+antibodies+cross-reacts+with+the+NR2+glutamate+receptor+in+systemic+lupus+erythematosus&doi=10.1038%2Fnm1101-1189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus</span></div><div class="casAuthors">DeGiorgio, Lorraine A.; Konstantinov, Konstantin N.; Lee, Sunhee C.; Hardin, John A.; Volpe, Bruce T.; Diamond, Betty</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1189-1193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">In systemic lupus erythematosus, antibodies against double-stranded DNA are a major contributor to renal disease.  The authors have previously demonstrated that the pentapeptide Asp/Glu-Trp-Asp/Glu-Tyr-Ser/Gly is a mol. mimic of double-stranded DNA.  This sequence is also present in the extracellular domain of murine and human NMDA (N-methyl-D-aspartate) receptor subunits NR2a and NR2b.  Here the authors show that the NR2 receptor is recognized by both murine and human anti-DNA antibodies.  Moreover, anti-DNA antibodies with this cross-reactivity mediate apoptotic death of neurons in vivo and in vitro.  Finally, the authors show that the cerebrospinal fluid of a patient with systemic lupus erythematosus contains these antibodies and also mediates neuronal death via an apoptotic pathway.  These observations indicate that lupus antibodies cross-react with DNA and NMDA receptors, gain access to cerebrospinal fluid and may mediate non-thrombotic and non-vasculitic abnormalities of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzOTioMlbqrVg90H21EOLACvtfcHk0ljlSgtOK9jGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlKltLw%253D&md5=1ed3326b45ef6d54febbd41123839c77</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm1101-1189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1101-1189%26sid%3Dliteratum%253Aachs%26aulast%3DDeGiorgio%26aufirst%3DL.%2BA.%26aulast%3DKonstantinov%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DHardin%26aufirst%3DJ.%2BA.%26aulast%3DVolpe%26aufirst%3DB.%2BT.%26aulast%3DDiamond%26aufirst%3DB.%26atitle%3DA%2520subset%2520of%2520lupus%2520anti-DNA%2520antibodies%2520cross-reacts%2520with%2520the%2520NR2%2520glutamate%2520receptor%2520in%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D1189%26epage%3D1193%26doi%3D10.1038%2Fnm1101-1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, G. E.</span></span> <span> </span><span class="NLM_article-title">Ultimate Translation: Developing Therapeutics Targeting on N-Methyl-D-Aspartate Receptor</span>. In  <i>Neuropsychopharmacology: A Tribute to Joseph T. Coyle</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarcz, R.</span>, <span class="NLM_string-name">Coyle, J. T.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">309</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=257-309&author=G.+E.+Tsaiauthor=R.+Schwarcz&author=J.+T.+Coyle&title=Neuropsychopharmacology%3A+A+Tribute+to+Joseph+T.+Coyle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DG.%2BE.%26atitle%3DUltimate%2520Translation%253A%2520Developing%2520Therapeutics%2520Targeting%2520on%2520N-Methyl-D-Aspartate%2520Receptor%26btitle%3DNeuropsychopharmacology%253A%2520A%2520Tribute%2520to%2520Joseph%2520T.%2520Coyle%26aulast%3DSchwarcz%26aufirst%3DR.%26pub%3DAcademic%2520Press%26date%3D2016%26spage%3D257%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M. F.</span></span> <span> </span><span class="NLM_article-title">Bidirectional synaptic plasticity: from theory to reality</span>. <i>Philos. Trans. R. Soc. London, Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1098/rstb.2002.1255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1098%2Frstb.2002.1255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=12740110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD3s3hvFCrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2003&pages=649-655&author=M.+F.+Bear&title=Bidirectional+synaptic+plasticity%3A+from+theory+to+reality&doi=10.1098%2Frstb.2002.1255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bidirectional synaptic plasticity: from theory to reality</span></div><div class="casAuthors">Bear Mark F</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical transactions of the Royal Society of London. Series B, Biological sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1432</span>),
    <span class="NLM_cas:pages">649-55</span>
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    </div><div class="casAbstract">Theories of receptive field plasticity and information storage make specific assumptions for how synapses are modified.  I give a personal account of how testing the validity of these assumptions eventually led to a detailed understanding of long-term depression and metaplasticity in hippocampal area CA1 and the visual cortex.  The knowledge of these molecular mechanisms now promises to reveal when and how sensory experience modifies synapses in the cerebral cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRumjSaqwyW3g5nADWVYHg1fW6udTcc2eam2UdQWA2i3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s3hvFCrtQ%253D%253D&md5=8411a21b3c5337af6240feae0584024b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1098%2Frstb.2002.1255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2002.1255%26sid%3Dliteratum%253Aachs%26aulast%3DBear%26aufirst%3DM.%2BF.%26atitle%3DBidirectional%2520synaptic%2520plasticity%253A%2520from%2520theory%2520to%2520reality%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D2003%26volume%3D358%26spage%3D649%26epage%3D655%26doi%3D10.1098%2Frstb.2002.1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M. F.</span></span> <span> </span><span class="NLM_article-title">Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4363</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1073/pnas.89.10.4363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1073%2Fpnas.89.10.4363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1350090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK38XktVWlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=4363-4367&author=S.+M.+Dudekauthor=M.+F.+Bear&title=Homosynaptic+long-term+depression+in+area+CA1+of+hippocampus+and+effects+of+N-methyl-D-aspartate+receptor+blockade&doi=10.1073%2Fpnas.89.10.4363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade</span></div><div class="casAuthors">Dudek, Serena M.; Bear, Mark F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4363-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The authors tested a theor. prediction that patterns of excitatory input activity that consistently fail to activate target neurons sufficiently to induce synaptic potentiation will instead cause a specific synaptic depression.  To realize this situation exptl., the Schaffer collateral projection to area CA1 in rat hippocampal slices was stimulated elec. at frequencies ranging from 0.5 to 50 Hz.  Nine hundred pulses at 1-3 Hz consistently yielded a depression of the CA1 population excitatory postsynaptic potential that persisted without signs of recovery for >1 h after cessation of the conditioning stimulation.  This long-term depression was specific to the conditioned input, ruling out generalized changes in postsynaptic responsiveness or excitability.  Three lines of evidence suggest that this effect is accounted for by a modification of synaptic effectiveness rather than damage to or fatigue of the stimulated inputs.  First, the effect was dependent on the stimulation frequency; 900 pulses at 10 Hz caused no lasting change, and at 50 Hz a synaptic potentiation was usually obsd.  Second, the depressed synapses continued to support long-term potentiation in response to high-frequency tetanus.  Third, the effect of conditioning stimulation could be prevented by application of N-methyl-D-aspartate (NMDA) receptor antagonists.  Thus, the data suggest that synaptic depression can be triggered by prolonged NMDA receptor activation that is below the threshold for inducing synaptic potentiation.  It is proposed that this mechanism is important for the modifications of hippocampal response properties that underlie some forms of learning and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7uSKrWqiALVg90H21EOLACvtfcHk0ljlSgtOK9jGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVWlsb0%253D&md5=2bcad070dd9774fc1005e4e6e5ff322a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.10.4363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.10.4363%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DS.%2BM.%26aulast%3DBear%26aufirst%3DM.%2BF.%26atitle%3DHomosynaptic%2520long-term%2520depression%2520in%2520area%2520CA1%2520of%2520hippocampus%2520and%2520effects%2520of%2520N-methyl-D-aspartate%2520receptor%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1992%26volume%3D89%26spage%3D4363%26epage%3D4367%26doi%3D10.1073%2Fpnas.89.10.4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/nm.4050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnm.4050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=26937618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=238-249&author=R.+S.+Dumanauthor=G.+K.+Aghajanianauthor=G.+Sanacoraauthor=J.+H.+Krystal&title=Synaptic+plasticity+and+depression%3A+New+insights+from+stress+and+rapid-acting+antidepressants&doi=10.1038%2Fnm.4050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants</span></div><div class="casAuthors">Duman, Ronald S.; Aghajanian, George K.; Sanacora, Gerard; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Depression is a common, devastating illness.  Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated.  However, new insights into the neurobiol. of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants.  Environmental events and other risk factors contribute to depression through converging mol. and cellular mechanisms that disrupt neuronal function and morphol., resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function.  Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants.  Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfcYim7-a4MrVg90H21EOLACvtfcHk0liJJGetLHY0FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGqsbc%253D&md5=5556f3a359ef7ec7d1f2d43fdac8d16d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnm.4050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4050%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DSynaptic%2520plasticity%2520and%2520depression%253A%2520New%2520insights%2520from%2520stress%2520and%2520rapid-acting%2520antidepressants%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D238%26epage%3D249%26doi%3D10.1038%2Fnm.4050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceusters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-6,7-dihydro-4<i>H</i>-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4559-4572&author=M.+A.+Letavicauthor=B.+M.+Savallauthor=B.+D.+Allisonauthor=L.+Aluisioauthor=J.+I.+Andresauthor=M.+De+Angelisauthor=H.+Aoauthor=D.+A.+Beauchampauthor=P.+Bonaventureauthor=S.+Bryantauthor=N.+I.+Carruthersauthor=M.+Ceustersauthor=K.+J.+Coeauthor=C.+A.+Dvorakauthor=I.+C.+Fraserauthor=C.+F.+Gelinauthor=T.+Koudriakovaauthor=J.+Liangauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=M.+A.+Otienoauthor=F.+Schoetensauthor=D.+M.+Swansonauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=A.+Bhattacharya&title=4-Methyl-6%2C7-dihydro-4H-triazolo%5B4%2C5-c%5Dpyridine-based+P2X7+receptor+antagonists%3A+optimization+of+pharmacokinetic+properties+leading+to+the+identification+of+a+clinical+candidate&doi=10.1021%2Facs.jmedchem.7b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span></div><div class="casAuthors">Letavic, Michael A.; Savall, Brad M.; Allison, Brett D.; Aluisio, Leah; Andres, Jose Ignacio; De Angelis, Meri; Ao, Hong; Beauchamp, Derek A.; Bonaventure, Pascal; Bryant, Stewart; Carruthers, Nicholas I.; Ceusters, Marc; Coe, Kevin J.; Dvorak, Curt A.; Fraser, Ian C.; Gelin, Christine F.; Koudriakova, Tatiana; Liang, Jimmy; Lord, Brian; Lovenberg, Timothy W.; Otieno, Monicah A.; Schoetens, Freddy; Swanson, Devin M.; Wang, Qi; Wickenden, Alan D.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4559-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of novel 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are potent and selective brain penetrant P2X7 antagonists are described.  Optimization efforts based on previously disclosed unsubstituted 6,7-dihydro-4H-triazolo[4,5-c]pyridines, Me substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazines, and several other series lead to the identification of a series of 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are selective P2X7 antagonists with potency at the rodent and human P2X7 ion channels.  These novel P2X7 antagonists have suitable physicochem. properties, and several analogs have an excellent pharmacokinetic profile, good partitioning into the CNS and show robust in vivo target engagement after oral dosing.  Improvements in metabolic stability led to the identification of JNJ-54175446 (I) as a candidate for clin. development.  The drug discovery efforts and strategies that resulted in the identification of the clin. candidate are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkx8e5Sq5aYbVg90H21EOLACvtfcHk0liJJGetLHY0FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D&md5=5b5465d8f64d527da6647997efe34aee</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00408%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DAllison%26aufirst%3DB.%2BD.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DCeusters%26aufirst%3DM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3D4-Methyl-6%252C7-dihydro-4H-triazolo%255B4%252C5-c%255Dpyridine-based%2520P2X7%2520receptor%2520antagonists%253A%2520optimization%2520of%2520pharmacokinetic%2520properties%2520leading%2520to%2520the%2520identification%2520of%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4559%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.7b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8535</span>– <span class="NLM_lpage">8548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8535-8548&author=D.+M.+Swansonauthor=B.+M.+Savallauthor=K.+J.+Coeauthor=F.+Schoetensauthor=T.+Koudriakovaauthor=J.+Skaptasonauthor=J.+Wallauthor=J.+Rechauthor=X.+Dengauthor=M.+De+Angelisauthor=A.+Eversonauthor=B.+Lordauthor=Q.+Wangauthor=H.+Aoauthor=B.+Scottauthor=K.+Sepassiauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Identification+of+%28R%29-%282-Chloro-3-%28trifluoromethyl%29phenyl%29%281-%285-fluoropyridin-2-yl%29-4-methyl-6%2C7-dihydro-1H-imidazo%5B4%2C5-c%5Dpyridin-5%284H%29-yl%29methanone+%28JNJ+54166060%29%2C+a+Small+Molecule+Antagonist+of+the+P2X7+receptor&doi=10.1021%2Facs.jmedchem.6b00989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor</span></div><div class="casAuthors">Swanson, Devin M.; Savall, Brad M.; Coe, Kevin J.; Schoetens, Freddy; Koudriakova, Tatiana; Skaptason, Judith; Wall, Jessica; Rech, Jason; Deng, Xiahou; De Angelis, Meri; Everson, Anita; Lord, Brian; Wang, Qi; Ao, Hong; Scott, Brian; Sepassi, Kia; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8535-8548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described.  Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded Me substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of JNJ 54166060.  JNJ 54166060 is a potent P2X7 antagonist with an ED50=2.3 mg/kg in rat, high oral bioavailability and low-moderate clearance in pre-clin. species, acceptable safety margins in rat, and a predicted human dose of 120 mg QD.  Addnl., JNJ 54166060 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQfT4dUZEP6bVg90H21EOLACvtfcHk0li0szM14QPtVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr%252FO&md5=a48451477fca4bec1fd13df7d5a22ea8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00989%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DJ.%26aulast%3DRech%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520%2528R%2529-%25282-Chloro-3-%2528trifluoromethyl%2529phenyl%2529%25281-%25285-fluoropyridin-2-yl%2529-4-methyl-6%252C7-dihydro-1H-imidazo%255B4%252C5-c%255Dpyridin-5%25284H%2529-yl%2529methanone%2520%2528JNJ%252054166060%2529%252C%2520a%2520Small%2520Molecule%2520Antagonist%2520of%2520the%2520P2X7%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8535%26epage%3D8548%26doi%3D10.1021%2Facs.jmedchem.6b00989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1<i>H</i>-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=207-223&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=A.+A.+Petersonauthor=C.+F.+Gelinauthor=X.+Dengauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=B.+Lordauthor=I.+Fraserauthor=L.+Aluisioauthor=K.+J.+Coeauthor=B.+Scottauthor=T.+Koudriakovaauthor=F.+Schoetensauthor=K.+Sepassiauthor=D.+J.+Gallacherauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=A+Dipolar+Cycloaddition+Reaction+To+Access+6-Methyl-4%2C5%2C6%2C7-tetrahydro-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-c%5Dpyridines+Enables+the+Discovery+Synthesis+and+Preclinical+Profiling+of+a+P2X7+Antagonist+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b01279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Peterson, Alexander A.; Gelin, Christine F.; Deng, Xiaohu; Dvorak, Curt A.; Carruthers, Nicholas I.; Lord, Brian; Fraser, Ian; Aluisio, Leah; Coe, Kevin J.; Scott, Brian; Koudriakova, Tatiana; Schoetens, Freddy; Sepassi, Kia; Gallacher, David J.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A single pot dipolar cycloaddn. reaction/Cope elimination sequence was developed to access novel 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridine P2X7 antagonists that contain a synthetically challenging chiral center.  The structure-activity relationships of the new compds. are described.  Two of these compds., (S)-(2-fluoro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (I) and (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (II), were found to have robust P2X7 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg, resp.  Compd. II had notable soly. compared to I and showed good tolerability in preclin. species.  Compd. II was chosen as a clin. candidate for advancement into phase I clin. trials to assess safety and tolerability in healthy human subjects prior to the initiation of proof of concept studies for the treatment of mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0Y2r79JhbbVg90H21EOLACvtfcHk0li0szM14QPtVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN&md5=a97dfbda53f249894c7e4ef409601c95</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01279%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BA.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DA%2520Dipolar%2520Cycloaddition%2520Reaction%2520To%2520Access%25206-Methyl-4%252C5%252C6%252C7-tetrahydro-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-c%255Dpyridines%2520Enables%2520the%2520Discovery%2520Synthesis%2520and%2520Preclinical%2520Profiling%2520of%2520a%2520P2X7%2520Antagonist%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D207%26epage%3D223%26doi%3D10.1021%2Facs.jmedchem.7b01279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiao-Xue  Han</span>, <span class="hlFld-ContribAuthor ">Yu  Lu</span>, <span class="hlFld-ContribAuthor ">Hui-Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiong-Wei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Highly diastereoselective synthesis of trifluoromethyl containing spiro[pyrrolidin-3,2′-oxindoles] from N-2,2,2-trifluoroethylsubstituted isatin imines and β,γ-unsaturated α-keto esters. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>87 </em>, 132112. <a href="https://doi.org/10.1016/j.tet.2021.132112" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132112%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DHighly%252Bdiastereoselective%252Bsynthesis%252Bof%252Btrifluoromethyl%252Bcontaining%252Bspiro%25255Bpyrrolidin-3%25252C2%2525E2%252580%2525B2-oxindoles%25255D%252Bfrom%252BN-2%25252C2%25252C2-trifluoroethylsubstituted%252Bisatin%252Bimines%252Band%252B%2525CE%2525B2%25252C%2525CE%2525B3-unsaturated%252B%2525CE%2525B1-keto%252Besters%26aulast%3DXiong%26aufirst%3DYa%26date%3D2021%26volume%3D87%26spage%3D132112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng‐Jun  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Liang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Phase‐Transfer Catalytic Strategy: Rapid Synthesis of Spiro‐Fused Heterocycles, Integrated with Four Pharmacophores‐Succinimide, Pyrrolidine, Oxindole, and Trifluoromethyl Group. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (5)
                                     , 788-793. <a href="https://doi.org/10.1002/ejoc.202001409" title="DOI URL">https://doi.org/10.1002/ejoc.202001409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001409%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPhase%2525E2%252580%252590Transfer%252BCatalytic%252BStrategy%25253A%252BRapid%252BSynthesis%252Bof%252BSpiro%2525E2%252580%252590Fused%252BHeterocycles%25252C%252BIntegrated%252Bwith%252BFour%252BPharmacophores%2525E2%252580%252590Succinimide%25252C%252BPyrrolidine%25252C%252BOxindole%25252C%252Band%252BTrifluoromethyl%252BGroup%26aulast%3DChen%26aufirst%3DZheng%25E2%2580%2590Jun%26date%3D2021%26date%3D2020%26volume%3D2021%26issue%3D5%26spage%3D788%26epage%3D793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GluN2B-selective NAMs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. GluN2B-selective NAMs. (A) Compound <b>4</b> was identified from a high throughput screen. (B) Compound <b>5</b> shows improved aqueous solubility, efflux ratio, and human plasma protein binding compared to HTS hit <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of 1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridine series SAR.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Compounds <b>5–7</b> and <b>10–17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 40% NH<sub>2</sub>CH<sub>3</sub> in water, THF, 0 °C, then rt 16 h (99%); (b) zinc, ammonium chloride, acetone/water (10:1), rt, 72 h; (c) CDI, DMF, rt to 60 °C, 16 h (88% over 2 steps); (d) sodium hydride, DMF, rt, 30 min; then 2-bromoethylacetate, DMF, rt, 4 h, 88%; (e) lithium hydroxide, THF/water, rt, 16 h (83%); (f) secondary amine, <i>n</i>-propylphosphonic anhydride (T3P, 50% in ethyl acetate), Hunig’s base, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h (61–85%); (g) boronic Acid, cesium carbonate, PdCl<sub>2</sub>(dppf), dioxane, 100 °C, 16 h (9–46%); (h) bromothiophene, bis(pinacolato)diboron, potassium acetate, PdCl<sub>2</sub>(dppf), dioxane, 90 °C, 2 h; then add <b>22</b>, cesium carbonate, 90 °C, 3 h addnl. (10–48%); (i) 4,4,5,5-tetramethyl-2-(5-(trifluoromethyl)thiophen-2-yl)-1,3,2-dioxaborolane, potassium carbonate, PdCl<sub>2</sub>(dppf), toluene/water (10:1), 105 °C, 3 h (91%); (j) lithium hydroxide, THF/water, rt, 16 h (98%).</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Biodistribution of <b>12</b> in rat brain regions at different time points after a single i.v. injection of 30 μg/kg. Each animal group was sacrificed at different time points (5, 10, 30, 60 and 120 min after the injection). The result is normalized by tissue weight (g). <i>*P</i> < 0.05 significant increased <i>vs</i> cerebellum. <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Multi-Gram Route for Compound <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl pyridin-2-yl carbonate, potassium carbonate, DMF, 75 °C (93%); (b) trityl chloride, triethylamine, rt (94%); (c) isopropylamine, THF, rt (100%); (d) sodium hydride, DMF, rt, 20 min; then 1-(azetidin-1-yl)-2-chloroethan-1-one, DMF, rt, 2 h (100%); (e) boronic Acid, cesium carbonate, PdCl<sub>2</sub>(dppf), dioxane, 100 °C, 16 h; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h (64% over 2 steps); (g) sodium hydride, DMF, rt, 30 min; then iodomethane, DMF, rt, 2 h (80%).</p></p></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>Ex vivo</i> GluN2B receptor occupancy with <b>12</b> in rat hippocampus: dose dependency after p.o. administration shown as (A) plasma concentration <i>vs</i> % GluN2B occupancy and (B) dose <i>vs</i> % GluN2B occupancy. Results are expressed as average percentage receptor occupancy <i>vs</i> naïve control rats ± SEM (<i>n</i> = 3) and vehicle is 20% HP-β-CD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat plasma concentrations of <b>12</b> over 24 h after four toleration doses administered as oral suspensions in 5% HPMC, <i>n</i> = 3. Error bars have been omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Rat plasma concentrations of <b>12</b> over 24 h after toleration doses administered as oral nanosuspensions (API/polymer = 4:1), <i>n</i> = 3 per dose ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/medium/jm9b02113_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Simulated human plasma concentration profile 120 mg of a single oral dose of <b>12</b> from a nanosuspension formulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02113/20200903/images/large/jm9b02113_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02113&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynelis, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollmuth, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span> <span> </span><span class="NLM_article-title">Glutamate receptor ion channels: structure, regulation, and function</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1124/pr.109.002451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1124%2Fpr.109.002451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=20716669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=405-496&author=S.+F.+Traynelisauthor=L.+P.+Wollmuthauthor=C.+J.+McBainauthor=F.+S.+Mennitiauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=K.+B.+Hansenauthor=H.+Yuanauthor=S.+J.+Myersauthor=R.+Dingledine&title=Glutamate+receptor+ion+channels%3A+structure%2C+regulation%2C+and+function&doi=10.1124%2Fpr.109.002451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate receptor ion channels: structure, regulation, and function</span></div><div class="casAuthors">Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-496</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The mammalian ionotropic glutamate receptor family encodes 18 gene products that coassemble to form ligand-gated ion channels contg. an agonist recognition site, a transmembrane ion permeation pathway, and gating elements that couple agonist-induced conformational changes to the opening or closing of the permeation pore.  Glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system and are localized on neuronal and non-neuronal cells.  These receptors regulate a broad spectrum of processes in the brain, spinal cord, retina, and peripheral nervous system.  Glutamate receptors are postulated to play important roles in numerous neurol. diseases and have attracted intense scrutiny.  The description of glutamate receptor structure, including its transmembrane elements, reveals a complex assembly of multiple semiautonomous extracellular domains linked to a pore-forming element with striking resemblance to an inverted potassium channel.  In this review we discuss International Union of Basic and Clin. Pharmacol. glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacol., allosteric modulation, mechanisms of gating and permeation, roles in normal physiol. function, as well as the potential therapeutic use of pharmacol. agents acting at glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0rj4nMr5ObVg90H21EOLACvtfcHk0lh3m7RJKj-ZtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ&md5=5d0a7945b5ad99113adf9f6312bafe13</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.109.002451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.109.002451%26sid%3Dliteratum%253Aachs%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26aulast%3DWollmuth%26aufirst%3DL.%2BP.%26aulast%3DMcBain%26aufirst%3DC.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMyers%26aufirst%3DS.%2BJ.%26aulast%3DDingledine%26aufirst%3DR.%26atitle%3DGlutamate%2520receptor%2520ion%2520channels%253A%2520structure%252C%2520regulation%252C%2520and%2520function%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D405%26epage%3D496%26doi%3D10.1124%2Fpr.109.002451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berberich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hvalby, Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhr, G.</span></span> <span> </span><span class="NLM_article-title">The role of NMDAR subtypes and charge transfer during hippocampal LTP induction</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2006.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuropharm.2006.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=16901514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhtFygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=77-86&author=S.+Berberichauthor=V.+Jensenauthor=%C3%98.+Hvalbyauthor=P.+H.+Seeburgauthor=G.+K%C3%B6hr&title=The+role+of+NMDAR+subtypes+and+charge+transfer+during+hippocampal+LTP+induction&doi=10.1016%2Fj.neuropharm.2006.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of NMDAR subtypes and charge transfer during hippocampal LTP induction</span></div><div class="casAuthors">Berberich Sven; Jensen Vidar; Hvalby Oivind; Seeburg Peter H; Kohr Georg</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">Activation of NMDA receptors (NMDARs) is a requirement for persistent synaptic alterations, such as long-term potentiation of synaptic transmission (LTP).  NMDARs are composed of NR1 and NR2 subunits, and NR2 subunit-dependent gating properties of NMDAR subtypes cause dramatic differences in the timing of charge transfer.  These postsynaptic temporal profiles are further influenced by the frequency of synaptic activation.  Here, we investigated in the CA1 region of hippocampal slices from P28 mice, whether particular NMDAR subtypes are recruited based on NR2 subunit-specific gating following different induction protocols.  For high frequency afferent stimulation (HFS), we found that genetic impairment of NR2A or pharmacological block of NR2A- or NR2B-type NMDARs can reduce field LTP.  In contrast, when pairing low frequency synaptic stimulation with postsynaptic depolarization (LFS pairing) in single CA1 neurons, pharmacological antagonism of either subtype modestly reduced the charge transfer during LFS pairing without reducing the LTP magnitude.  These results indicate that HFS-triggered LTP is induced by more than one NMDAR subtype, whereas a single subtype is sufficient during LFS pairing.  Analysis of charge transfer during LFS pairing in 13 different conditions revealed a threshold for LTP induction, which was independent of the NR2 antagonist tested.  Thus, at least for LFS pairing, the amount of charge transfer, and thus Ca2+ influx, during LTP induction is a factor more critical than the participation of a particular NMDAR subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbpgtPeBjOUSXXDYhVZBdlfW6udTcc2eYmFRJdpoaTEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhtFygsQ%253D%253D&md5=16556c251d9b9221dc90d2c5ff483f88</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2006.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2006.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBerberich%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DV.%26aulast%3DHvalby%26aufirst%3D%25C3%2598.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26aulast%3DK%25C3%25B6hr%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520NMDAR%2520subtypes%2520and%2520charge%2520transfer%2520during%2520hippocampal%2520LTP%2520induction%26jtitle%3DNeuropharmacology%26date%3D2007%26volume%3D52%26spage%3D77%26epage%3D86%26doi%3D10.1016%2Fj.neuropharm.2006.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massey, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moult, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collingridge, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, Z. I.</span></span> <span> </span><span class="NLM_article-title">Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7821</span>– <span class="NLM_lpage">7828</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.1697-04.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1523%2FJNEUROSCI.1697-04.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=15356193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVWntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=7821-7828&author=P.+V.+Masseyauthor=B.+E.+Johnsonauthor=P.+R.+Moultauthor=Y.+P.+Aubersonauthor=M.+W.+Brownauthor=E.+Molnarauthor=G.+L.+Collingridgeauthor=Z.+I.+Bashir&title=Differential+roles+of+NR2A+and+NR2B-containing+NMDA+receptors+in+cortical+long-term+potentiation+and+long-term+depression&doi=10.1523%2Fjneurosci.1697-04.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression</span></div><div class="casAuthors">Massey, Peter V.; Johnson, Benjamin E.; Moult, Peter R.; Auberson, Yves P.; Brown, Malcolm W.; Molnar, Elek; Collingridge, Graham L.; Bashir, Zafar I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">7821-7828</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">It is widely believed that long-term depression (LTD) and its counterpart, long-term potentiation (LTP), involve mechanisms that are crucial for learning and memory.  However, LTD is difficult to induce in adult cortex for reasons that are not known.  Here we show that LTD can be readily induced in adult cortex by the activation of NMDA receptors (NMDARs), after inhibition of glutamate uptake.  Interestingly there is no need to activate synaptic NMDARs to induce this LTD, suggesting that LTD is triggered primarily by extrasynaptic NMDA receptors.  We also find that de novo LTD requires the activation of NR2B-contg. NMDAR, whereas LTP requires activation of NR2A-contg. NMDARs.  Surprisingly another form of LTD, depotentiation, requires activation of NR2A-contg. NMDARs.  Therefore, NMDARs with different synaptic locations and subunit compns. are involved in various forms of synaptic plasticity in adult cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoM_I4GoJ6pbVg90H21EOLACvtfcHk0lg9stUtdz0MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVWntLc%253D&md5=397cbbd1e24743da5920b46ece2aad25</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1697-04.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1697-04.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DP.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMoult%26aufirst%3DP.%2BR.%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BW.%26aulast%3DMolnar%26aufirst%3DE.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26aulast%3DBashir%26aufirst%3DZ.%2BI.%26atitle%3DDifferential%2520roles%2520of%2520NR2A%2520and%2520NR2B-containing%2520NMDA%2520receptors%2520in%2520cortical%2520long-term%2520potentiation%2520and%2520long-term%2520depression%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D7821%26epage%3D7828%26doi%3D10.1523%2Fjneurosci.1697-04.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1038/nrd2462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnrd2462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=18425072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=426-437&author=G.+Sanacoraauthor=C.+A.+Zarateauthor=J.+H.+Krystalauthor=H.+K.+Manji&title=Targeting+the+glutamatergic+system+to+develop+novel%2C+improved+therapeutics+for+mood+disorders&doi=10.1038%2Fnrd2462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders</span></div><div class="casAuthors">Sanacora, Gerard; Zarate, Carlos A.; Krystal, John H.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-437</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is mounting evidence of the involvement of the glutamatergic system in mood-disorder pathophysiol. as well as of the efficacy of glutamatergic agents in mood disorders.  In this review, the authors examine the contribution of abnormalities in the glutamatergic system to the impairments in neural plasticity that are obsd. in patients with mood disorders, and how this knowledge can be applied to the development of antidepressants with more rapid and sustained effects.  Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide.  To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiol. studies of mood disorders, and most therapeutics target these systems.  However, there is growing evidence that the glutamatergic system is central to the neurobiol. and treatment of these disorders.  Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiol. as well as the efficacy of glutamatergic agents in mood disorders.  We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBmJwxpcwdt7Vg90H21EOLACvtfcHk0lg9stUtdz0MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbw%253D&md5=93fb1fc22d329aa9337ba38f5efe4677</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2462%26sid%3Dliteratum%253Aachs%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DTargeting%2520the%2520glutamatergic%2520system%2520to%2520develop%2520novel%252C%2520improved%2520therapeutics%2520for%2520mood%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D426%26epage%3D437%26doi%3D10.1038%2Fnrd2462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuron.2019.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=30946828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Olt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2019&pages=75-90&author=R.+S.+Dumanauthor=G.+Sanacoraauthor=J.+H.+Krystal&title=Altered+connectivity+in+depression%3A+GABA+and+glutamate+neurotransmitter+deficits+and+reversal+by+novel+treatments&doi=10.1016%2Fj.neuron.2019.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments</span></div><div class="casAuthors">Duman, Ronald S.; Sanacora, Gerard; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-90</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanisms underlying the pathophysiol. and treatment of depression and stress-related disorders remain unclear, but studies in depressed patients and rodent models are beginning to yield promising insights.  These studies demonstrate that depression and chronic stress exposure cause atrophy of neurons in cortical and limbic brain regions implicated in depression, and brain imaging studies demonstrate altered connectivity and network function in the brains of depressed patients.  Studies of the neurobiol. basis of the these alterations have focused on both the principle, excitatory glutamate neurons, as well as inhibitory GABA interneurons.  They demonstrate structural, functional, and neurochem. deficits in both major neuronal types that could lead to degrdn. of signal integrity in cortical and hippocampal regions.  The mol. mechanisms underlying these changes have not been identified but are thought to be related to stress induced excitotoxic effects in combination with elevated adrenal glucocorticoids and inflammatory cytokines as well as other environmental factors.  Transcriptomic studies are beginning to demonstrate important sex differences and, together with genomic studies, are starting to reveal mechanistic domains of overlap and uniqueness with regards to risk and pathophysiol. mechanisms with schizophrenia and bipolar disorder.  These studies also implicate GABA and glutamate dysfunction as well as immunol. mechanisms.  While current antidepressants have significant time lag and efficacy limitations, new rapid-acting agents that target the glutamate and GABA systems address these issues and offer superior therapeutic interventions for this widespread and debilitating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM2GZdT3C2qLVg90H21EOLACvtfcHk0lg9stUtdz0MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Olt74%253D&md5=433761ac0a26ddbff59aedbfb20bd141</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DAltered%2520connectivity%2520in%2520depression%253A%2520GABA%2520and%2520glutamate%2520neurotransmitter%2520deficits%2520and%2520reversal%2520by%2520novel%2520treatments%26jtitle%3DNeuron%26date%3D2019%26volume%3D102%26spage%3D75%26epage%3D90%26doi%3D10.1016%2Fj.neuron.2019.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treccani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, M.</span></span> <span> </span><span class="NLM_article-title">Towards a glutamate hypothesis of depression</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.neuropharm.2011.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=21827775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaktbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=63-77&author=G.+Sanacoraauthor=G.+Treccaniauthor=M.+Popoli&title=Towards+a+glutamate+hypothesis+of+depression&doi=10.1016%2Fj.neuropharm.2011.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a glutamate hypothesis of depression</span></div><div class="casAuthors">Sanacora, Gerard; Treccani, Giulia; Popoli, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-77</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Half a century after the first formulation of the monoamine hypothesis, compelling evidence implies that long-term changes in an array of brain areas and circuits mediating complex cognitive-emotional behaviors represent the biol. underpinnings of mood/anxiety disorders.  A large no. of clin. studies suggest that pathophysiol. is assocd. with dysfunction of the predominant glutamatergic system, malfunction in the mechanisms regulating clearance and metab. of glutamate, and cytoarchitectural/morphol. maladaptive changes in a no. of brain areas mediating cognitive-emotional behaviors.  Concurrently, a wealth of data from animal models have shown that different types of environmental stress enhance glutamate release/transmission in limbic/cortical areas and exert powerful structural effects, inducing dendritic remodeling, redn. of synapses and possibly volumetric redns. resembling those obsd. in depressed patients.  Because a vast majority of neurons and synapses in these areas and circuits use glutamate as neurotransmitter, it would be limiting to maintain that glutamate is in some way involved' in mood/anxiety disorders; rather it should be recognized that the glutamatergic system is a primary mediator of psychiatric pathol. and, potentially, also a final common pathway for the therapeutic action of antidepressant agents.  A paradigm shift from a monoamine hypothesis of depression to a neuroplasticity hypothesis focused on glutamate may represent a substantial advancement in the working hypothesis that drives research for new drugs and therapies.  Importantly, despite the availability of multiple classes of drugs with monoamine-based mechanisms of action, there remains a large percentage of patients who fail to achieve a sustained remission of depressive symptoms.  The unmet need for improved pharmacotherapies for treatment-resistant depression means there is a large space for the development of new compds. with novel mechanisms of action such as glutamate transmission and related pathways.  This article is part of a Special Issue entitled Anxiety and Depression'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQIbSu99Fht7Vg90H21EOLACvtfcHk0lh0GTL0hBkfzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaktbnI&md5=3f98d26ae55b973366de4f7f1c4902c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DTreccani%26aufirst%3DG.%26aulast%3DPopoli%26aufirst%3DM.%26atitle%3DTowards%2520a%2520glutamate%2520hypothesis%2520of%2520depression%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D63%26epage%3D77%26doi%3D10.1016%2Fj.neuropharm.2011.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomeli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span> <span> </span><span class="NLM_article-title">Heteromeric NMDA receptors: molecular and functional distinction of subtypes</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1126/science.256.5060.1217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1126%2Fscience.256.5060.1217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1350383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1217-1221&author=H.+Monyerauthor=R.+Sprengelauthor=R.+Schoepferauthor=A.+Herbauthor=M.+Higuchiauthor=H.+Lomeliauthor=N.+Burnashevauthor=B.+Sakmannauthor=P.+H.+Seeburg&title=Heteromeric+NMDA+receptors%3A+molecular+and+functional+distinction+of+subtypes&doi=10.1126%2Fscience.256.5060.1217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Heteromeric NMDA receptors:  molecular and functional distinction of subtypes</span></div><div class="casAuthors">Monyer, Hannah; Sprengel, Rolf; Schoepfer, Ralf; Herb, Anne; Higuchi, Miyoko; Lomeli, Hilda; Burnashev, Nail; Sakmann, Bert; Seeburg, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5060</span>),
    <span class="NLM_cas:pages">1217-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The N-methyl-D-aspartate (NMDA) receptor subtype of glutamate-gated ion channels possesses high calcium permeability and unique voltage-dependent sensitivity to magnesium and is modulated by glycine.  Mol. cloning identified three cDNA species of rat brain, encoding NMDA receptor subunits NMDAR2A (NR2A), NR2B, and NR2C, which are 55 to 70% identical in sequence.  These are structurally related, with less than 20% sequence identity, to other excitatory amino acid receptor subunits, including the NMDA receptor subunit NMDAR1 (NR1).  Upon expression in cultured cells, the new subunits yielded prominent, typical glutamate- and NMDA-activated currents only when they were in heteromeric configurations with NR1.  NR1-NR2A and NR1-NR2C channels differed in gating behavior and magnesium sensitivity.  Such heteromeric NMDA receptor subtypes may exist in neurons, since NR1 mRNA is synthesized throughout the mature rat brain, while NR2 mRNA show a different distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4zIpgEOOwfbVg90H21EOLACvtfcHk0lh0GTL0hBkfzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOrs7o%253D&md5=5f8027d13a038707c014b2654db628b7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.256.5060.1217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.256.5060.1217%26sid%3Dliteratum%253Aachs%26aulast%3DMonyer%26aufirst%3DH.%26aulast%3DSprengel%26aufirst%3DR.%26aulast%3DSchoepfer%26aufirst%3DR.%26aulast%3DHerb%26aufirst%3DA.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DLomeli%26aufirst%3DH.%26aulast%3DBurnashev%26aufirst%3DN.%26aulast%3DSakmann%26aufirst%3DB.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26atitle%3DHeteromeric%2520NMDA%2520receptors%253A%2520molecular%2520and%2520functional%2520distinction%2520of%2520subtypes%26jtitle%3DScience%26date%3D1992%26volume%3D256%26spage%3D1217%26epage%3D1221%26doi%3D10.1126%2Fscience.256.5060.1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrn3504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnrn3504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=23686171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=383-400&author=P.+Paolettiauthor=C.+Belloneauthor=Q.+Zhou&title=NMDA+receptor+subunit+diversity%3A+impact+on+receptor+properties%2C+synaptic+plasticity+and+disease&doi=10.1038%2Fnrn3504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</span></div><div class="casAuthors">Paoletti, Pierre; Bellone, Camilla; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">383-400</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  NMDA receptors (NMDARs) are glutamate-gated ion channels and are crucial for neuronal communication.  NMDARs form tetrameric complexes that consist of several homologous subunits.  The subunit compn. of NMDARs is plastic, resulting in a large no. of receptor subtypes.  As each receptor subtype has distinct biophys., pharmacol. and signaling properties, there is great interest in detg. whether individual subtypes carry out specific functions in the CNS in both normal and pathol. conditions.  Here, we review the effects of subunit compn. on NMDAR properties, synaptic plasticity and cellular mechanisms implicated in neuropsychiatric disorders.  Understanding the rules and roles of NMDAR diversity could provide new therapeutic strategies against dysfunctions of glutamatergic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqubMsb4ZP2U7Vg90H21EOLACvtfcHk0lh0GTL0hBkfzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSit7Y%253D&md5=f69790da360242d491bf1a5eb146613d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrn3504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn3504%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DBellone%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DNMDA%2520receptor%2520subunit%2520diversity%253A%2520impact%2520on%2520receptor%2520properties%252C%2520synaptic%2520plasticity%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2013%26volume%3D14%26spage%3D383%26epage%3D400%26doi%3D10.1038%2Fnrn3504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyton, J.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor subunits: function and pharmacology</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2006.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.coph.2006.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=17088105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=39-47&author=P.+Paolettiauthor=J.+Neyton&title=NMDA+receptor+subunits%3A+function+and+pharmacology&doi=10.1016%2Fj.coph.2006.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor subunits: function and pharmacology</span></div><div class="casAuthors">Paoletti, Pierre; Neyton, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels widely expressed in the central nervous system that play key roles in excitatory synaptic transmission.  Because of their involvement in numerous neurol. disorders, NMDARs are also targets of therapeutic interest.  NMDARs occur as multiple subtypes which differ in their subunit compn. and in their biophys. and pharmacol. properties.  In particular, NMDARs contain a diversity of sites at which endogenous ligands or pharmacol. agents can act to modulate receptor activity in a subunit-selective manner, and recent structural and functional data have started to reveal the mol. determinants for this subunit selectivity.  These include the binding sites for glutamate, the ion-channel pore and the recently identified allosteric sites on the N-terminal domain.  Other potential sites yet unexplored by medicinal chem. programs are also considered, in particular at the interface between subunits.  Given the growing body of evidence that diverse brain disorders implicate different NMDAR subtypes, such as NR2B in pain or NR3A in white matter injury, there is a growing interest in exploiting the pharmacol. heterogeneity of NMDARs for the development of novel NMDAR subtype-selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5E8KNWeeb7Vg90H21EOLACvtfcHk0lgHyRHMPt4zDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlGitQ%253D%253D&md5=18296410fb9b50af0b2a7ceae124faf4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DNeyton%26aufirst%3DJ.%26atitle%3DNMDA%2520receptor%2520subunits%253A%2520function%2520and%2520pharmacology%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D39%26epage%3D47%26doi%3D10.1016%2Fj.coph.2006.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregestovski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochiantz, A.</span></span> <span> </span><span class="NLM_article-title">Magnesium gates glutamate-activated channels in mouse central neurones</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1038/307462a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2F307462a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=6320006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaL2cXhtVSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=1984&pages=462-465&author=L.+Nowakauthor=P.+Bregestovskiauthor=P.+Ascherauthor=A.+Herbetauthor=A.+Prochiantz&title=Magnesium+gates+glutamate-activated+channels+in+mouse+central+neurones&doi=10.1038%2F307462a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Magnesium gates glutamate-activated channels in mouse central neurons</span></div><div class="casAuthors">Nowak, L.; Bregestovski, P.; Ascher, P.; Herbet, A.; Prochiantz, A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5950</span>),
    <span class="NLM_cas:pages">462-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Studies on mouse embryo mesencephalic or striatal neurons using the patch-clamp technique indicated a link between voltage sensitivity and Mg2+ sensitivity.  In Mg2+-free solns., L-glutamate, L-aspartate, and N-methyl-D-aspartate (NMDA) opened cation channels, the properties of which were voltage independent.  In the presence of Mg2+, the single-channel currents measured at resting potential were chopped in bursts and the probability of opening the channels was reduced.  Both effects increased with hyperpolarization, thereby accounting for the neg. slope of the I-V relation of the glutamate response.  Thus, the voltage dependence of the NMDA receptor-linked conductance appears to be a consequence of the voltage dependence of the Mg2+ block, and its interpretation does not require the implication of an intramembrane voltage-dependent gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNI5KPbMeMT7Vg90H21EOLACvtfcHk0lgHyRHMPt4zDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhtVSktrg%253D&md5=cc393236b9af6184c9b936bf2b61c83b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F307462a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F307462a0%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DL.%26aulast%3DBregestovski%26aufirst%3DP.%26aulast%3DAscher%26aufirst%3DP.%26aulast%3DHerbet%26aufirst%3DA.%26aulast%3DProchiantz%26aufirst%3DA.%26atitle%3DMagnesium%2520gates%2520glutamate-activated%2520channels%2520in%2520mouse%2520central%2520neurones%26jtitle%3DNature%26date%3D1984%26volume%3D307%26spage%3D462%26epage%3D465%26doi%3D10.1038%2F307462a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, P. B.</span></span> <span> </span><span class="NLM_article-title">Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1038/309261a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2F309261a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=6325946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaL2cXktFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=1984&pages=261-263&author=M.+L.+Mayerauthor=G.+L.+Westbrookauthor=P.+B.+Guthrie&title=Voltage-dependent+block+by+Mg2%2B+of+NMDA+responses+in+spinal+cord+neurones&doi=10.1038%2F309261a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Voltage-dependent block by magnesium(2+) of NMDA responses in spinal cord neurons</span></div><div class="casAuthors">Mayer, Mark L.; Westbrook, Gary L.; Guthrie, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5965</span>),
    <span class="NLM_cas:pages">261-3</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Voltage-clamp expts. on mouse spinal cord neurons showed that the voltage-sensitivity of N-methyl-D-aspartic acid (NMDA)  [6384-92-5] action is greatly reduced on the withdrawal of physiol. concns. (∼1 mM) of Mg2+ from the extracellular fluid.  Thus, Mg2+ blocks inward current flow through ion channels linked to NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLE_6GreNx3rVg90H21EOLACvtfcHk0lgHyRHMPt4zDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktFyjtrk%253D&md5=5f44b8f339efde1dc09259c308373c8d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F309261a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F309261a0%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DM.%2BL.%26aulast%3DWestbrook%26aufirst%3DG.%2BL.%26aulast%3DGuthrie%26aufirst%3DP.%2BB.%26atitle%3DVoltage-dependent%2520block%2520by%2520Mg2%252B%2520of%2520NMDA%2520responses%2520in%2520spinal%2520cord%2520neurones%26jtitle%3DNature%26date%3D1984%26volume%3D309%26spage%3D261%26epage%3D263%26doi%3D10.1038%2F309261a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span> <span> </span><span class="NLM_article-title">Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">859</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=7901753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2cXitlCnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1993&pages=851-859&author=K.+Williams&title=Ifenprodil+discriminates+subtypes+of+the+N-methyl-D-aspartate+receptor%3A+selectivity+and+mechanisms+at+recombinant+heteromeric+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors</span></div><div class="casAuthors">Williams, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">851-9</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The effects of the atypical N-methyl-D-aspartate (NMDA) receptor antagonist ifenprodil were studied by voltage-clamp recording of Xenopus oocytes expressing heteromeric NMDA receptors from cloned NR1 and NR2 subunit RNAs.  In oocytes voltage-clamped at -70 mV, ifenprodil inhibited NMDA-induced currents at NR1A/NR2B receptors with high affinity (IC50 = 0.34 μM).  The affinity of NR1A/NR2A receptors for ifenprodil (IC50 = 146 μM) was 400-fold lower than that of NR1A/NR2B receptors.  The rate of onset of inhibition by low concns. of ifenprodil acting at NR1A/NR2B receptors was considerably slower than the onset of inhibition seen with high concns. of ifenprodil acting at NR1A/NR2A receptors.  The onset and recovery of blockade by ifenprodil at NR1A/NR2B receptors were not activity dependent.  The inhibitory effects of low concns. of ifenprodil at NR1A/NR2B receptors were not voltage dependent.  In contrast, the inhibitory effects of high concns. of ifenprodil at NR1A/NR2A receptors were partially voltage dependent, and a greater inhibition of NMDA-induced currents was seen at hyperpolarized membrane potentials than at depolarized membrane potentials.  The reversal potential of NMDA currents was not altered in the presence of ifenprodil.  Ifenprodil may act as a weak open-channel blocker of NR1A/NR2A receptors.  The degree of inhibition seen with 100 μM ifenprodil at NR1A/NR2A receptors was not altered by changes in the concn. of extracellular glycine.  However, the inhibitory effect of 1 μM ifenprodil at NR1A/NR2B receptors was reduced by increasing the concn. of glycine.  Thus, part of the mechanism of action of ifenprodil at NR1A/NR2B receptors may involve noncompetitive antagonism of the effects of glycine.  Apparently, the mechanism of action of ifenprodil, as well as the potency of this antagonist, is different at NR1A/NR2B and NR1A/NR2A receptors expressed in Xenopus oocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffD1y7apqXrVg90H21EOLACvtfcHk0ljQ11qIMIyvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlCnsw%253D%253D&md5=27f84915114a10b17c5f5c02740d84f8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%26atitle%3DIfenprodil%2520discriminates%2520subtypes%2520of%2520the%2520N-methyl-D-aspartate%2520receptor%253A%2520selectivity%2520and%2520mechanisms%2520at%2520recombinant%2520heteromeric%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D1993%26volume%3D44%26spage%3D851%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carron, M. C. E.</span>; <span class="NLM_string-name">Carron, C. L. C.</span>; <span class="NLM_string-name">Bucher, B. P.</span></span> <i>1-(p-Hydroxyphenyl)-2-(4-alkyl- or -aralkyl-1-piperidino)-1-propanols Vasodilators</i>, FR 1966-77770, <span class="NLM_year">1966</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&author=M.+C.+E.+Carron&author=C.+L.+C.+Carron&author=B.+P.+Bucher&title=1-%28p-Hydroxyphenyl%29-2-%284-alkyl-+or+-aralkyl-1-piperidino%29-1-propanols+Vasodilators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DCarron%26aufirst%3DM.%2BC.%2BE.%26jtitle%3D1-%2528p-Hydroxyphenyl%2529-2-%25284-alkyl-%2520or%2520-aralkyl-1-piperidino%2529-1-propanols%2520Vasodilators%26date%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perin-Dureau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5955</span>– <span class="NLM_lpage">5965</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.22-14-05955.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1523%2FJNEUROSCI.22-14-05955.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=12122058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFOjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=5955-5965&author=F.+Perin-Dureauauthor=J.+Rachlineauthor=J.+Neytonauthor=P.+Paoletti&title=Mapping+the+binding+site+of+the+neuroprotectant+ifenprodil+on+NMDA+receptors&doi=10.1523%2Fjneurosci.22-14-05955.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors</span></div><div class="casAuthors">Perin-Dureau, Florent; Rachline, Julie; Neyton, Jacques; Paoletti, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5955-5965</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ifenprodil is a noncompetitive antagonist of NMDA receptors highly selective for the NMDA receptor 2B (NR2B) subunit.  It is widely used as a pharmacol. tool to discriminate subpopulations of NMDA receptors, and derivs. are currently being developed as candidate neuroprotectants.  Despite numerous studies on the mechanism of action of ifenprodil on NMDA receptors, the structural determinants responsible for the subunit selectivity have not been identified.  By combining functional studies on recombinant NMDA receptors and biochem. studies on isolated domains, we now show that ifenprodil binds to the N-terminal leucine/isoleucine/valine-binding protein (LIVBP)-like domain of NR2B.  In this domain, several residues, both hydrophilic and hydrophobic, were found to control ifenprodil inhibition.  Their location in a modeled three-dimensional structure suggests that ifenprodil binds in the cleft of the LIVBP-like domain of NR2B by a mechanism (Venus-flytrap) resembling that of the binding of Zn on the LIVBP-like domain of NR2A.  These results reinforce the proposal that the LIVBP-like domains of NMDA receptors, and possibly of other ionotropic glutamate receptors, bind modulatory ligands.  Moreover, they identify the LIVBP-like domain of the NR2B subunit as a promising therapeutic target and provide a framework for designing structurally novel NR2B-selective antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8blkWf0Z1c7Vg90H21EOLACvtfcHk0ljQ11qIMIyvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFOjsb4%253D&md5=996a97d37425b46d1bf74e26139c7339</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.22-14-05955.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.22-14-05955.2002%26sid%3Dliteratum%253Aachs%26aulast%3DPerin-Dureau%26aufirst%3DF.%26aulast%3DRachline%26aufirst%3DJ.%26aulast%3DNeyton%26aufirst%3DJ.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DMapping%2520the%2520binding%2520site%2520of%2520the%2520neuroprotectant%2520ifenprodil%2520on%2520NMDA%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2002%26volume%3D22%26spage%3D5955%26epage%3D5965%26doi%3D10.1523%2Fjneurosci.22-14-05955.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mony, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kew, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthorpe, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00304.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1111%2Fj.1476-5381.2009.00304.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19594762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=1301-1317&author=L.+Monyauthor=J.+N.+Kewauthor=M.+J.+Gunthorpeauthor=P.+Paoletti&title=Allosteric+modulators+of+NR2B-containing+NMDA+receptors%3A+molecular+mechanisms+and+therapeutic+potential&doi=10.1111%2Fj.1476-5381.2009.00304.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of NR2B-Containing NMDA receptors: Molecular mechanisms and therapeutic potential</span></div><div class="casAuthors">Mony, Laetitia; Kew, James N. C.; Gunthorpe, Martin J.; Paoletti, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1301-1317</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  N-methyl-D-aspartate receptors (NMDARs) are ion channels gated by glutamate, the major excitatory neurotransmitter in the mammalian central nervous system (CNS).  They are widespread in the CNS and are involved in numerous physiol. and pathol. processes including synaptic plasticity, chronic pain and psychosis.  Aberrant NMDAR activity also plays an important role in the neuronal loss assocd. with ischemic insults and major degenerative disorders including Parkinson's and Alzheimer's disease.  Agents that target and alter NMDAR function may, thus, have therapeutic benefit.  Interestingly, NMDARs are endowed with multiple extracellular regulatory sites that recognize ions or small mol. ligands, some of which are likely to regulate receptor function in vivo.  These allosteric sites, which differ from agonist-binding and channel-permeation sites, provide means to modulate, either pos. or neg., NMDAR activity.  The present review focuses on allosteric modulation of NMDARs contg. the NR2B subunit.  Indeed, the NR2B subunit confers a particularly rich pharmacol. with distinct recognition sites for exogenous and endogenous allosteric ligands.  Moreover, NR2B-contg. receptors, compared with other NMDAR subtypes, appear to contribute preferentially to pathol. processes linked to overexcitation of glutamatergic pathways.  The actions of extracellular H+, Mg2+, Zn2+, of polyamines and neurosteroids, and of the synthetic compds. ifenprodil and derivs. ('prodils') are presented.  Particular emphasis is put upon the structural determinants and mol. mechanisms that underlie the effects exerted by these agents.  A better understanding of how NR2B-contg. NMDARs (and NMDARs in general) operate and how they can be modulated should help define new strategies to counteract the deleterious effects of dysregulated NMDAR activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyWhJvTXZ9FLVg90H21EOLACvtfcHk0ljQ11qIMIyvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu77M&md5=9ca937f24cea113866e9467f298c95ed</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00304.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00304.x%26sid%3Dliteratum%253Aachs%26aulast%3DMony%26aufirst%3DL.%26aulast%3DKew%26aufirst%3DJ.%2BN.%26aulast%3DGunthorpe%26aufirst%3DM.%2BJ.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DAllosteric%2520modulators%2520of%2520NR2B-containing%2520NMDA%2520receptors%253A%2520molecular%2520mechanisms%2520and%2520therapeutic%2520potential%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D1301%26epage%3D1317%26doi%3D10.1111%2Fj.1476-5381.2009.00304.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malchow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falkai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span> <span> </span><span class="NLM_article-title">Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders</span>. <i>Eur. Arch. Psychiatr. Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1007/s00406-013-0399-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1007%2Fs00406-013-0399-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=23455590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BC3svis12lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2013&pages=367-377&author=K.+Hashimotoauthor=B.+Malchowauthor=P.+Falkaiauthor=A.+Schmitt&title=Glutamate+modulators+as+potential+therapeutic+drugs+in+schizophrenia+and+affective+disorders&doi=10.1007%2Fs00406-013-0399-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders</span></div><div class="casAuthors">Hashimoto Kenji; Malchow Berend; Falkai Peter; Schmitt Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe psychiatric disorders such as schizophrenia are related to cognitive and negative symptoms, which often are resistant to current treatment approaches.  The glutamatergic system has been implicated in the pathophysiology of schizophrenia and affective disorders.  A key component is the dysfunction of the glutamatergic N-methyl-D-aspartate (NMDA) receptor.  Substances regulating activation/inhibition of the NMDA receptor have been investigated in schizophrenia and major depression and are promising in therapeutic approaches of negative symptoms, cognition, and mood.  In schizophrenia, add-on treatments with glycine, D-serine, D-alanine, D-cycloserine, D-amino acid oxidase inhibitors, glycine transporter-1 (GlyT-1) inhibitors (e.g., sarcosine, bitopertin) and agonists (e.g., LY2140023) or positive allosteric modulator (e.g., ADX71149) of group II metabotropic glutamate receptors (mGluRs) have been studied.  In major depression, the NMDA receptor antagonists (e.g., ketamine, AZD6765), GluN2B subtype antagonists (e.g., traxoprodil, MK-0657), and partial agonists (e.g., D-cycloserine, GLYX-13) at the glycine site of the NMDA receptor have been proven to be effective in animal studies and first clinical trials.  In addition, clinical studies of mGluR2/3 antagonist BCI-838 (a prodrug of BCI-632 (MGS0039)), mGluR2/3-negative allosteric modulators (NMAs) (e.g., RO499819, RO4432717), and mGluR5 NAMs (e.g., AZD2066, RO4917523) are in progress.  Future investigations should include effects on brain structure and activation to elucidate neural mechanisms underlying efficacy of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7MlQKb0V41QHqQV89nF-2fW6udTcc2eawi_11j_0Ygrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svis12lsg%253D%253D&md5=7048ce47b308c5f34a71fb3f6f0f2277</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00406-013-0399-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-013-0399-y%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DMalchow%26aufirst%3DB.%26aulast%3DFalkai%26aufirst%3DP.%26aulast%3DSchmitt%26aufirst%3DA.%26atitle%3DGlutamate%2520modulators%2520as%2520potential%2520therapeutic%2520drugs%2520in%2520schizophrenia%2520and%2520affective%2520disorders%26jtitle%3DEur.%2520Arch.%2520Psychiatr.%2520Clin.%2520Neurosci.%26date%3D2013%26volume%3D263%26spage%3D367%26epage%3D377%26doi%3D10.1007%2Fs00406-013-0399-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preskorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolluri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, J. W.</span></span> <span> </span><span class="NLM_article-title">An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1097/jcp.0b013e31818a6cea</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1097%2FJCP.0b013e31818a6cea" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19011431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=631-637&author=S.+H.+Preskornauthor=B.+Bakerauthor=S.+Kolluriauthor=F.+S.+Mennitiauthor=M.+Kramsauthor=J.+W.+Landen&title=An+innovative+design+to+establish+proof+of+concept+of+the+antidepressant+effects+of+the+NR2B+subunit+selective+N-methyl-D-aspartate+antagonist%2C+CP-101%2C606%2C+in+patients+with+treatment-refractory+major+depressive+disorder&doi=10.1097%2Fjcp.0b013e31818a6cea"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder</span></div><div class="casAuthors">Preskorn, Sheldon H.; Baker, Bryan; Kolluri, Sheela; Menniti, Frank S.; Krams, Michael; Landen, Jaren W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This randomized, placebo-controlled, double-blind study was the first to evaluate the antidepressant efficacy, safety, and tolerability of an NR2B subunit-selective N-methyl-D-aspartate receptor antagonist, CP-101,606.  Subjects had major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and a history of treatment refractoriness to least 1 adequate trial of a selective serotonin reuptake inhibitor.  The study had 2 treatment periods.  In period 1, subjects first received a 6-wk open-label trial of paroxetine and a single-blind, i.v. placebo infusion.  Period 1 nonresponders (n = 30) then received a randomized double-blind single infusion of CP-101,606 or placebo plus continued treatment with paroxetine for up to an addnl. 4 wk (period 2).  Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale.  On the prespecified main outcome measure (change from baseline in the Montgomery-Åsberg Depression Rating Scale total score at day 5 of period 2), CP-101,606 produced a greater decrease than did placebo (mean difference, 8.6; 80% confidence interval, -12.3 to -4.5) (P < 0.10).  Hamilton Depression Rating Scale response rate was 60% for CP-101,606 vs. 20% for placebo.  Seventy-eight percent of CP-101,606-treated responders maintained response status for at least 1 wk after the infusion.  CP-101,606 was safe, generally well tolerated, and capable of producing an antidepressant response without also producing a dissociative reaction.  Antagonism of the NR2B subtype of the N-methyl-D-aspartate receptor may be a fruitful target for the development of a new antidepressant with more robust effects and a faster onset compared with those currently available and capable of working when existing antidepressants do not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZntM4kxsekrVg90H21EOLACvtfcHk0lgiOsKA2uz7gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqu7zE&md5=78d4ce7302daed034db7cb802a36a673</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e31818a6cea&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e31818a6cea%26sid%3Dliteratum%253Aachs%26aulast%3DPreskorn%26aufirst%3DS.%2BH.%26aulast%3DBaker%26aufirst%3DB.%26aulast%3DKolluri%26aufirst%3DS.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DKrams%26aufirst%3DM.%26aulast%3DLanden%26aufirst%3DJ.%2BW.%26atitle%3DAn%2520innovative%2520design%2520to%2520establish%2520proof%2520of%2520concept%2520of%2520the%2520antidepressant%2520effects%2520of%2520the%2520NR2B%2520subunit%2520selective%2520N-methyl-D-aspartate%2520antagonist%252C%2520CP-101%252C606%252C%2520in%2520patients%2520with%2520treatment-refractory%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2008%26volume%3D28%26spage%3D631%26epage%3D637%26doi%3D10.1097%2Fjcp.0b013e31818a6cea" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C. B.</span></span> <span> </span><span class="NLM_article-title">(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3138</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1021/jm00016a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00016a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2MXmvF2htLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3138-3145&author=B.+L.+Chenardauthor=J.+Bordnerauthor=T.+W.+Butlerauthor=L.+K.+Chambersauthor=M.+A.+Collinsauthor=D.+L.+De+Costaauthor=M.+F.+Ducatauthor=M.+L.+Dumontauthor=C.+B.+Fox&title=%281S%2C2S%29-1-%284-Hydroxyphenyl%29-2-%284-hydroxy-4-phenylpiperidino%29-1-propanol%3A+a+potent+new+neuroprotectant+which+blocks+N-methyl-D-aspartate+responses&doi=10.1021%2Fjm00016a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses</span></div><div class="casAuthors">Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins, M. A.; De Costa, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3138-45</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(+)-4-Hydroxy-α-(4-hydroxyphenyl)-β-methyl-4-phenyl-1-piperidinethanol (CP-101,606) was identified as a potent and selective N-methyl-D-aspartate (NMDA) antagonist through a structure activity relation (SAR) program based on ifenprodil, a known antihypertensive agent with NMDA antagonist activity.  Sites on the threo-ifenprodil skeleton explored in this report include the pendent Me group (H, Me, and Et nearly equipotent; Pr much weaker), the spacer group connecting the C-4 Ph group to the piperidine ring (an alternating potency pattern with 0 and 2 carbon atoms yielding the greatest potency), and simple Ph substitution (little effect).  While potent NMDA antagonists were obtained with a two atom spacer, this arrangement also increased α1 adrenergic affinity.  Introduction of a hydroxyl group into the C-4 position on the piperidine ring resulted in substantial redn. in α1 adrenergic affinity.  The combination of these observations was instrumental in the discovery of CP-101,606 .  This compd. potently protects cultured hippocampal neurons from glutamate toxicity (IC50 = 10 nM) while possessing little of the undesired α1 adrenergic affinity (IC50 ∼ 20 μM) of ifenprodil.  Furthermore, CP-101,606 appears to lack the psychomotor stimulant effects of nonselective competitive and channel-blocking NMDA antagonists.  Thus, CP-101,606 shows great promise as a neuroprotective agent and may lack the side effects of compds. currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHHnh0i9mUbVg90H21EOLACvtfcHk0lgiOsKA2uz7gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvF2htLs%253D&md5=a926516f42014a514e771e7a4f78501a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm00016a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00016a017%26sid%3Dliteratum%253Aachs%26aulast%3DChenard%26aufirst%3DB.%2BL.%26aulast%3DBordner%26aufirst%3DJ.%26aulast%3DButler%26aufirst%3DT.%2BW.%26aulast%3DChambers%26aufirst%3DL.%2BK.%26aulast%3DCollins%26aufirst%3DM.%2BA.%26aulast%3DDe%2BCosta%26aufirst%3DD.%2BL.%26aulast%3DDucat%26aufirst%3DM.%2BF.%26aulast%3DDumont%26aufirst%3DM.%2BL.%26aulast%3DFox%26aufirst%3DC.%2BB.%26atitle%3D%25281S%252C2S%2529-1-%25284-Hydroxyphenyl%2529-2-%25284-hydroxy-4-phenylpiperidino%2529-1-propanol%253A%2520a%2520potent%2520new%2520neuroprotectant%2520which%2520blocks%2520N-methyl-D-aspartate%2520responses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3138%26epage%3D3145%26doi%3D10.1021%2Fjm00016a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F.</span></span> <span> </span><span class="NLM_article-title">CP-101,606, a potent neuroprotectant selective for forebrain neurons</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(97)10092-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS0014-2999%2897%2910092-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=9274969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK2sXksFeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=1997&pages=117-126&author=F.+Mennitiauthor=B.+Chenardauthor=M.+Collinsauthor=M.+Ducatauthor=I.+Shalabyauthor=F.+White&title=CP-101%2C606%2C+a+potent+neuroprotectant+selective+for+forebrain+neurons&doi=10.1016%2Fs0014-2999%2897%2910092-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CP-101,606, a potent neuroprotectant selective for forebrain neurons</span></div><div class="casAuthors">Menniti, Frank; Chenard, Bertrand; Collins, Mary; Ducat, Mary; Shalaby, Ismail; White, Frost</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">117-126</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The neuroprotective activity of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606), an N-methyl-D-aspartate (NMDA) receptor antagonist structurally similar to ((±)-(R*,S*)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidineethanol) (ifenprodil), was investigated in neurons in primary culture.  CP-101,606 potently and efficaciously protected hippocampal neurons from glutamate toxicity but was >900-fold less effective for cerebellar granule neurons.  The neuroprotective activity in the hippocampal neurons is mediated through a high affinity binding site distinct from the agonist and thienylcyclohexylpiperidine (TCP) binding sites of the NMDA receptor.  Autoradiog. indicates the CP-101,606 binding site is localized in forebrain, most notably in hippocampus and the outer layers of cortex.  The functional selectivity for hippocampal neurons, forebrain localization of binding sites, and structural relation to ifenprodil suggest that CP-101,606 is an NMDA antagonist highly selective for NR2B subunit contg. receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8dsxm9cYtFLVg90H21EOLACvtfcHk0lgiOsKA2uz7gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFeitLs%253D&md5=b982493b88c4f85b88d86242706452e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2910092-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252910092-9%26sid%3Dliteratum%253Aachs%26aulast%3DMenniti%26aufirst%3DF.%26aulast%3DChenard%26aufirst%3DB.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDucat%26aufirst%3DM.%26aulast%3DShalaby%26aufirst%3DI.%26aulast%3DWhite%26aufirst%3DF.%26atitle%3DCP-101%252C606%252C%2520a%2520potent%2520neuroprotectant%2520selective%2520for%2520forebrain%2520neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D331%26spage%3D117%26epage%3D126%26doi%3D10.1016%2Fs0014-2999%2897%2910092-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmack, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span> <span> </span><span class="NLM_article-title">A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>890</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07979.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1111%2Fj.1749-6632.1999.tb07979.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10668412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=890&publication_year=1999&pages=42-50&author=R.+E.+Merchantauthor=M.+R.+Bullockauthor=C.+A.+Carmackauthor=A.+K.+Shahauthor=K.+D.+Wilnerauthor=G.+Koauthor=S.+A.+Williams&title=A+double-blind%2C+placebo-controlled+study+of+the+safety%2C+tolerability+and+pharmacokinetics+of+CP-101%2C606+in+patients+with+a+mild+or+moderate+traumatic+brain+injury&doi=10.1111%2Fj.1749-6632.1999.tb07979.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury</span></div><div class="casAuthors">Merchant, Randall E.; Bullock, M. Ross; Carmack, Cynthia A.; Shah, Ajit K.; Wilner, Keith D.; Ko, Grant; Williams, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">890</span>
        (<span class="NLM_cas:issue">Neuroprotective Agents</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">CP-101,606 is a postsynaptic antagonist of the glutamate-mediated NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor.  When administered i.v. (i.v.) at the time of injury, CP-101,606 is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia.  Minimal adverse effects have been obsd. in normal human volunteers given i.v. doses of up to 3 mg/kg/h for 72 h.  The objective of the present clin. trial was to assess the safety, pharmacokinetics, and tolerability of CP-101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9-14) or hemorrhagic stroke.  Patients began receiving treatment within 12 h of brain injury.  A total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double-blind fashion to receive CP-101,606 or placebo (4 drug:1 placebo).  Drug/placebo was administered by i.v. infusion (0.75 mg/kg/h) for 2 h and then stopped (n = 25) or continued for 22 h (n = 4) or 70 h (n = 24) at a rate of 0.37 mg/kg/h.  Mean plasma drug concns. were well above the predicted therapeutic concn. of 200 ng/mL within two hours of initiating treatment and were sustained as long as drug was infused.  All the patients tolerated their drug/placebo treatment, and there were no clin. significant cardiovascular or hematol. abnormalities in either group.  A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo.  Modified Kurtzke Scoring also showed a similar pattern of improvement irresp. of type of head injury or drug/placebo treatment.  This study suggests that CP-101,606, infused for up to 72 h has no psychotropic effects and is well-tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwfoQV3IRudbVg90H21EOLACvtfcHk0lg6ln9vk6XQmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVGjsg%253D%253D&md5=a09833feed7a3bc99964a39b725025ca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07979.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07979.x%26sid%3Dliteratum%253Aachs%26aulast%3DMerchant%26aufirst%3DR.%2BE.%26aulast%3DBullock%26aufirst%3DM.%2BR.%26aulast%3DCarmack%26aufirst%3DC.%2BA.%26aulast%3DShah%26aufirst%3DA.%2BK.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKo%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520the%2520safety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520CP-101%252C606%2520in%2520patients%2520with%2520a%2520mild%2520or%2520moderate%2520traumatic%2520brain%2520injury%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D890%26spage%3D42%26epage%3D50%26doi%3D10.1111%2Fj.1749-6632.1999.tb07979.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span>; <span class="NLM_string-name">Claiborne, C. F.</span>; <span class="NLM_string-name">Claremon, D. A.</span>; <span class="NLM_string-name">McCauley, J. A.</span></span> <span> </span><span class="NLM_article-title">Heteroarylamino-Substituted 3-Fluoro-piperidines as NMDA/NR2B Antagonists, and their Preparation, Pharmaceutical Compositions, and Methods of Use</span>. <span class="NLM_patent">WO 2004108705 A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+J.+Liverton&author=C.+F.+Claiborne&author=D.+A.+Claremon&author=J.+A.+McCauley&title=Heteroarylamino-Substituted+3-Fluoro-piperidines+as+NMDA%2FNR2B+Antagonists%2C+and+their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DHeteroarylamino-Substituted%25203-Fluoro-piperidines%2520as%2520NMDA%252FNR2B%2520Antagonists%252C%2520and%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Methods%2520of%2520Use%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Addy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hreniuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinnah, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitz, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetrud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoch, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesdiener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span> <span> </span><span class="NLM_article-title">Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1177/0091270009336735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1177%2F0091270009336735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=19491335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Smsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=856-864&author=C.+Addyauthor=C.+Assaidauthor=D.+Hreniukauthor=M.+Strohauthor=Y.+Xuauthor=W.+J.+Herringauthor=A.+Ellenbogenauthor=H.+A.+Jinnahauthor=L.+Kirbyauthor=M.+T.+Leibowitzauthor=R.+M.+Stewartauthor=D.+Tarsyauthor=J.+Tetrudauthor=S.+A.+Stochauthor=K.+Gottesdienerauthor=J.+Wagner&title=Single-dose+administration+of+MK-0657%2C+an+NR2B-selective+NMDA+antagonist%2C+does+not+result+in+clinically+meaningful+improvement+in+motor+function+in+patients+with+moderate+Parkinson%E2%80%99s+disease&doi=10.1177%2F0091270009336735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease</span></div><div class="casAuthors">Addy, Carol; Assaid, Chris; Hreniuk, David; Stroh, Mark; Xu, Yang; Herring, W. Joseph; Ellenbogen, Aaron; Jinnah, H. A.; Kirby, Louis; Leibowitz, Mark T.; Stewart, R. Malcolm; Tarsy, Daniel; Tetrud, James; Stoch, S. Aubrey; Gottesdiener, Keith; Wagner, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The glutamatergic system is thought to contribute to the motor disturbances obsd. in Parkinson's disease.  Blockade of glutamatergic activity by a selective antagonist of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor is assocd. with improvement in motor symptoms in a preclin. model of Parkinson's disease.  A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study was conducted in patients with moderate Parkinson's disease to evaluate the pharmacol. activity of MK-0657, an NR2B-selective NMDA receptor antagonist.  Patients (n = 16) received single oral doses of MK-0657 7 mg, carbidopa/levodopa 25/250 mg (LD) as a pos. control, and placebo, after which motor function was serially evaluated by means of the Unified Parkinson's Disease Rating Scale-Motor Examn. (UPDRS-ME).  LD administration resulted in significant improvement in the UPDRS-ME relative to placebo (P = .025), confirming the sensitivity of the test paradigm; however, the UPDRS-ME change following MK-0657 administration showed no improvement compared with placebo (P = .110) despite exceeding the target MK-0657 plasma concn. of 400 nM.  Although the administration of MK-0657 was generally well tolerated, it was assocd. with increases in systolic and diastolic blood pressure relative to placebo.  The results of this study do not support ongoing clin. development of MK-0657 as a novel monotherapy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8Pl1Bga_47Vg90H21EOLACvtfcHk0lg6ln9vk6XQmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Smsbc%253D&md5=809bbc2c5023b6771592313a407008c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270009336735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009336735%26sid%3Dliteratum%253Aachs%26aulast%3DAddy%26aufirst%3DC.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DHreniuk%26aufirst%3DD.%26aulast%3DStroh%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHerring%26aufirst%3DW.%2BJ.%26aulast%3DEllenbogen%26aufirst%3DA.%26aulast%3DJinnah%26aufirst%3DH.%2BA.%26aulast%3DKirby%26aufirst%3DL.%26aulast%3DLeibowitz%26aufirst%3DM.%2BT.%26aulast%3DStewart%26aufirst%3DR.%2BM.%26aulast%3DTarsy%26aufirst%3DD.%26aulast%3DTetrud%26aufirst%3DJ.%26aulast%3DStoch%26aufirst%3DS.%2BA.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%26atitle%3DSingle-dose%2520administration%2520of%2520MK-0657%252C%2520an%2520NR2B-selective%2520NMDA%2520antagonist%252C%2520does%2520not%2520result%2520in%2520clinically%2520meaningful%2520improvement%2520in%2520motor%2520function%2520in%2520patients%2520with%2520moderate%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D856%26epage%3D864%26doi%3D10.1177%2F0091270009336735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGranados, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder</span>. <i>J. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1097/jcp.0b013e31825d70d6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1097%2FJCP.0b013e31825d70d6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=22722512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=551-557&author=L.+Ibrahimauthor=N.+DiazGranadosauthor=L.+Jolkovskyauthor=N.+Brutscheauthor=D.+A.+Luckenbaughauthor=W.+J.+Herringauthor=W.+Z.+Potterauthor=C.+A.+Zarate&title=A+randomized%2C+placebo-controlled%2C+crossover+pilot+trial+of+the+oral+selective+NR2B+antagonist+MK-0657+in+patients+with+treatment-resistant+major+depressive+disorder&doi=10.1097%2Fjcp.0b013e31825d70d6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder</span></div><div class="casAuthors">Ibrahim, Lobna; Diaz Granados, Nancy; Jolkovsky, Libby; Brutsche, Nancy; Luckenbaugh, David A.; Herring, W. Joseph; Potter, William Z.; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-557</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of novel therapeutics for major depressive disorder (MDD), particularly agents assocd. with rapid antidepressant effects.  Diverse glutamatergic modulators targeting N-methyl-D-aspartate receptors have shown efficacy in MDD, but their assocd. psychotomimetic effects presently preclude their use in larger samples.  This small, randomized, double-blind, placebo-controlled, crossover pilot study evaluated the potential antidepressant efficacy and tolerability of an oral formulation of the selective N-methyl-D-aspartate NR2B antagonist MK-0657 in patients with treatment-resistant MDD (TRD).  The TRD subjects underwent a 1-wk drug-free period and were subsequently randomized to receive either MK-0657 monotherapy (4-8 mg/d) or placebo for 12 days.  Because of recruitment challenges and the discontinuation of the compd.'s development by the manufacturer, only 5 of the planned 21 patients completed both periods of the crossover administration of MK-0657 and placebo.  Significant antidepressant effects were obsd. as early as day 5 in patients receiving MK-0657 compared with those receiving placebo, as assessed by the Hamilton Depression Rating Scale and Beck Depression Inventory; however, no improvement was noted when symptoms were assessed with the Montgomery-Asberg Depression Rating Scale, the primary efficacy measure.  No serious or dissociative adverse effects were obsd. in patients receiving this oral formulation of MK-0657.  Despite the small sample size, this pilot study suggests that an oral formulation of the NR2B antagonist MK-0657 may have antidepressant properties in TRD patients.  Further studies with larger sample sizes are necessary to confirm these preliminary findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorGhDGnv54AbVg90H21EOLACvtfcHk0ljQ85RWx51Olg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjtrjO&md5=23417cfe7941393c1792fd61df8f373f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e31825d70d6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e31825d70d6%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DL.%26aulast%3DDiazGranados%26aufirst%3DN.%26aulast%3DJolkovsky%26aufirst%3DL.%26aulast%3DBrutsche%26aufirst%3DN.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DHerring%26aufirst%3DW.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520crossover%2520pilot%2520trial%2520of%2520the%2520oral%2520selective%2520NR2B%2520antagonist%2520MK-0657%2520in%2520patients%2520with%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2012%26volume%3D32%26spage%3D551%26epage%3D557%26doi%3D10.1097%2Fjcp.0b013e31825d70d6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, B.</span>; <span class="NLM_string-name">Fraser, H.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Marcus, R.</span></span> <span> </span><span class="NLM_article-title">A Randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment</span>.  <i>2015 National Network of Depression Centers Annual Conference, November 15, Ann Arbor, MI, USA</i>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+Paterson&author=H.+Fraser&author=C.+Wang&author=R.+Marcus&title=A+Randomized%2C+double-blind%2C+placebo-controlled%2C+sequential+parallel+study+of+CERC-301+in+the+adjunctive+treatment+of+subjects+with+severe+depression+and+recent+active+suicidal+ideation+despite+antidepressant+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DB.%26atitle%3DA%2520Randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520sequential%2520parallel%2520study%2520of%2520CERC-301%2520in%2520the%2520adjunctive%2520treatment%2520of%2520subjects%2520with%2520severe%2520depression%2520and%2520recent%2520active%2520suicidal%2520ideation%2520despite%2520antidepressant%2520treatment%26jtitle%3D2015%2520National%2520Network%2520of%2520Depression%2520Centers%2520Annual%2520Conference%252C%2520November%252015%252C%2520Ann%2520Arbor%252C%2520MI%252C%2520USA%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Cerecor</span>. <a href="https://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" class="extLink">https://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study</a> (accessed June 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cerecor.+https%3A%2F%2Fir.cerecor.com%2Fpress-releases%2Fdetail%2F30%2Fcerecor-reports-top-line-data-from-cerc-301-phase-2-study+%28accessed+June+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span> <span> </span><span class="NLM_article-title">A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2Fj.drudis.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=30447328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=606-615&author=S.+T.+Wilkinsonauthor=G.+Sanacora&title=A+new+generation+of+antidepressants%3A+an+update+on+the+pharmaceutical+pipeline+for+novel+and+rapid-acting+therapeutics+in+mood+disorders+based+on+glutamate%2FGABA+neurotransmitter+systems&doi=10.1016%2Fj.drudis.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems</span></div><div class="casAuthors">Wilkinson, Samuel T.; Sanacora, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">606-615</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mood disorders represent the largest cause of disability worldwide.  The monoaminergic deficiency hypothesis, which has dominated the conceptual framework for researching the pathophysiol. of mood disorders and the development of novel treatment strategies, cannot fully explain the underlying neurobiol. of mood disorders.  Mounting evidence collected over the past two decades suggests the amino acid neurotransmitter systems (glutamate and GABA) serve central roles in the pathophysiol. of mood disorders.  Here, we review progress in the development of compds. that act on these systems as well as their purported mechanisms of action.  We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_UMrNA-mQYrVg90H21EOLACvtfcHk0ljQ85RWx51Olg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymsrfE&md5=46fd4d154103a9e1a6ab408a17f16b02</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DS.%2BT.%26aulast%3DSanacora%26aufirst%3DG.%26atitle%3DA%2520new%2520generation%2520of%2520antidepressants%253A%2520an%2520update%2520on%2520the%2520pharmaceutical%2520pipeline%2520for%2520novel%2520and%2520rapid-acting%2520therapeutics%2520in%2520mood%2520disorders%2520based%2520on%2520glutamate%252FGABA%2520neurotransmitter%2520systems%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D606%26epage%3D615%26doi%3D10.1016%2Fj.drudis.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohar, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushelle, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batley, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahring, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span> <span> </span><span class="NLM_article-title">Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure–Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1915</span>– <span class="NLM_lpage">1926</span>, <span class="refDoi"> DOI: 10.1021/jm0004291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0004291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Sgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1915-1926&author=M.+C.+Schroederauthor=J.+M.+Hambyauthor=C.+J.+C.+Connollyauthor=P.+J.+Groharauthor=R.+T.+Wintersauthor=M.+R.+Barvianauthor=C.+W.+Mooreauthor=S.+L.+Boushelleauthor=S.+M.+Creanauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=G.+H.+Luauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=T.+C.+Majorauthor=R.+L.+Panekauthor=A.+M.+Dohertyauthor=H.+D.+H.+Showalter&title=Soluble+2-Substituted+Aminopyrido%5B2%2C3-d%5Dpyrimidin-7-yl+Ureas.+Structure%E2%80%93Activity+Relationships+against+Selected+Tyrosine+Kinases+and+Exploration+of+in+Vitro+and+in+Vivo+Anticancer+Activity&doi=10.1021%2Fjm0004291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure-Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity</span></div><div class="casAuthors">Schroeder, Mel C.; Hamby, James M.; Connolly, Cleo J. C.; Grohar, Patrick J.; Winters, R. Thomas; Barvian, Mark R.; Moore, Charles W.; Boushelle, Stacey L.; Crean, Sheila M.; Kraker, Alan J.; Driscoll, Denise L.; Vincent, Patrick W.; Elliott, William L.; Lu, Gina H.; Batley, Brian L.; Dahring, Tawny K.; Major, Terry C.; Panek, Robert L.; Doherty, Annette M.; Showalter, H. D. Hollis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1915-1926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a search for medicinal agents to treat proliferative diseases, 2-substituted aminopyrido[2,3-d]pyrimidin-7-ylureas were discovered as a novel class of sol., potent, broadly active tyrosine kinase (TK) inhibitors.  An efficient route was developed that enabled the synthesis of a wide variety of analogs with substitution on several positions of the template.  From the lead structure, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-2-yl]-3-tert.-butylurea , several series of analogs were made that examd. the C-6 aryl substituent, a variety of water solubilizing substituents at the C-2 position, and urea or other acyl functionality at the N-7 position.  Compds. of this series were competitive with ATP and displayed submicromolar to low nanomolar potency against a panel of TKs, including receptor (platelet-derived growth factor, PDGFr; fibroblast growth factor, FGFr;) and non-receptor (c-Src) classes.  Several of the most potent compds. displayed submicromolar inhibition of PDGF-mediated receptor autophosphorylation in rat aortic vascular smooth muscle cells and low micromolar inhibition of cellular growth in five human tumor cell lines.  One of the more thoroughly evaluated members, I, with IC50 values of 0.21 μM (PDGFr), 0.049 μM (bFGFr), and 0.018 μM (c-Src), was evaluated in in vivo studies against a panel of five human tumor xenografts, with known and/or inferred dependence on the EGFr, PDGFr, and c-Src TKs.  I produced a tumor growth delay of 14 days against the Colo-205 colon xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcRg2byGKHbVg90H21EOLACvtfcHk0lgLn1oscc797A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Sgtbg%253D&md5=c9ba4118c6610b92bbab7603b9f79067</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0004291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0004291%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DGrohar%26aufirst%3DP.%2BJ.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26aulast%3DBoushelle%26aufirst%3DS.%2BL.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3DSoluble%25202-Substituted%2520Aminopyrido%255B2%252C3-d%255Dpyrimidin-7-yl%2520Ureas.%2520Structure%25E2%2580%2593Activity%2520Relationships%2520against%2520Selected%2520Tyrosine%2520Kinases%2520and%2520Exploration%2520of%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Anticancer%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1915%26epage%3D1926%26doi%3D10.1021%2Fjm0004291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/s1056-8719(00)00107-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=11274893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability&doi=10.1016%2Fs1056-8719%2800%2900107-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski C A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-49</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">There are currently about 10000 drug-like compounds.  These are sparsely, rather than uniformly, distributed through chemistry space.  True diversity does not exist in experimental combinatorial chemistry screening libraries.  Absorption, distribution, metabolism, and excretion (ADME) and chemical reactivity-related toxicity is low, while biological receptor activity is higher dimensional in chemistry space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME experimental screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biological receptor activity precedes or is concurrent with screening for properties related to "drugability." In the future, "drugability" screening may precede biological receptor activity screening.  The level of permeability or solubility needed for oral absorption is related to potency.  The relative importance of poor solubility and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clinical candidates leads to time-dependent higher molecular weight, higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher molecular weight, unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aqueous solubility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTa_EeosoOnpOLfW6udTcc2eYaFFqoD4CLn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D&md5=aeb705afe1eccaceaf441c7a19f13ecc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2000%26volume%3D44%26spage%3D235%26epage%3D249%26doi%3D10.1016%2Fs1056-8719%2800%2900107-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoellerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">1<i>H</i>-Pyrrolo[3,2-<i>b</i>]pyridine GluN2B-selective negative allosteric modulators</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=261-266&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=J.+L.+Wallauthor=J.+C.+Rechauthor=J.+Schoellermanauthor=B.+Lordauthor=K.+J.+Coeauthor=N.+I.+Carruthersauthor=L.+Nguyenauthor=X.+Jiangauthor=T.+Koudriakovaauthor=B.+Balanaauthor=M.+A.+Letavic&title=1H-Pyrrolo%5B3%2C2-b%5Dpyridine+GluN2B-selective+negative+allosteric+modulators&doi=10.1021%2Facsmedchemlett.8b00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Wall, Jessica L.; Rech, Jason C.; Schoellerman, Jeff; Lord, Brian; Coe, Kevin J.; Carruthers, Nicholas I.; Nguyen, Leslie; Jiang, Xiaohui; Koudriakova, Tatiana; Balana, Bartosz; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-266</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we disclose a series of selective GluN2B neg. allosteric modulators contg. a 1H-pyrrolo[3,2-b]pyridine core.  Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P 450 inhibition and hERG channel binding.  The series was also optimized to reduce metabolic turnover in human and rat.  Compds. 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance.  They were assessed in vivo to det. their target engagement.  All four compds. achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat.  Compd. 9 receptor occupancy was measured in a dose-response expt., and its ED50 was found to be 2.0 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7WstLp_w3rVg90H21EOLACvtfcHk0liGHcRkknR_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCnsA%253D%253D&md5=6f0d5a3297578f89d3101fea650174c8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00542%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DWall%26aufirst%3DJ.%2BL.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSchoellerman%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DBalana%26aufirst%3DB.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3D1H-Pyrrolo%255B3%252C2-b%255Dpyridine%2520GluN2B-selective%2520negative%2520allosteric%2520modulators%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D261%26epage%3D266%26doi%3D10.1021%2Facsmedchemlett.8b00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleichman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessain, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balice-Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. R.</span></span> <span> </span><span class="NLM_article-title">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/s1474-4422(08)70224-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1016%2FS1474-4422%2808%2970224-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=18851928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCrsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1091-1098&author=J.+Dalmauauthor=A.+J.+Gleichmanauthor=E.+G.+Hughesauthor=J.+E.+Rossiauthor=X.+Pengauthor=M.+Laiauthor=S.+K.+Dessainauthor=M.+R.+Rosenfeldauthor=R.+Balice-Gordonauthor=D.+R.+Lynch&title=Anti-NMDA-receptor+encephalitis%3A+case+series+and+analysis+of+the+effects+of+antibodies&doi=10.1016%2Fs1474-4422%2808%2970224-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</span></div><div class="casAuthors">Dalmau, Josep; Gleichman, Amy J.; Hughes, Ethan G.; Rossi, Jeffrey E.; Peng, Xiaoyu; Lai, Meizan; Dessain, Scott K.; Rosenfeld, Myrna R.; Balice-Gordon, Rita; Lynch, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1098</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A severe form of encephalitis assocd. with antibodies against NR1-NR2 heteromers of the NMDA receptor was recently identified.  We aimed to analyze the clin. and immunol. features of patients with the disorder and examine the effects of antibodies against NMDA receptors in neuronal cultures.  We describe the clin. characteristics of 100 patients with encephalitis and NR1-NR2 antibodies.  HEK293 cells ectopically expressing single or assembled NR1-NR2 subunits were used to det. the epitope targeted by the antibodies.  Antibody titers were measured with ELISA.  The effect of antibodies on neuronal cultures was detd. by quant. anal. of NMDA-receptor clusters.  Median age of patients was 23 years (range 5-76 years); 91 were women.  All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased consciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.  58 (59%) Of 98 patients for whom results of oncol. assessments were available had tumors, most commonly ovarian teratoma.  Patients who received early tumor treatment (usually with immunotherapy) had better outcome (p=0.004) and fewer neurol. relapses (p=0.009) than the rest of the patients.  Seventy-five patients recovered or had mild deficits and 25 had severe deficits or died.  Improvement was assocd. with a decrease of serum antibody titers.  The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit.  Patients' antibodies decreased the nos. of cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect that could be reversed by antibody removal.  A well-defined set of clin. characteristics are assocd. with anti-NMDA-receptor encephalitis.  The pathogenesis of the disorder seems to be mediated by antibodies.  Funding National Institutes for Health, University of Pennsylvania Institute for Translational Medicine, Lankenau Institute for Medical Research, Foederer Foundation of the Children's Hospital of Philadelphia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvbKVlmZeRbVg90H21EOLACvtfcHk0liGHcRkknR_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCrsLrF&md5=cfa7bfdcd2c41b075c7f473ea559d10b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2808%2970224-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252808%252970224-2%26sid%3Dliteratum%253Aachs%26aulast%3DDalmau%26aufirst%3DJ.%26aulast%3DGleichman%26aufirst%3DA.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BG.%26aulast%3DRossi%26aufirst%3DJ.%2BE.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DDessain%26aufirst%3DS.%2BK.%26aulast%3DRosenfeld%26aufirst%3DM.%2BR.%26aulast%3DBalice-Gordon%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DD.%2BR.%26atitle%3DAnti-NMDA-receptor%2520encephalitis%253A%2520case%2520series%2520and%2520analysis%2520of%2520the%2520effects%2520of%2520antibodies%26jtitle%3DLancet%2520Neurol.%26date%3D2008%26volume%3D7%26spage%3D1091%26epage%3D1098%26doi%3D10.1016%2Fs1474-4422%2808%2970224-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGiorgio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinov, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpe, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, B.</span></span> <span> </span><span class="NLM_article-title">A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.1038/nm1101-1189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnm1101-1189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=11689882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlKltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1189-1193&author=L.+A.+DeGiorgioauthor=K.+N.+Konstantinovauthor=S.+C.+Leeauthor=J.+A.+Hardinauthor=B.+T.+Volpeauthor=B.+Diamond&title=A+subset+of+lupus+anti-DNA+antibodies+cross-reacts+with+the+NR2+glutamate+receptor+in+systemic+lupus+erythematosus&doi=10.1038%2Fnm1101-1189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus</span></div><div class="casAuthors">DeGiorgio, Lorraine A.; Konstantinov, Konstantin N.; Lee, Sunhee C.; Hardin, John A.; Volpe, Bruce T.; Diamond, Betty</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1189-1193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">In systemic lupus erythematosus, antibodies against double-stranded DNA are a major contributor to renal disease.  The authors have previously demonstrated that the pentapeptide Asp/Glu-Trp-Asp/Glu-Tyr-Ser/Gly is a mol. mimic of double-stranded DNA.  This sequence is also present in the extracellular domain of murine and human NMDA (N-methyl-D-aspartate) receptor subunits NR2a and NR2b.  Here the authors show that the NR2 receptor is recognized by both murine and human anti-DNA antibodies.  Moreover, anti-DNA antibodies with this cross-reactivity mediate apoptotic death of neurons in vivo and in vitro.  Finally, the authors show that the cerebrospinal fluid of a patient with systemic lupus erythematosus contains these antibodies and also mediates neuronal death via an apoptotic pathway.  These observations indicate that lupus antibodies cross-react with DNA and NMDA receptors, gain access to cerebrospinal fluid and may mediate non-thrombotic and non-vasculitic abnormalities of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzOTioMlbqrVg90H21EOLACvtfcHk0liGHcRkknR_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlKltLw%253D&md5=1ed3326b45ef6d54febbd41123839c77</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm1101-1189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1101-1189%26sid%3Dliteratum%253Aachs%26aulast%3DDeGiorgio%26aufirst%3DL.%2BA.%26aulast%3DKonstantinov%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DHardin%26aufirst%3DJ.%2BA.%26aulast%3DVolpe%26aufirst%3DB.%2BT.%26aulast%3DDiamond%26aufirst%3DB.%26atitle%3DA%2520subset%2520of%2520lupus%2520anti-DNA%2520antibodies%2520cross-reacts%2520with%2520the%2520NR2%2520glutamate%2520receptor%2520in%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D1189%26epage%3D1193%26doi%3D10.1038%2Fnm1101-1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, G. E.</span></span> <span> </span><span class="NLM_article-title">Ultimate Translation: Developing Therapeutics Targeting on N-Methyl-D-Aspartate Receptor</span>. In  <i>Neuropsychopharmacology: A Tribute to Joseph T. Coyle</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarcz, R.</span>, <span class="NLM_string-name">Coyle, J. T.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">309</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=257-309&author=G.+E.+Tsaiauthor=R.+Schwarcz&author=J.+T.+Coyle&title=Neuropsychopharmacology%3A+A+Tribute+to+Joseph+T.+Coyle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DG.%2BE.%26atitle%3DUltimate%2520Translation%253A%2520Developing%2520Therapeutics%2520Targeting%2520on%2520N-Methyl-D-Aspartate%2520Receptor%26btitle%3DNeuropsychopharmacology%253A%2520A%2520Tribute%2520to%2520Joseph%2520T.%2520Coyle%26aulast%3DSchwarcz%26aufirst%3DR.%26pub%3DAcademic%2520Press%26date%3D2016%26spage%3D257%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M. F.</span></span> <span> </span><span class="NLM_article-title">Bidirectional synaptic plasticity: from theory to reality</span>. <i>Philos. Trans. R. Soc. London, Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1098/rstb.2002.1255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1098%2Frstb.2002.1255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=12740110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A280%3ADC%252BD3s3hvFCrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2003&pages=649-655&author=M.+F.+Bear&title=Bidirectional+synaptic+plasticity%3A+from+theory+to+reality&doi=10.1098%2Frstb.2002.1255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bidirectional synaptic plasticity: from theory to reality</span></div><div class="casAuthors">Bear Mark F</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical transactions of the Royal Society of London. Series B, Biological sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1432</span>),
    <span class="NLM_cas:pages">649-55</span>
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    </div><div class="casAbstract">Theories of receptive field plasticity and information storage make specific assumptions for how synapses are modified.  I give a personal account of how testing the validity of these assumptions eventually led to a detailed understanding of long-term depression and metaplasticity in hippocampal area CA1 and the visual cortex.  The knowledge of these molecular mechanisms now promises to reveal when and how sensory experience modifies synapses in the cerebral cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRumjSaqwyW3g5nADWVYHg1fW6udTcc2eataxHlgvLQ7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s3hvFCrtQ%253D%253D&md5=8411a21b3c5337af6240feae0584024b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1098%2Frstb.2002.1255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2002.1255%26sid%3Dliteratum%253Aachs%26aulast%3DBear%26aufirst%3DM.%2BF.%26atitle%3DBidirectional%2520synaptic%2520plasticity%253A%2520from%2520theory%2520to%2520reality%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D2003%26volume%3D358%26spage%3D649%26epage%3D655%26doi%3D10.1098%2Frstb.2002.1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M. F.</span></span> <span> </span><span class="NLM_article-title">Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4363</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1073/pnas.89.10.4363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1073%2Fpnas.89.10.4363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1350090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADyaK38XktVWlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=4363-4367&author=S.+M.+Dudekauthor=M.+F.+Bear&title=Homosynaptic+long-term+depression+in+area+CA1+of+hippocampus+and+effects+of+N-methyl-D-aspartate+receptor+blockade&doi=10.1073%2Fpnas.89.10.4363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade</span></div><div class="casAuthors">Dudek, Serena M.; Bear, Mark F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4363-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The authors tested a theor. prediction that patterns of excitatory input activity that consistently fail to activate target neurons sufficiently to induce synaptic potentiation will instead cause a specific synaptic depression.  To realize this situation exptl., the Schaffer collateral projection to area CA1 in rat hippocampal slices was stimulated elec. at frequencies ranging from 0.5 to 50 Hz.  Nine hundred pulses at 1-3 Hz consistently yielded a depression of the CA1 population excitatory postsynaptic potential that persisted without signs of recovery for >1 h after cessation of the conditioning stimulation.  This long-term depression was specific to the conditioned input, ruling out generalized changes in postsynaptic responsiveness or excitability.  Three lines of evidence suggest that this effect is accounted for by a modification of synaptic effectiveness rather than damage to or fatigue of the stimulated inputs.  First, the effect was dependent on the stimulation frequency; 900 pulses at 10 Hz caused no lasting change, and at 50 Hz a synaptic potentiation was usually obsd.  Second, the depressed synapses continued to support long-term potentiation in response to high-frequency tetanus.  Third, the effect of conditioning stimulation could be prevented by application of N-methyl-D-aspartate (NMDA) receptor antagonists.  Thus, the data suggest that synaptic depression can be triggered by prolonged NMDA receptor activation that is below the threshold for inducing synaptic potentiation.  It is proposed that this mechanism is important for the modifications of hippocampal response properties that underlie some forms of learning and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7uSKrWqiALVg90H21EOLACvtfcHk0lj1rgr9q6VnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVWlsb0%253D&md5=2bcad070dd9774fc1005e4e6e5ff322a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.10.4363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.10.4363%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DS.%2BM.%26aulast%3DBear%26aufirst%3DM.%2BF.%26atitle%3DHomosynaptic%2520long-term%2520depression%2520in%2520area%2520CA1%2520of%2520hippocampus%2520and%2520effects%2520of%2520N-methyl-D-aspartate%2520receptor%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1992%26volume%3D89%26spage%3D4363%26epage%3D4367%26doi%3D10.1073%2Fpnas.89.10.4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanacora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/nm.4050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=10.1038%2Fnm.4050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=26937618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=238-249&author=R.+S.+Dumanauthor=G.+K.+Aghajanianauthor=G.+Sanacoraauthor=J.+H.+Krystal&title=Synaptic+plasticity+and+depression%3A+New+insights+from+stress+and+rapid-acting+antidepressants&doi=10.1038%2Fnm.4050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants</span></div><div class="casAuthors">Duman, Ronald S.; Aghajanian, George K.; Sanacora, Gerard; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Depression is a common, devastating illness.  Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated.  However, new insights into the neurobiol. of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants.  Environmental events and other risk factors contribute to depression through converging mol. and cellular mechanisms that disrupt neuronal function and morphol., resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function.  Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants.  Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfcYim7-a4MrVg90H21EOLACvtfcHk0lj1rgr9q6VnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGqsbc%253D&md5=5556f3a359ef7ec7d1f2d43fdac8d16d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnm.4050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4050%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DSanacora%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DSynaptic%2520plasticity%2520and%2520depression%253A%2520New%2520insights%2520from%2520stress%2520and%2520rapid-acting%2520antidepressants%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D238%26epage%3D249%26doi%3D10.1038%2Fnm.4050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceusters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-6,7-dihydro-4<i>H</i>-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4559-4572&author=M.+A.+Letavicauthor=B.+M.+Savallauthor=B.+D.+Allisonauthor=L.+Aluisioauthor=J.+I.+Andresauthor=M.+De+Angelisauthor=H.+Aoauthor=D.+A.+Beauchampauthor=P.+Bonaventureauthor=S.+Bryantauthor=N.+I.+Carruthersauthor=M.+Ceustersauthor=K.+J.+Coeauthor=C.+A.+Dvorakauthor=I.+C.+Fraserauthor=C.+F.+Gelinauthor=T.+Koudriakovaauthor=J.+Liangauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=M.+A.+Otienoauthor=F.+Schoetensauthor=D.+M.+Swansonauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=A.+Bhattacharya&title=4-Methyl-6%2C7-dihydro-4H-triazolo%5B4%2C5-c%5Dpyridine-based+P2X7+receptor+antagonists%3A+optimization+of+pharmacokinetic+properties+leading+to+the+identification+of+a+clinical+candidate&doi=10.1021%2Facs.jmedchem.7b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span></div><div class="casAuthors">Letavic, Michael A.; Savall, Brad M.; Allison, Brett D.; Aluisio, Leah; Andres, Jose Ignacio; De Angelis, Meri; Ao, Hong; Beauchamp, Derek A.; Bonaventure, Pascal; Bryant, Stewart; Carruthers, Nicholas I.; Ceusters, Marc; Coe, Kevin J.; Dvorak, Curt A.; Fraser, Ian C.; Gelin, Christine F.; Koudriakova, Tatiana; Liang, Jimmy; Lord, Brian; Lovenberg, Timothy W.; Otieno, Monicah A.; Schoetens, Freddy; Swanson, Devin M.; Wang, Qi; Wickenden, Alan D.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4559-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of novel 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are potent and selective brain penetrant P2X7 antagonists are described.  Optimization efforts based on previously disclosed unsubstituted 6,7-dihydro-4H-triazolo[4,5-c]pyridines, Me substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazines, and several other series lead to the identification of a series of 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are selective P2X7 antagonists with potency at the rodent and human P2X7 ion channels.  These novel P2X7 antagonists have suitable physicochem. properties, and several analogs have an excellent pharmacokinetic profile, good partitioning into the CNS and show robust in vivo target engagement after oral dosing.  Improvements in metabolic stability led to the identification of JNJ-54175446 (I) as a candidate for clin. development.  The drug discovery efforts and strategies that resulted in the identification of the clin. candidate are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkx8e5Sq5aYbVg90H21EOLACvtfcHk0liXPwdaoFuUTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D&md5=5b5465d8f64d527da6647997efe34aee</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00408%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DAllison%26aufirst%3DB.%2BD.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DCeusters%26aufirst%3DM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3D4-Methyl-6%252C7-dihydro-4H-triazolo%255B4%252C5-c%255Dpyridine-based%2520P2X7%2520receptor%2520antagonists%253A%2520optimization%2520of%2520pharmacokinetic%2520properties%2520leading%2520to%2520the%2520identification%2520of%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4559%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.7b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8535</span>– <span class="NLM_lpage">8548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8535-8548&author=D.+M.+Swansonauthor=B.+M.+Savallauthor=K.+J.+Coeauthor=F.+Schoetensauthor=T.+Koudriakovaauthor=J.+Skaptasonauthor=J.+Wallauthor=J.+Rechauthor=X.+Dengauthor=M.+De+Angelisauthor=A.+Eversonauthor=B.+Lordauthor=Q.+Wangauthor=H.+Aoauthor=B.+Scottauthor=K.+Sepassiauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Identification+of+%28R%29-%282-Chloro-3-%28trifluoromethyl%29phenyl%29%281-%285-fluoropyridin-2-yl%29-4-methyl-6%2C7-dihydro-1H-imidazo%5B4%2C5-c%5Dpyridin-5%284H%29-yl%29methanone+%28JNJ+54166060%29%2C+a+Small+Molecule+Antagonist+of+the+P2X7+receptor&doi=10.1021%2Facs.jmedchem.6b00989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor</span></div><div class="casAuthors">Swanson, Devin M.; Savall, Brad M.; Coe, Kevin J.; Schoetens, Freddy; Koudriakova, Tatiana; Skaptason, Judith; Wall, Jessica; Rech, Jason; Deng, Xiahou; De Angelis, Meri; Everson, Anita; Lord, Brian; Wang, Qi; Ao, Hong; Scott, Brian; Sepassi, Kia; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8535-8548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described.  Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded Me substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of JNJ 54166060.  JNJ 54166060 is a potent P2X7 antagonist with an ED50=2.3 mg/kg in rat, high oral bioavailability and low-moderate clearance in pre-clin. species, acceptable safety margins in rat, and a predicted human dose of 120 mg QD.  Addnl., JNJ 54166060 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQfT4dUZEP6bVg90H21EOLACvtfcHk0liXPwdaoFuUTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr%252FO&md5=a48451477fca4bec1fd13df7d5a22ea8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00989%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DJ.%26aulast%3DRech%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520%2528R%2529-%25282-Chloro-3-%2528trifluoromethyl%2529phenyl%2529%25281-%25285-fluoropyridin-2-yl%2529-4-methyl-6%252C7-dihydro-1H-imidazo%255B4%252C5-c%255Dpyridin-5%25284H%2529-yl%2529methanone%2520%2528JNJ%252054166060%2529%252C%2520a%2520Small%2520Molecule%2520Antagonist%2520of%2520the%2520P2X7%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8535%26epage%3D8548%26doi%3D10.1021%2Facs.jmedchem.6b00989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1<i>H</i>-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=207-223&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=A.+A.+Petersonauthor=C.+F.+Gelinauthor=X.+Dengauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=B.+Lordauthor=I.+Fraserauthor=L.+Aluisioauthor=K.+J.+Coeauthor=B.+Scottauthor=T.+Koudriakovaauthor=F.+Schoetensauthor=K.+Sepassiauthor=D.+J.+Gallacherauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=A+Dipolar+Cycloaddition+Reaction+To+Access+6-Methyl-4%2C5%2C6%2C7-tetrahydro-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-c%5Dpyridines+Enables+the+Discovery+Synthesis+and+Preclinical+Profiling+of+a+P2X7+Antagonist+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b01279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Peterson, Alexander A.; Gelin, Christine F.; Deng, Xiaohu; Dvorak, Curt A.; Carruthers, Nicholas I.; Lord, Brian; Fraser, Ian; Aluisio, Leah; Coe, Kevin J.; Scott, Brian; Koudriakova, Tatiana; Schoetens, Freddy; Sepassi, Kia; Gallacher, David J.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A single pot dipolar cycloaddn. reaction/Cope elimination sequence was developed to access novel 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridine P2X7 antagonists that contain a synthetically challenging chiral center.  The structure-activity relationships of the new compds. are described.  Two of these compds., (S)-(2-fluoro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (I) and (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (II), were found to have robust P2X7 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg, resp.  Compd. II had notable soly. compared to I and showed good tolerability in preclin. species.  Compd. II was chosen as a clin. candidate for advancement into phase I clin. trials to assess safety and tolerability in healthy human subjects prior to the initiation of proof of concept studies for the treatment of mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0Y2r79JhbbVg90H21EOLACvtfcHk0ljMN835j1Yy9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN&md5=a97dfbda53f249894c7e4ef409601c95</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01279%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BA.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DA%2520Dipolar%2520Cycloaddition%2520Reaction%2520To%2520Access%25206-Methyl-4%252C5%252C6%252C7-tetrahydro-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-c%255Dpyridines%2520Enables%2520the%2520Discovery%2520Synthesis%2520and%2520Preclinical%2520Profiling%2520of%2520a%2520P2X7%2520Antagonist%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D207%26epage%3D223%26doi%3D10.1021%2Facs.jmedchem.7b01279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i73"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02113">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62470"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02113?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02113</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and IC<sub>50</sub> data of compounds <b>10–17</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_001.csv">CSV</a>)</p></li><li><p class="inline">Plasma and brain levels for <b>12–14</b> from receptor occupancy time course studies, plasma and brain levels of <b>12</b> for dose response receptor occupancy studies, brain levels of <b>12</b> in rat from microdosing study, <i>in vitro</i> CL data for <b>12</b> in 5 species, CYP450 inhibition data for <b>12</b>, solubility results for <b>12</b> in enabling excipients, off target selectivity panel data for <b>12</b>, and RP-LCMS purity traces for key compounds <b>11–14</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_001.csv">jm9b02113_si_001.csv (0.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02113/suppl_file/jm9b02113_si_002.pdf">jm9b02113_si_002.pdf (950.94 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02113&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02113%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02113" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995167ef9f3c28","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
